Document:

EX-10.1

 Exhibit 10.1 

$210,000,000 
 OMEROS
CORPORATION 
 6.25% Convertible Senior Notes due 2023 

PURCHASE AGREEMENT 

November 8, 2018 
 Cantor
Fitzgerald & Co. 
 UBS Securities LLC 

As Initial Purchasers 
 c/o Cantor
Fitzgerald & Co. 
 499 Park Avenue 
 New York, New
York 10022 
 c/o UBS Securities LLC 
 1285 Avenue of the
Americas 
 New York, New York 10019 
 Ladies and Gentlemen:

 1. Introductory. Omeros Corporation, a Washington corporation (the “Company”), proposes to
issue and sell to Cantor Fitzgerald & Co. and UBS Securities LLC (the “Initial Purchasers” and each an “Initial Purchaser”) $210,000,000 in aggregate principal amount of 6.25% Convertible Senior Notes due
2023 (the “Initial Securities”). The Initial Securities will be issued pursuant to an indenture (the “Indenture”), to be dated as of November 15, 2018, by and among the Company and Wells Fargo Bank, National
Association, as trustee (the “Trustee”). In addition, the Company has granted to the Initial Purchasers an option to purchase up to an additional $40,000,000 aggregate principal amount of its 6.25% Convertible Senior Notes due 2023
on the terms and conditions and for the purposes set forth herein (the “Option Securities” and, together with the Initial Securities, the “Securities”). The Securities will be convertible into cash or duly and
validly issued, fully paid and non-assessable shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), including any such shares issuable upon conversion in
connection with a “make-whole fundamental change” (as defined in the Final Offering Memorandum) (such shares, the “Conversion Shares”) or a combination of cash and Common Stock, on the terms, and subject to the conditions,
set forth in the Indenture. Capitalized terms used, but not defined herein, shall have the meanings set forth in the “Description of Notes” section of the Final Offering Memorandum (as hereinafter defined). 

 The Securities will be offered and sold to the Initial Purchasers pursuant to an exemption
from the registration requirements of the Securities Act of 1933, as amended, and the rules and regulations of the Securities and Exchange Commission (the “SEC”) thereunder (collectively, the “Securities Act”). Upon
original issuance thereof, and until such time as the same is no longer required under the applicable requirements of the Securities Act, the Securities shall bear the legends set forth in the final offering memorandum, dated the date hereof (the
“Final Offering Memorandum”). The Company has prepared a preliminary offering memorandum, dated November 8, 2018 (the “Preliminary Offering Memorandum”), (ii) a pricing term sheet, dated the date hereof,
attached hereto as Schedule I, which includes pricing terms and other information with respect to the Securities and the Conversion Shares (the “Pricing Supplement”), and (iii) the Final Offering Memorandum, in each
case, relating to the offer and sale of the Securities (the “Offering”). All references in this Agreement to the Preliminary Offering Memorandum, the Time of Sale Document (as defined herein) or the Final Offering Memorandum
include, with respect to the date or time referred to in this Agreement, unless expressly stated otherwise, (i) all amendments or supplements thereto, and (ii) all documents, financial statements and schedules and other information
contained, incorporated by reference or deemed incorporated by reference therein (and references in this Agreement to such information being “contained,” “included” or “stated” (and other references of like import) in
the Preliminary Offering Memorandum, the Time of Sale Document or the Final Offering Memorandum shall be deemed to mean all such information contained, incorporated by reference or deemed incorporated by reference therein). The Preliminary Offering
Memorandum and the Pricing Supplement are collectively referred to herein as the “Time of Sale Document.” 
 In connection
with the offering of the Initial Securities, the Company is separately entering into a capped call transaction with Royal Bank of Canada (the “Capped Call Counterparty”), pursuant to a capped call confirmation (the “Base
Capped Call Confirmation”), to be dated the date hereof, and in connection with any exercise by the Initial Purchasers of their option to purchase any Option Securities solely for the purpose of covering sales of Securities in excess of the
number of Initial Securities, the Company and the Capped Call Counterparty may enter into an additional capped call transaction pursuant to an additional capped call confirmation (an “Additional Capped Call Confirmation”), to be
dated the date on which the Initial Purchasers exercise their over-allotment option to purchase such Option Securities. We refer to the Base Capped Call Confirmation and the Additional Capped Call Confirmation collectively herein as the
“Capped Call Confirmations.” 
 2. Terms of Offering. The Initial Purchasers have advised the Company,
and the Company understands, that the Initial Purchasers will make offers to sell (the “Exempt Resales”) some or all of the Securities purchased by the Initial Purchasers hereunder on the terms set forth in the Time of Sale Document
to persons (the “Subsequent Purchasers”) whom the Initial Purchasers reasonably believe are “qualified institutional buyers” (“QIBs”) (as defined in Rule 144A under the Securities Act). As used herein,
“Time of Sale” means 9:45 p.m. (New York City time) on the date of this Agreement. 
 This Agreement, the Indenture, the Capped
Call Confirmations and the Securities are collectively referred to herein as the “Documents”, and the transactions contemplated hereby and thereby are collectively referred to herein as the “Transactions.” 

  
 Page 2 

 3. Purchase, Sale and Delivery. 

(a) On the basis of the representations, warranties, agreements and covenants herein contained and subject to the terms and conditions herein set forth, the
Company agrees to issue and sell to the Initial Purchasers, and the Initial Purchasers, severally and not jointly, agree to purchase from the Company, the aggregate principal amount of Initial Securities at a purchase price of 97% of the aggregate
principal amount thereof. 
 (b) The Company hereby grants to the Initial Purchasers an option to purchase up to $40,000,000 in aggregate principal amount
of Option Securities at the same purchase price as set forth above in Section 3(a) solely for the purpose of covering sales of Securities in excess of the number of Initial Securities. The option will expire 30 days after the date of the Final
Offering Memorandum and may be exercised in whole or in part from time to time by written notice given to the Company by the Initial Purchasers prior to such expiration. Such notice shall set forth the aggregate principal amount of Option Securities
as to which the option is being exercised, the names in which the principal amount of Option Securities are to be registered, the denominations in which the Option Securities are to be issued and the date and time, as determined by the Initial
Purchasers, when the Option Securities are to be delivered; provided, however, that this date and time shall not be earlier than the Initial Closing Date, and if later than the Initial Closing Date, shall not be earlier than the second business day
after the date on which the option shall have been exercised nor later than the fifth business day after the date on which the option shall have been exercised. If any Option Securities are to be purchased, each Initial Purchaser, severally and not
jointly, agrees to purchase from the Company the principal amount of Option Securities that bears the same proportion to the total principal amount of Option Securities to be purchased as the total principal amount of Initial Securities such Initial
Purchaser purchased bears to the total principal amount of Initial Securities purchased. 
 (c) Delivery to the Initial Purchasers of and payment for the
Initial Securities shall be made at a closing (the “Initial Closing”) to be held at 10:00 a.m., New York City time, on November 15, 2018 (the “Initial Closing Date”) and delivery to the Initial Purchasers of
and payment for the Option Securities shall be made at a closing (the “Option Closing” and, together with the Initial Closing, a “Closing”) to be held at a date and time specified by the Initial Purchasers in the
written notice of the Initial Purchasers’ election to purchase the Option Securities (the “Option Closing Date” and, together with the Initial Closing Date, a “Closing Date”), in each case, at the New York City
offices of Latham & Watkins LLP (or such other place as shall be reasonably acceptable to the Initial Purchasers). 
 (d) Delivery of the Initial
Securities and the Option Securities at each Closing Date shall be made through the facilities of The Depository Trust Company (“DTC”) unless the Initial Purchasers shall otherwise instruct. 

4. Representations and Warranties of the Company. The Company hereby represents, warrants and covenants to each Initial
Purchaser that, as of the date of this Agreement, as of the Initial Closing Date and as of each Option Closing Date, if any, as follows: 
 (a)
Limitation on Offering Materials. The Company has not prepared, made, used, authorized, approved or distributed and will not, and will not cause or allow its agents or 

  
 Page 3 

 
representatives to, prepare, make, use, authorize, approve or distribute any written communication that constitutes an offer to sell or a solicitation of an offer to buy the Securities, or
otherwise is prepared to market the Securities, other than (i) the Time of Sale Document, (ii) the Final Offering Memorandum and (iii) any marketing materials (including any roadshow or investor presentation materials) or other
written communications, in each case used in accordance with Section 5(c) hereof (each such communication by the Company or its agents or representatives described in this clause (iii), a “Company Additional Written
Communication”). 
 (b) Disclosure. As of the Time of Sale, the Time of Sale Document did not, and at the Initial Closing Date and at
each applicable Option Closing Date, will not, contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading.
The Final Offering Memorandum, as of its date, did not, and at the Initial Closing Date and at each applicable Option Closing Date, will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make
the statements therein, in the light of the circumstances under which they were made, not misleading. Each Company Additional Written Communication does not conflict with the information contained in the Time of Sale Document or the Final Offering
Memorandum, and when taken together with the Time of Sale Document, did not, and, at the Closing Date, will not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light
of the circumstances under which they were made, not misleading, except in each case that the representations and warranties set forth in this paragraph do not apply to statements or omissions made in reliance upon and in conformity with information
relating to the Initial Purchasers and furnished to the Company in writing by the Initial Purchasers expressly for use in the Time of Sale Document or the Final Offering Memorandum as set forth in Section 14(d). 

(c) No Injunction. No injunction or order has been issued that either (i) asserts that any of the Transactions is subject
to the registration requirements of the Securities Act or (ii) would prevent or suspend the issuance or sale of any of the Securities or the use of the Time of Sale Document or the Final Offering Memorandum in any jurisdiction, and no
proceeding for either such purpose has commenced or is pending or, to the knowledge of the Company, is contemplated. 
 (d) Documents Incorporated by
Reference. The documents incorporated by reference in the Time of Sale Document or the Final Offering Memorandum, at the time they were or hereafter are filed with the SEC, or became effective under the Securities Exchange Act of 1934, as
amended, and the rules and regulations promulgated thereunder (collectively, the “Exchange Act”), conformed in all material respects to the requirements of the Securities Act or the Exchange Act, as applicable, and the rules and
regulations of the SEC thereunder and none of such documents when filed contained any untrue statement of a material fact or omitted to state any material fact required to be stated therein or necessary to make the statements therein, in light of
the circumstances under which they were made, not misleading; and any further documents so filed and incorporated by reference in the Final Offering Memorandum, when such documents are filed with SEC or become effective under the Exchange Act will
conform in all material respects to the requirements of the Securities Act or the Exchange Act, as applicable, and the rules and regulations of the SEC thereunder and will not contain any untrue statement of

  
 Page 4 

 
a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not
misleading. 
 (e) Reporting Compliance. The Company is subject to, and is in compliance in all material respects with, the reporting
requirements of Section 13 and Section 15(d), as applicable, of the Exchange Act.  
 (f) The Purchase
Agreement and the Indenture. This Agreement has been duly authorized, executed and delivered by the Company. The Indenture has been duly and validly authorized by the Company and, at the Initial Closing Date, will have
been duly executed and delivered by the Company and will constitute a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except that the enforcement thereof may be subject to
(i) bankruptcy, insolvency, reorganization, receivership, moratorium, fraudulent conveyance, fraudulent transfer or other similar laws now or hereafter in effect relating to creditors’ rights generally and (ii) general principles of
equity (whether applied by a court of law or equity) and the discretion of the court before which any proceeding therefor may be brought (collectively, the “Enforceability Exceptions”). When executed and delivered, this Agreement,
the Capped Call Confirmations and the Indenture will conform in all material respects to the descriptions thereof in the Time of Sale Document and the Final Offering Memorandum. 

(g) The Securities. The Securities have been duly and validly authorized by the Company and, when issued and delivered to
and paid for by the Initial Purchasers in accordance with the terms of this Agreement and the Indenture, will have been duly executed, authenticated, issued and delivered and will constitute legal, valid and binding obligations of the Company,
entitled to the benefit of the Indenture, and enforceable against the Company in accordance with their terms, except that the enforcement thereof may be subject to (i) bankruptcy, insolvency, reorganization, receivership, moratorium, fraudulent
conveyance, fraudulent transfer or other similar laws now or hereafter in effect relating to creditors’ rights generally and (ii) general principles of equity (whether applied by a court of law or equity) and the discretion of the court
before which any proceeding therefor may be brought. When executed and delivered, the Securities will conform in all material respects to the descriptions thereof in the Time of Sale Document and the Final Offering Memorandum and will be in the form
contemplated by the Indenture. 
 (h) Enforceability of Capped Call Confirmations. The Base Capped Call Confirmation has been, and the
Additional Capped Call Confirmation (if any) on the date or dates that the Initial Purchasers exercise their right to purchase the relevant Option Securities solely for the purpose of covering sales of Securities in excess of the number of Initial
Securities will have been, duly authorized, executed and delivered by the Company and, assuming due execution and delivery thereof by the Capped Call Counterparty, constitute, or will constitute, as the case may be, valid and legally binding
agreements of the Company enforceable against the Company in accordance with their terms, subject to the Enforceability Exceptions. 
 (i)
Incorporation and Good Standing of the Company. The Company and each of its Subsidiaries (as defined in Section 14(g)) have been duly organized and are validly existing as 

  
 Page 5 

 
corporations or other legal entities in good standing (or the foreign equivalent thereof) under the laws of their respective jurisdictions of organization. The Company and each of its
Subsidiaries are duly qualified to do business and are in good standing as foreign corporations or other legal entities in each jurisdiction in which their respective ownership or lease of property or the conduct of their respective businesses
requires such qualification and have all power and authority (corporate or other) necessary to own or hold their respective properties and to conduct the businesses in which they are engaged, except where the failure to so qualify or have such power
or authority would not (i) have, singularly or in the aggregate, a material adverse effect on the condition (financial or otherwise), results of operations, assets, business or prospects of the Company and its Subsidiaries taken as a whole, or
(ii) impair in any material respect the ability of the Company to perform its obligations under this Agreement or to consummate any transactions contemplated by this Agreement, the Time of Sale Document or the Final Offering Memorandum (any
such effect as described in clauses (i) or (ii), a “Material Adverse Effect”). The Company owns or controls, directly or indirectly, only the following corporations, partnerships, limited liability partnerships, limited
liability companies, associations or other entities: nura, inc. and the Foreign Subsidiaries (as hereinafter defined). 
 (j) Capitalization and Other
Capital Stock Matters. The Company has an authorized capitalization as set forth in the Time of Sale Document and the Final Offering Memorandum under the caption “Description of Capital Stock”, and all of the issued shares of
capital stock of the Company have been duly and validly authorized and issued, are fully paid and non-assessable, have been issued in compliance with federal and state securities laws, and conform to the
description thereof contained in the Time of Sale Document and the Final Offering Memorandum. As of November 6, 2018, there were 49,009,310 shares of Common Stock issued and outstanding, and no shares of preferred stock, par value $0.01 of the
Company, issued and outstanding, and as of September 30, 2018, 10,366,645 shares of Common Stock were issuable upon the exercise of all options, warrants and convertible securities outstanding as of such date. Since such date, the Company has
not issued any securities (other than options to purchase Common Stock pursuant to the Company’s stock option plan or securities issued upon the exercise of stock options or warrants in the ordinary course of business). All of the
Company’s options, warrants and other rights to purchase or exchange any securities for shares of the Company’s capital stock have been duly authorized and validly issued and were issued in compliance with federal and state securities
laws. The maximum number of Conversion Shares have been duly authorized and reserved for issuance upon such conversion by all necessary corporate action and such shares, when issued upon such conversion in accordance with the terms of the
Securities, will be validly issued, fully paid and non-assessable; no holder of the Conversion Shares will be subject to personal liability by reason of being such a holder; and the issuance of the Conversion
Shares upon such conversion will not be subject to the preemptive or other similar rights of any securityholder of the Company. None of the outstanding shares of Common Stock was issued in violation of any preemptive rights, rights of first refusal
or other similar rights to subscribe for or purchase securities of the Company. There are no authorized or outstanding shares of capital stock, options, warrants, preemptive rights, rights of first refusal or other rights to purchase, or equity or
debt securities convertible into or exchangeable or exercisable for, any capital stock of the Company or any of its Subsidiaries other than those described above or accurately described in the Time of Sale Document. The description of the
Company’s stock option plans and the options or other rights granted thereunder, as described in the Time of Sale Document and the Final Offering Memorandum, accurately and fairly present 

  
 Page 6 

 
the information required to be shown with respect to such plans, arrangements, options and rights. 

(k) Subsidiary Capitalization. All the outstanding shares of capital stock (if any) of each Subsidiary of the Company have been duly authorized
and validly issued, are fully paid and nonassessable and, except to the extent set forth in the Time of Sale Document or the Final Offering Memorandum, are owned by the Company directly or indirectly through one or more wholly owned Subsidiaries,
free and clear of any claim, lien, encumbrance, security interest, restriction upon voting or transfer or any other claim of any third party, other than pursuant to the Company’s Term Loan Agreement with CRG Servicing LLC. 

(l) No Conflicts. The execution, delivery and performance by the Company of this Agreement and the Capped Call Confirmations and the
transactions contemplated thereby, the issue and sale of the Securities by the Company, the issuance of any Conversion Shares upon conversion thereof and the consummation of the transactions contemplated hereby will not (with or without notice or
lapse of time or both) (i) conflict with or result in a breach or violation of any of the terms or provisions of, constitute a default or a Debt Repayment Triggering Event (as defined below) under, give rise to any right of termination or other
right or the cancellation or acceleration of any right or obligation or loss of a benefit under, or give rise to the creation or imposition of any lien, encumbrance, security interest, claim or charge upon any property or assets of the Company or
any Subsidiary pursuant to, any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any of its Subsidiaries is a party or by which the Company or any of its Subsidiaries is bound or to which
any of the property or assets of the Company or any of its Subsidiaries is subject, (ii) result in any violation of the provisions of the charter or by-laws (or analogous governing instruments, as
applicable) of the Company or any of its Subsidiaries or (iii) result in a violation of any law, statute, rule, regulation, judgment, order or decree of any court or governmental agency or body, domestic or foreign, having jurisdiction over the
Company or any of its Subsidiaries or any of their properties or assets. A “Debt Repayment Triggering Event” means any event or condition that gives, or with the giving of notice or lapse of time would give the holder of any note,
debenture or other evidence of indebtedness (or any person (which for purposes of this Agreement shall mean, as appropriate, an individual, corporation, partnership, association, trust, unincorporated organization, limited liability company or other
legal entity) acting on such holder’s behalf) the right to require the repurchase, redemption or repayment of all or a portion of such indebtedness by the Company of any of its Subsidiaries. 

(m) No Required Consents. No consent, approval, authorization or order of, or filing, qualification or registration (each an
“Authorization”) with, any court, governmental or non-governmental agency or body, foreign or domestic, which has not been made, obtained or taken and is not in full force and effect, is
required for the execution, delivery and performance of this Agreement by the Company, the offer or sale of the Securities, the issuance of the Conversion Shares upon conversion thereof, the entry into the Capped Call Confirmations or the
consummation of the transactions contemplated hereby or thereby; and no event has occurred that allows or results in, or after notice or lapse of time or both would allow or result in, revocation, suspension, termination or invalidation of any such
Authorization or any other impairment of the rights of the holder or maker of any such Authorization. All corporate 

  
 Page 7 

 
approvals (including those of shareholders) necessary for the Company to consummate the transactions contemplated by this Agreement have been obtained and are in effect 

(n) Audited Financial Statements. Ernst & Young LLP, which has certified certain financial statements included or incorporated by
reference in the Time of Sale Document and the Final Offering Memorandum, and has audited the Company’s internal control over financial reporting and management’s assessment thereof, is an independent registered public accounting firm
within the meaning of Article 2-01 of Regulation S-X and the Public Company Accounting Oversight Board. 

(o) Financial Statements. The financial statements, together with the related notes, included or incorporated by reference in the Time of Sale
Document and the Final Offering Memorandum fairly present in all material respects the financial position and the results of operations and changes in financial position of the Company and its consolidated Subsidiaries at the respective dates or for
the respective periods therein specified. Such statements and related notes have been prepared in accordance with the generally accepted accounting principles in the United States (“GAAP”) applied on a consistent basis throughout
the periods involved except as may be set forth in the related notes included or incorporated by reference in the Time of Sale Document. The financial statements, together with the related notes, included or incorporated by reference in the Time of
Sale Document and the Final Offering Memorandum comply in all material respects with Regulation S-X. No other financial statements or supporting schedules or exhibits are required by Regulation S-X to be described, included or incorporated by reference in the Time of Sale Document or the Final Offering Memorandum. The summary and selected financial data included or incorporated by reference in the Time of
Sale Document and the Final Offering Memorandum fairly present in all material respects the information shown therein as at the respective dates and for the respective periods specified and are derived from the consolidated financial statements set
forth or incorporated by reference in the Time of Sale Document and the Final Offering Memorandum and other financial information. All information contained in the Time of Sale Document and the Final Offering Memorandum regarding “non-GAAP financial measures” (as defined in Regulation G) complies with Regulation G and Item 10 of Regulation S-K, to the extent applicable. 

(p) eXtensible Business Reporting Language. The interactive data in eXtensible Business Reporting Language included or incorporated by reference
in the Time of Sale Document or the Final Offering Memorandum fairly presents the information called for in all material respects and has been prepared in accordance with the SEC’s rules and guidelines applicable thereto. 

(q) No Material Uninsured Loss. Neither the Company nor any of its Subsidiaries has sustained, since the date of the latest audited financial
statements included or incorporated by reference in the Time of Sale Document, any material loss or interference with its business from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor dispute or court
or governmental action, order or decree, otherwise than as set forth or contemplated in the Time of Sale Document; and, since such date, there has not been any material change in the capital stock or long-term debt of the Company or any of its
Subsidiaries (other than stock option and warrant exercises and stock repurchases in the ordinary course of business or the repayment of long-term debt, or otherwise as described in the Time of Sale Document), or any material adverse changes, or any
development that reasonably would have a 

  
 Page 8 

 
Material Adverse Effect, in or affecting the business, assets, general affairs, management, financial position, prospects, shareholders’ equity or results of operations of the Company and
its Subsidiaries taken as a whole, otherwise than as set forth or contemplated in the Time of Sale Document. 
 (r) No Legal Proceedings.
Except as set forth in the Time of Sale Document, there is no legal or governmental proceeding to which the Company or any of its Subsidiaries is a party or of which any property or assets of the Company or any of its Subsidiaries is the
subject, including any proceeding before the United States Food and Drug Administration of the U.S. Department of Health and Human Services (“FDA”) or comparable federal, state, local or foreign governmental bodies (it being
understood that the interaction between the Company and the FDA and such comparable governmental bodies relating to the clinical development and product approval process shall not be deemed proceedings for purposes of this representation), which is
required to be described in the Time of Sale Document or the Final Offering Memorandum or a document incorporated by reference therein and is not described therein, or which, singularly or in the aggregate, if determined adversely to the Company or
any of its Subsidiaries, could reasonably be expected to have a Material Adverse Effect; and except as set forth in the Time of Sale Document, to the best of the Company’s knowledge, no such proceedings are threatened or contemplated by
governmental authorities. The Company is in compliance with all applicable federal, state, local and foreign laws, regulations, orders and decrees governing its business as prescribed by the FDA, or any other federal, state or foreign agencies or
bodies engaged in the regulation of pharmaceuticals or biohazardous substances or materials, except where noncompliance would not, singly or in the aggregate, have a Material Adverse Effect. All preclinical studies and clinical trials conducted by
or on behalf of the Company that the Company reasonably expects will be used to support approval for commercialization of the Company’s products have been conducted by the Company, or to the Company’s knowledge by third parties, in
compliance with all applicable federal, state and foreign laws, rules, orders and regulations, except for such failure or failures to be in compliance as could not reasonably be expected to have, singly or in the aggregate, a Material Adverse
Effect. 
 (s) Compliance with Health Care Laws. The Company and each of its Subsidiaries have operated and currently are in compliance with
all applicable health care laws, rules and regulations (except where such failure to operate or non-compliance would not, singly or in the aggregate, result in a Material Adverse Effect), including, without
limitation, (i) the Federal, Food, Drug and Cosmetic Act (21 U.S.C. §§ 301 et seq.); (ii) all applicable federal, state, local and all applicable foreign healthcare related fraud and abuse laws, including, without limitation, the
federal Anti-kickback Statute (42 U.S.C. § 1320a-7b(b)), the U.S. Physician Payments Sunshine Act (42 U.S.C. § 1320a-7h), the civil False Claims Act (31 U.S.C.
§§ 3729 et seq.), the criminal False Claims Law (42 U.S.C. § 1320a-7b(a)), all criminal laws relating to healthcare fraud and abuse, including but not limited to 18 U.S.C. Sections 286 and 287,
the healthcare fraud criminal provisions under the U.S. Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) (42 U.S.C. Section 1320d et seq.), the exclusion laws (42 U.S.C. § 1320a-7), and the civil monetary penalties law (42 U.S.C. § 1320a-7a); (iii) HIPAA, as amended by the Health Information Technology for Economic Clinical Health Act
(42 U.S.C. Section 17921 et seq.); (iv) the regulations promulgated pursuant to such laws; and (v) any other similar local, state, federal or foreign laws (collectively, the “Health Care Laws”). None of the Company,
any 

  
 Page 9 

 
of its Subsidiaries, or to the Company’s knowledge, any of its or their officers, directors or agents have engaged in activities which are, as applicable, cause for false claims liability,
civil penalties, or mandatory or permissive exclusion from Medicare, Medicaid, or any other state or federal healthcare program. The Company has not received written notice of any claim, action, suit, audit, survey, proceeding, hearing, enforcement,
investigation, arbitration or other action (“Action”) from any court or arbitrator or governmental or regulatory authority or third party alleging that any product operation or activity is in violation of any Health Care Laws, and,
to the Company’s knowledge, no such claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action is threatened. None of the Company nor any of its Subsidiaries is a party to or have any ongoing reporting
obligations pursuant to any corporate integrity agreement, deferred prosecution agreement, monitoring agreement, consent decree, settlement order, plan of correction or similar agreement imposed by any governmental or regulatory authority.
Additionally, none of the Company, any of its Subsidiaries, or to the Company’s knowledge, any of its or their employees, officers or directors, has been excluded, suspended or debarred from participation in any U.S. state or federal health
care program or human clinical research or, to the knowledge of the Company, is subject to a governmental inquiry, investigation, proceeding, or other similar action that could reasonably be expected to result in debarment, suspension, or exclusion.

 (t) No Violation or Default. Neither the Company nor any of its Subsidiaries (i) is in violation of its respective charter or by- laws (or analogous governing instrument, as applicable), (ii) is in default in any respect, and no event has occurred which, with notice or lapse of time or both, would constitute such a default, in the due
performance or observance of any term, covenant or condition contained in any indenture, mortgage, deed of trust, loan agreement, lease or other agreement or instrument to which it is a party or by which it is bound or to which any of its property
or assets is subject or (iii) is in violation in any respect of any law, ordinance, governmental rule, regulation or court order, decree or judgment to which it or its property or assets may be subject (including, without limitation, those
administered by the FDA or by any foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA) except, in the case of clauses (ii) and (iii) of this paragraph (s), as
disclosed in the Time of Sale Document and the Final Offering Memorandum and for any violations or defaults which, singularly or in the aggregate, would not have a Material Adverse Effect. 

(u) Governmental Permits. The Company and each of its Subsidiaries possess all licenses, certificates, authorizations and permits issued by, and
have made all declarations and filings with, the appropriate local, state, federal or foreign regulatory agencies or bodies which are necessary for the ownership of their respective properties or the conduct of their respective businesses as
currently conducted and as described in the Time of Sale Document and the Final Offering Memorandum (collectively, the “Governmental Permits”) except (i) where any failures to possess or make the same, singularly or in the
aggregate, would not have a Material Adverse Effect and (ii) as disclosed in the Time of Sale Document and the Final Offering Memorandum. The Company and its Subsidiaries are in compliance with all such Governmental Permits; all such
Governmental Permits are valid and in full force and effect, except where the validity or failure to be in full force and effect would not, singularly or in the aggregate, have a Material Adverse Effect. All such Governmental Permits are free and
clear of any restriction or condition that are in addition to, or materially different from those normally applicable to similar 

  
 Page 10 

 
licenses, certificates, authorizations and permits. Neither the Company nor any Subsidiary has received notification of any revocation, modification, suspension, termination or invalidation (or
proceedings related thereto) of any such Governmental Permit and to the knowledge of the Company, no event has occurred that allows or results in, or after notice or lapse of time or both would allow or result in, revocation, modification,
suspension, termination or invalidation (or proceedings related thereto) of any such Governmental Permit and the Company has no reason to believe that any such Governmental Permit will not be renewed. The preclinical studies and clinical trials
conducted by or on behalf of the Company that are described in the Time of Sale Document and the Final Offering Memorandum (the “Company Studies and Trials”) were and, if still pending, are being, conducted in all material respects
in accordance with experimental protocols, procedures and controls pursuant to, where applicable, accepted professional scientific standards, except where noncompliance with such protocols, procedures and controls would not, singularly or in the
aggregate, have a Material Adverse Effect; the descriptions of the results of the Company Studies and Trials contained in the Time of Sale Document and the Final Offering Memorandum are accurate in all material respects; and except as set forth in
the Time of Sale Document and the Final Offering Memorandum, the Company has not received any notices or correspondence from the FDA or any foreign, state or local governmental body exercising comparable authority requiring the termination,
suspension or material modification of any Company Studies or Trials that termination, suspension or material modification would reasonably be expected to have a Material Adverse Effect. 

(v) Investment Company. Neither the Company nor any of its Subsidiaries is or, after giving effect to (i) the offering of the Securities
and the application of the proceeds thereof as described in the Time of Sale Document and the Final Offering Memorandum or (ii) the transactions contemplated by the Capped Call Confirmations, will become required to register as an
“investment company” within the meaning of the Investment Company Act of 1940, as amended, and the rules and regulations of the SEC thereunder. 

(w) No Stabilization. Neither the Company nor any of its officers, directors or affiliates has taken or will take, directly or indirectly, any
action designed or intended to stabilize or manipulate the price of any security of the Company, or which caused or resulted in, or which might in the future reasonably be expected to cause or result in, stabilization or manipulation of the price of
any security of the Company to facilitate the sale or resale of the Securities in violation of the Exchange Act. 
 (x) Intellectual Property.
Except as disclosed in the Time of Sale Document, the Company and its Subsidiaries own or possess the valid right to use all (i) valid and enforceable material patents, patent applications, trademarks, trademark registrations, service
marks, service mark registrations, Internet domain name registrations, copyrights, copyright registrations, licenses, trade secret rights necessary to conduct their respective businesses as currently conducted, and as currently proposed to be
conducted and described in the Time of Sale Document and the Final Offering Memorandum (“Intellectual Property Rights”) and (ii) inventions, software, works of authorships, trademarks, service marks, trade names, databases,
formulae, know how, Internet domain names and other intellectual property (including trade secrets and other unpatented and/or unpatentable proprietary confidential information, systems, or procedures) necessary to conduct their respective
businesses as currently conducted, and as currently proposed to be conducted and described in the Time of Sale Document and the Final Offering Memorandum 

  
 Page 11 

 
(collectively, “Intellectual Property Assets”). Except as described in the Time of Sale Document, the Company and its Subsidiaries have not received written notice of any
challenge by any person to the rights of the Company and its Subsidiaries with respect to any Intellectual Property Rights or Intellectual Property Assets owned or used by the Company or its Subsidiaries. To the knowledge of the Company, the Company
and its Subsidiaries’ respective businesses as now conducted and as currently proposed to be conducted and described in the Time of Sale Document and the Final Offering Memorandum do not give rise to any infringement of, any misappropriation
of, or other violation of, any valid and enforceable Intellectual Property Rights of any other person that could reasonably be expected to have a Material Adverse Effect. All licenses for the use of the Intellectual Property Rights described in the
Time of Sale Document and the Final Offering Memorandum are valid, binding upon, and enforceable by or against the parties thereto in accordance to its terms. The Company has complied in all material respects with, and is not in breach nor has
received any asserted or threatened claim of breach of any Intellectual Property license, and the Company has no knowledge of any breach by any other person to any Intellectual Property license that could reasonably be expected to have a Material
Adverse Effect. No claim has been made against the Company alleging the infringement by the Company of any patent, trademark, service mark, trade name, copyright, trade secret, license in or other intellectual property right or franchise right of
any person nor to the Company’s knowledge is there any reasonable basis for such a claim that could reasonably be expected to have a Material Adverse Effect. The Company has taken reasonable steps to protect, maintain and safeguard its
Intellectual Property Rights, including the execution of appropriate nondisclosure and confidentiality agreements, proprietary information and invention agreements, consulting agreements and services agreements by relevant contractors, consultants
and employees. The consummation of the transactions contemplated by this Agreement will not result in the loss or impairment of or payment of any additional amounts with respect to, nor require the consent of any other person in respect of, the
Company’s right to own, use, or hold for use any of the Intellectual Property Rights as owned, used or held for use in the conduct of the business as currently conducted. The Company has at all times complied in all material respects with all
applicable laws relating to privacy, data protection, and the collection and use of personal information collected, used, or held for use by the Company in the conduct of the Company’s business. No claims have been asserted or, to the knowledge
of the Company, threatened against the Company alleging a violation of any person’s privacy or personal information or data rights and the consummation of the transactions contemplated hereby will not breach or otherwise cause any violation of
any law related to privacy, data protection, or the collection and use of personal information collected, used, or held for use by the Company in the conduct of the Company’s business. The Company takes reasonable measures to ensure that such
information is protected against unauthorized access, use, or modification. The Company has taken all necessary actions to obtain ownership of all works of authorship and inventions made by its employees, consultants and contractors during the time
they were employed by or under contract with the Company and which relate to the Company’s business. All scientific founders and key employees have signed confidentiality, invention assignment or proprietary information and invention agreements
with the Company. 
 (y) Title to Property. The Company and each of its Subsidiaries have valid title to, or have valid rights to lease or
otherwise use, all items of real or personal property which are material to the business of the Company and its Subsidiaries taken as a whole, in each case and except as described in the Time of Sale Document and the Final Offering Memorandum, free
and clear of 

  
 Page 12 

 
all liens, encumbrances, security interests, claims and defects that do not, singularly or in the aggregate, materially affect the value of such property and do not interfere with the use made
and proposed to be made of such property by the Company or any of its Subsidiaries; and all of the leases and subleases material to the business of the Company and its Subsidiaries, considered as one enterprise, and under which the Company or any of
its Subsidiaries holds properties described in the Time of Sale Document and the Final Offering Memorandum, are in full force and effect, and neither the Company nor any Subsidiary has any notice of any material claim of any sort that has been
asserted by anyone adverse to the rights of the Company or any Subsidiary under any of the leases or subleases mentioned above, or affecting or questioning the rights of the Company or such Subsidiary to the continued possession of the leased or
subleased premises under any such lease or sublease. 
 (z) Labor Disputes. There is (A) no material unfair labor practice complaint
pending against the Company, or any of its Subsidiaries, nor to the knowledge of the Company, threatened against it or any of its Subsidiaries, before the National Labor Relations Board, any state or local labor relation board or any foreign labor
relations board, and no material grievance or significant arbitration proceeding arising out of or under any collective bargaining agreement is so pending against the Company or any of its Subsidiaries, or, to the knowledge of the Company,
threatened against it and (B) no labor disturbance by the employees of the Company or any of its Subsidiaries exists or, to the Company’s knowledge, is imminent, and the Company is not aware of any existing or imminent labor disturbance by
the employees of any of its or its Subsidiaries principal suppliers, manufacturers, customers or contractors, that could reasonably be expected, singularly or in the aggregate, to have a Material Adverse Effect. The Company is not aware that any key
employee or significant group of employees of the Company or any Subsidiary plans to terminate employment with the Company or any such Subsidiary. 
 (aa)
No Prohibited Transactions. No “prohibited transaction” (as defined in Section 406 of the Employee Retirement Income Security Act of 1974, as amended, including the regulations and published interpretations thereunder
(“ERISA”), or Section 4975 of the Internal Revenue Code of 1986, as amended from time to time (the “Code”)) or “accumulated funding deficiency” (as defined in Section 302 of ERISA) or any of the
events set forth in Section 4043(b) of ERISA (other than events with respect to which the thirty (30)-day notice requirement under Section 4043 of ERISA has been waived) has occurred or could
reasonably be expected to occur with respect to any employee benefit plan of the Company or any of its Subsidiaries which could, singularly or in the aggregate, have a Material Adverse Effect. Each employee benefit plan of the Company or any of its
Subsidiaries is in compliance in all material respects with applicable law, including ERISA and the Code. The Company and its Subsidiaries have not incurred and could not reasonably be expected to incur liability under Title IV of ERISA with respect
to the termination of, or withdrawal from, any pension plan (as defined in ERISA). Each pension plan for which the Company or any of its Subsidiaries would have any liability that is intended to be qualified under Section 401(a) of the Code is
so qualified, and nothing has occurred, whether by action or by failure to act, which could, singularly or in the aggregate, cause the loss of such qualification. 

(bb) Compliance with Environmental Laws. The Company and its Subsidiaries are in compliance with all foreign, federal, state and local rules,
laws and regulations relating to the use, treatment, storage and disposal of hazardous or toxic substances or waste and protection of 

  
 Page 13 

 
health and safety or the environment which are applicable to their businesses (“Environmental Laws”) except where such noncompliance with Environmental Laws would not,
individually or in the aggregate, have a Material Adverse Effect. There has been no storage, generation, transportation, handling, treatment, disposal, discharge, emission, or other release of any kind of toxic or other wastes or other hazardous
substances by, due to, or caused by the Company or any of its Subsidiaries (or, to the Company’s knowledge, any other entity for whose acts or omissions the Company or any of its Subsidiaries is or may otherwise be liable) upon any of the
property now or previously owned or leased by the Company or any of its Subsidiaries, or upon any other property, in violation of any law, statute, ordinance, rule, regulation, order, judgment, decree or permit or which would, under any law,
statute, ordinance, rule (including rule of common law), regulation, order, judgment, decree or permit, give rise to any material liability; and there has been no disposal, discharge, emission or other release of any kind onto such property or into
the environment surrounding such property of any toxic or other wastes or other hazardous substances with respect to which the Company or any of its Subsidiaries has knowledge. In the ordinary course of business, the Company and its Subsidiaries
conduct periodic reviews of the effect of Environmental Laws on their business and assets, in the course of which they identify and evaluate associated costs and liabilities (including, without limitation, any material capital or operating
expenditures required for clean-up, closure of properties or compliance with Environmental Laws or Governmental Permits issued thereunder, any related material constraints on operating activities and any
potential material liabilities to third parties). On the basis of such reviews, the Company has reasonably concluded that such associated costs and liabilities would not have, singularly or in the aggregate, a Material Adverse Effect. 

(cc) Taxes. The Company and its Subsidiaries each (i) have timely filed all federal, state, local and foreign tax returns (or timely filed
applicable extensions therefor) that have been required to be filed, and all such returns were true, complete and correct, (ii) have paid all federal, state, local and foreign taxes, assessments, governmental or other charges due and payable
for which it is liable, including, without limitation, all sales and use taxes and all taxes which the Company or any of its Subsidiaries is obligated to withhold from amounts owing to employees, creditors and third parties, and (iii) do not
have any tax deficiency or claims outstanding or assessed or, to its knowledge, proposed against any of them, except those, in each of the cases described in clauses (i), (ii) and (iii) of this paragraph (bb), that would not, singularly or
in the aggregate, have a Material Adverse Effect. The Company and its Subsidiaries have not engaged in any transaction which is a corporate tax shelter or which could be characterized as such by the Internal Revenue Service or any other taxing
authority. The accruals and reserves on the books and records of the Company and its Subsidiaries in respect of tax liabilities for any taxable period not yet finally determined are adequate to meet any assessments and related liabilities for any
such period, and since September 30, 2018 the Company and its Subsidiaries have not incurred any liability for taxes other than in the ordinary course. 

(dd) Insurance. The Company and each of its Subsidiaries carry, or are covered by, insurance in such amounts and covering such risks as is
adequate for the conduct of their respective businesses and the value of their respective properties and as is customary for companies engaged in similar businesses in similar industries. Neither the Company nor any of its Subsidiaries has any
reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business at a cost that would not have a
Material Adverse 

  
 Page 14 

 
Effect. All policies of insurance owned by the Company or any of its Subsidiaries are, to the Company’s knowledge, in full force and effect and the Company and its Subsidiaries are in
compliance with the terms of such policies. Neither the Company nor any of its Subsidiaries has received written notice from any insurer, agent of such insurer or the broker of the Company or any of its Subsidiaries that any material capital
improvements or any other material expenditures (other than premium payments) are required or necessary to be made in order to continue such insurance. None of the Company or any of its Subsidiaries insures risk of loss through any captive
insurance, risk retention group, reciprocal group or by means of any fund or pool of assets specifically set aside for contingent liabilities other than as described in the Time of Sale Document. 

(ee) Internal Controls. The Company maintains a system of internal control over financial reporting (as such term is defined in Rule 13a-15(f) of the General Rules and Regulations under the Exchange Act (the “Exchange Act Rules”)) that complies with the requirements of the Exchange Act and has been designed by the Company’s
principal executive officer and principal financial officer, or under their supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with GAAP. The Company’s internal control over financial reporting, as evaluated pursuant to Rule 13a-15 under the Exchange Act Rules, is effective. Since the end of the Company’s most recent audited
fiscal year, there has been (A) no material weakness in the Company’s internal control over financial reporting (whether or not remediated) and (B) except as disclosed in the Time of Sale Document, no change in the Company’s
internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting. The Company’s internal control over financial reporting is
overseen by the Audit Committee of the Board of Directors of the Company (the “Audit Committee”) in accordance with the Exchange Act Rules. The Company has not publicly disclosed, and within the next 90 days the Company does not reasonably
expect to publicly disclose, a significant deficiency, material weakness, change in internal control over financial reporting or fraud involving management or other employees who have a significant role in the internal control over financial
reporting, any violation of, or failure to comply with, the federal securities laws, or any matter which if determined adversely, would have a Material Adverse Effect. 

(ff) Books and Records. The Company and each of its Subsidiaries have made and keep books, records and accounts, which, in reasonable detail,
accurately and fairly reflect the transactions and dispositions of the assets of the Company and its Subsidiaries in all material respects. 
 (gg)
Disclosure Controls and Procedures. The Company maintains disclosure controls and procedures (as such is defined in Rule 13a-15(e) of the Exchange Act Rules) that comply with the requirements of
the Exchange Act; such disclosure controls and procedures have been designed to ensure that information required to be disclosed by the Company is accumulated and communicated to the Company’s management, including the Company’s principal
executive officer and principal financial officer by others within the Company and is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and as of September 30, 2018, such
disclosure controls and procedures were effective. 

  
 Page 15 

 (hh) Minute Books. The minute books of the Company have been made available to the Initial
Purchasers and counsel for the Initial Purchasers, and such books contain a complete summary of all meetings and actions of the board of directors (including each board committee) and shareholders of the Company (or analogous governing bodies and
interest holders, as applicable), from January 1, 2015 through the date of this Agreement. 
 (ii) No Undisclosed Agreements. There is no
franchise agreement, lease, contract, or other agreement or document required by the Securities Act or by the Rules and Regulations to be described in the Time of Sale Document and the Final Offering Memorandum or a document incorporated by
reference therein or to be filed as an exhibit thereto or a document incorporated by reference therein which is not so described or filed therein as required; and all descriptions of any such franchise agreements, leases, contracts, or other
agreements or documents contained in the Time of Sale Document and the Final Offering Memorandum or in a document incorporated by reference therein are accurate and complete descriptions of such documents in all material respects. Other than as
described in the Time of Sale Document, no such franchise agreement, lease, contract or other agreement has been suspended or terminated for convenience or default by the Company or any of the other parties thereto, and neither the Company nor any
of its Subsidiaries has received notice of and the Company does not have knowledge of any such pending or threatened suspension or termination. 
 (jj)
Related Party Matters. No relationship, direct or indirect, exists between or among the Company on the one hand, and the directors, officers, shareholders (or analogous interest holders), customers or suppliers of the Company or any of
its affiliates on the other hand, which is required to be described in the Time of Sale Document and the Final Offering Memorandum or a document incorporated by reference therein and which is not so described. 

(kk) No Registration Rights. Except as described in the Time of Sale Document, there are no persons with registration rights or similar rights
to have any securities registered by the Company or any of its Subsidiaries under the Securities Act. 
 (ll) No Margin Securities. Neither
the Company nor any of its Subsidiaries own any “margin securities” as that term is defined in Regulation U of the Board of Governors of the Federal Reserve System (the “Federal Reserve Board”), and none of the proceeds of
the sale of the Securities or the entry into the Capped Call Confirmations will be used, directly or indirectly, for the purpose of purchasing or carrying any margin security, for the purpose of reducing or retiring any indebtedness which was
originally incurred to purchase or carry any margin security or for any other purpose which might cause any of the Securities to be considered a “purpose credit” within the meanings of Regulation T, U or X of the Federal Reserve Board.

 (mm) No Brokers. Neither the Company nor any of its Subsidiaries is a party to any contract, agreement or understanding with any person
that would give rise to a valid claim against the Company or the Initial Purchasers for a brokerage commission, finder’s fee or like payment in connection with the offering and sale of the Securities or any transaction contemplated by this
Agreement, the Time of Sale Document and the Final Offering Memorandum. 
 (nn) Exercise Price of Outstanding Options. The exercise price of
each option issued under the Company’s stock option or other employee benefit plans has been no less than the fair market 

  
 Page 16 

 
value of a share of Common Stock as determined on the date of grant of such option. All grants of options were validly issued and properly approved by the board of directors of the Company (or a
duly authorized committee thereof, or its designee) in material compliance with all applicable laws and regulations and recorded in the Company’s financial statements in accordance with GAAP and, to the Company’s knowledge, no such grants
involved “back dating,” “forward dating” or similar practice with respect to the effective date of grant. 
 (oo) Subsidiary
Repayments. Except as described in the Time of Sale Document and the Final Offering Memorandum, no Subsidiary of the Company is currently prohibited, directly or indirectly, under any agreement or other instrument to which it is a party or
is subject, from paying any dividends to the Company, from making any other distribution on such Subsidiary’s capital stock, from repaying to the Company any loans or advances to such Subsidiary from the Company or from transferring any of such
Subsidiary’s properties or assets to the Company or any other Subsidiary of the Company. 
 (pp) No Undisclosed Issuances or Liabilities.
Since the date as of which information is given in the Time of Sale Document and the Final Offering Memorandum through the date hereof, and except as set forth in the Final Offering Memorandum, neither the Company nor any of its Subsidiaries
has (i) issued or granted any securities other than options to purchase Common Stock pursuant to the Company’s stock option plan or securities issued upon the exercise of stock options or warrants in the ordinary course of business,
(ii) incurred any material liability or obligation, direct or contingent, other than liabilities and obligations which were incurred in the ordinary course of business, (iii) entered into any material transaction other than in the ordinary
course of business or (iv) declared or paid any dividend on its capital stock. 
 (qq) Forward-looking Statements. No forward-looking
statement (within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act) contained in either the Time of Sale Document and the Final Offering Memorandum has been made or reaffirmed without a reasonable basis
or has been disclosed other than in good faith. 
 (rr) No Business with Cuba. None of the Company or any of its Subsidiaries does business
with the government of Cuba or with any person or affiliate located in Cuba within the meaning of Florida Statutes Section 517.075. 
 (ss)
Compliance with Exchange Act Reporting Requirements. The Company is subject to and in compliance in all material respects with the reporting requirements of Section 13 or Section 15(d) of the Exchange Act. The Common Stock is
registered pursuant to Section 12(b) or 12(g) of the Exchange Act and is listed on the Exchange, and the Company has taken no action designed to, or reasonably likely to have the effect of, terminating the registration of the Common Stock under
the Exchange Act or delisting the Common Stock from the Exchange, nor has the Company received any notification that the SEC or FINRA is contemplating terminating such registration or listing. 

(tt) Compliance with Sarbanes-Oxley Act. The Company is in compliance in all material respects with all applicable provisions of the
Sarbanes-Oxley Act of 2002 and all rules and regulations promulgated thereunder or implementing the provisions thereof (the “Sarbanes-Oxley Act”) that are in effect. 

  
 Page 17 

 (uu) Compliance with Corporate Governance Requirements of Exchange Act. The Company is in
compliance with all applicable corporate governance requirements set forth in the rules of the Exchange that are in effect. 
 (vv) No Unlawful
Payments; FCPA Compliance. Neither the Company nor any of its Subsidiaries nor any of their respective executive officers or directors nor, to the Company’s knowledge, any other employee, or agent while acting on behalf of the Company
or any Subsidiary, has (i) used any corporate funds for unlawful contributions, gifts, entertainment or other unlawful expenses relating to political activity, (ii) made any unlawful payment to foreign or domestic government officials or
employees or to foreign or domestic political parties or campaigns from corporate funds or knowingly received or retained any funds in violation of any law, rule or regulation (including, without limitation, the Foreign Corrupt Practices Act of
1977, as amended), (iii) violated any provision of the Foreign Corrupt Practices Act of 1977, as amended, or (iv) made any other unlawful payment. 

(ww) No Transactions with Unconsolidated Entities. There are no transactions, arrangements or other relationships between and/or among the
Company, any of its affiliates (as such term is defined in Rule 405 of the Rules and Regulations) and any unconsolidated entity, including, but not limited to, any structured finance, special purpose or limited purpose entity that could reasonably
be expected to materially affect the Company’s liquidity or the availability of or requirements for its capital resources required to be described in the Time of Sale Document and the Final Offering Memorandum or a document incorporated by
reference therein which have not been described as required. 
 (xx) No Undisclosed Indebtedness. There are no outstanding loans, advances
(except normal advances for business expenses in the ordinary course of business) or guarantees of indebtedness by the Company or any of its Subsidiaries to or for the benefit of any of the officers or directors of the Company, any of its
Subsidiaries or any of their respective family members, except as disclosed in the Time of Sale Document and the Final Offering Memorandum. All transactions by the Company with office holders or control persons of the Company have been duly approved
by the board of directors of the Company, or duly appointed committees or officers thereof, if and to the extent required under U.S. law. 
 (yy)
Statistical and Market Related Data. The statistical and market related data included in the Time of Sale Document and the Final Offering Memorandum are based on or derived from sources that the Company believes to be reliable and
accurate, and such data are consistent with the sources from which they are derived. 
 (zz) Compliance with Money Laundering Laws. The
operations of the Company and its Subsidiaries are and have been conducted at all times in compliance in all material respects with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act
of 1970, as amended, applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the “Money Laundering Laws”), and no action, suit or proceeding by or before any court or governmental agency,
authority or body or any arbitrator involving the Company or any of its Subsidiaries with respect to the Money Laundering Laws is pending, or to the Company’s knowledge, threatened. 

  
 Page 18 

 (aaa) Compliance with Sanctions Laws. Neither the Company nor any of its Subsidiaries nor any
director or officer of the Company or any of its Subsidiaries nor, to the Company’s knowledge, any other agent, employee or affiliate of the Company or any of its Subsidiaries is currently (a) subject to any sanctions administered by the
Office of Foreign Assets Control of the U.S. Treasury Department (“OFAC”), the United Nations Security Council, the European Union, Her Majesty’s Treasury or other relevant sanctions authority (collectively,
“Sanctions”) or (b) located, organized or resident in a country or territory that is the subject of Sanctions (including, without limitation, Burma/Myanmar, Cuba, Iran, North Korea, Sudan and Syria). The Company represents and
covenants that it will not, directly or indirectly, use the proceeds of the offering, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person (a) to fund or facilitate any
activities or business of or with any person or in any country or territory that, at the time of such funding or facilitation, is the subject of Sanctions; or (b) in any other manner that will result in a violation of Sanctions by any person
(including any person participating in the offering, whether as underwriter, advisor, investor or otherwise). The Company represents and covenants that, except as detailed in the Preliminary Offering Memorandum, for the past five years, it has not
knowingly engaged in, is not now knowingly engaged in, and will not knowingly engage in, any dealings or transactions with any person, or in any country or territory, that at the time of the dealing or transaction is or was the subject of Sanctions.
The Company will not directly or indirectly use the proceeds of the offering, or lend, contribute or otherwise make available such proceeds to any Subsidiary, joint venture partner or other person or entity, for the purpose of financing the
activities of any person currently subject to any U.S. sanctions administered by OFAC. For purposes of this Section 4(aaa), no person shall be an affiliate of the Company solely by reason of owning less than a majority of any class of voting
securities of the Company. 
 (bbb) No Insolvency. The Company and its Subsidiaries, individually and on a consolidated basis, are not as of
the date hereof, and after giving effect to the transactions contemplated hereby to occur on the Closing Date, will not be Insolvent (as defined below). For purposes of this Section 4(bbb), “Insolvent” means, with respect to any
person, (i) the present fair saleable value of such person’s assets is less than the amount required to pay such person’s total Indebtedness, (ii) such person is unable to pay its debts and liabilities, subordinated, contingent
or otherwise, as such debts and liabilities become absolute and matured, (iii) such person intends to incur or believes that it will incur debts that would be beyond its ability to pay as such debts mature or such person has unreasonably small
capital with which to conduct the business in which it is engaged as such business is now conducted. 
 (ccc) No Foreign Subsidiary Assets or
Liabilities. Omeros London Limited and Omeros Ireland Limited (collectively, the “Foreign Subsidiaries”) have no material assets or any liabilities, contingent or otherwise, other than (i) the European Marketing
Authorization for OMIDRIA and (ii) any such liabilities that could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. 

(ddd) FINRA. Neither the Company nor, to the Company’s knowledge, any of its affiliates (within the meaning of FINRA Conduct Rule
2720(b)(1)(a)) directly or indirectly controls, is controlled by, or is under common control with, or is an associated person (within the meaning of Article I, Section 1(ee) of the By-laws of FINRA) of,
any member firm of FINRA. 

  
 Page 19 

 5. Covenants of the Company. 

(a) Securities Law Compliance. The Company agrees, at any time prior to the completion of the initial resales of the Securities
by the Initial Purchasers, to (i) advise the Initial Purchasers promptly after obtaining knowledge (and, if requested by the Initial Purchasers, confirm such advice in writing) of (A) the issuance by any U.S. or non-U.S. federal or state securities commission of any stop order suspending the qualification or exemption from qualification of any of the Securities for offer or sale in any jurisdiction, or the initiation of any
proceeding for such purpose by any U.S. or non-U.S. federal or state securities commission or other regulatory authority, or (B) the happening of any event that makes any statement of a material fact made
in the Time of Sale Document, any Company Additional Written Communication or the Final Offering Memorandum, untrue or that requires the making of any additions to or changes in the Time of Sale Document, any Company Additional Written
Communication, or the Final Offering Memorandum, to make the statements therein, in the light of the circumstances under which they were made, not misleading, (ii) use its reasonable best efforts to prevent the issuance of any stop order or
order suspending the qualification or exemption from qualification of any of the Securities under any securities or “Blue Sky” laws of U.S. state or non-U.S. jurisdictions and (iii) if, at any
time, any U.S. or non-U.S. federal or state securities commission or other regulatory authority shall issue an order suspending the qualification or exemption from qualification of any of the Securities under
any such laws, use its reasonable best efforts to obtain the withdrawal or lifting of such order at the earliest possible time. 
 (b) Offering
Documents. The Company agrees to (i) furnish the Initial Purchasers, without charge, as many copies of the Time of Sale Document and the Final Offering Memorandum, and any amendments or supplements thereto, as the Initial Purchasers may
reasonably request, and (ii) promptly prepare, upon the Initial Purchasers’ reasonable request, any amendment or supplement to the Time of Sale Document or Final Offering Memorandum that the Initial Purchasers, upon advice of legal
counsel, determine may be necessary in connection with Exempt Resales (and the Company hereby consents to the use of the Time of Sale Document and the Final Offering Memorandum, and any amendments and supplements thereto, by the Initial Purchasers
in connection with Exempt Resales). 
 (c) Consent to Amendments and Supplements. Before finalizing any Time of Sale Document or the Final
Offering Memorandum or making or distributing any amendment or supplement to any of the Time of Sale Document or the Final Offering Memorandum or filing with the SEC any document that will be incorporated by reference therein, the Company will
furnish to the Initial Purchasers and counsel for the Initial Purchasers a copy of the proposed Time of Sale Document or the Final Offering Memorandum or such amendment or supplement or document to be incorporated by reference therein for review,
and will not distribute any such proposed Time of Sale Document or the Final Offering Memorandum, amendment or supplement or file any such document with the SEC to which the Initial Purchasers reasonably object. Before making, preparing, using,
authorizing, approving or referring to any Company Additional Written Communications, the Company will furnish to the Initial Purchasers and counsel for the Initial Purchasers a copy of such written communication for review and will not make,
prepare, use, authorize, approve or refer to any such written communication to which the Initial Purchasers reasonably object. 

  
 Page 20 

 (d) Preparation of Amendments and Supplements to Offering Documents. The Company agrees, so
long as the Initial Purchasers shall hold any of the Securities, (i) if any event shall occur as a result of which, in the reasonable judgment of the Company or the Initial Purchasers (or counsel for the Initial Purchasers), it becomes
necessary or advisable to amend or supplement the Time of Sale Document or the Final Offering Memorandum to correct any untrue statement of a material fact or omission to state any material fact necessary to make the statements therein, in the light
of the circumstances under which they were made, not misleading, or if it is necessary to amend or supplement the Time of Sale Document or the Final Offering Memorandum to comply with any applicable law, to prepare, at the expense of the Company, an
appropriate amendment or supplement to the Time of Sale Document and the Final Offering Memorandum (in form and substance reasonably satisfactory to the Initial Purchasers) so that (A) as so amended or supplemented, the Time of Sale Document
and the Final Offering Memorandum will not include an untrue statement of material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, and
(B) the Time of Sale Document and the Final Offering Memorandum will comply with applicable law and (ii) if in the reasonable judgment of the Company it becomes necessary or advisable to amend or supplement the Time of Sale Document or the
Final Offering Memorandum so that the Time of Sale Document and the Final Offering Memorandum will contain all of the information specified in, and meet the requirements of, Rule 144A(d)(4) of the Securities Act, to prepare an appropriate amendment
or supplement to the Time of Sale Document or the Final Offering Memorandum (in form and substance reasonably satisfactory to the Initial Purchasers) so that the Time of Sale Document or the Final Offering Memorandum, as so amended or supplemented,
will contain the information specified in, and meet the requirements of, such Rule. 
 (e) “Blue Sky” Law
Compliance. The Company agrees to cooperate with the Initial Purchasers and the Initial Purchasers’ counsel in connection with the qualification of the Securities under the securities or “Blue Sky” laws of U.S. state or non-U.S. jurisdictions as the Initial Purchasers may request and continue such qualification in effect so long as required for Exempt Resales; provided that in connection therewith the Company shall not be
required to (i) qualify as a foreign corporation in any jurisdiction in which it would not otherwise be required to so qualify, (ii) file a general consent to service of process in any such jurisdiction, or (iii) subject itself to
taxation in any jurisdiction in which it would not otherwise be subject. 
 (f) Payment of Expenses. The Company agrees to
pay, or reimburse if paid by the Initial Purchasers whether or not the transactions contemplated hereby are consummated or this Agreement is terminated: (i) the costs incident to the authorization, issuance, sale, preparation and delivery of
the Securities (and the Conversion Shares issuable upon conversion thereof) and any taxes payable in that connection; (ii) the costs incident to the preparation, printing and distribution of the Time of Sale Document and the Final Offering
Memorandum, any amendments, supplements and exhibits thereto or any document incorporated by reference therein and the Documents; (iii) the fees and expenses (including related fees and expenses of counsel for the Initial Purchasers) incurred
in connection with securing any required review by FINRA of the terms of the sale of the Securities and any filings made with FINRA (not to exceed $5,000 in the aggregate); (iv) any applicable listing or other fees, including, without limitation,
the fees and expenses associated with listing the Conversion Shares on Nasdaq; (v) the fees and expenses (including related fees and expenses of counsel to the Initial Purchasers) of qualifying 

  
 Page 21 

 
the Securities under the securities laws of such jurisdictions (domestic or foreign) as the Initial Purchasers may designate and of preparing, printing and distributing wrappers, Blue Sky
Memoranda and Legal Investment Surveys (not to exceed $2,000 in the aggregate) (vi) the cost of preparing and printing stock certificates; (vii) all fees and expenses of the registrar and transfer agent of the Common Stock and of the
Trustee; (viii) the costs and expenses (including, without limitation, any damages or other amounts payable in connection with the legal or contractual liability) associated with the reforming of any contracts for sale of the Securities made by
the Initial Purchasers caused by a breach of the representation contained in Section 4(c); (ix) the costs and expenses of the Company relating to investor presentations on any “road show” undertaken in connection with the
marketing of the offering of the Securities, including, without limitation, expenses associated with the preparation or dissemination of any electronic road show, expenses associated with the production of road show slides and graphics, fees and
expenses of any consultants engaged in connection with the road show presentations with the prior approval of the Company, travel and lodging expenses of the officers of the Company and such consultants, including the cost of any aircraft chartered
in connection with the road show; and (x) all other costs and expenses incident to the offering of the Securities or the performance of the obligations of the Company under this Agreement (including, without limitation, the fees and expenses of
the Company’s counsel and the Company’s independent accountants; provided that, except to the extent otherwise provided herein in Section 5(f) and Section 10, the Initial Purchasers shall pay their own costs and expenses
incurred in connection with the transactions contemplated hereby, including the fees and expenses of their counsel, and any transfer taxes on the resale of any Securities by them. 

(g) Use of Proceeds. The Company agrees to use the proceeds of the Offering in the manner described in the Time of Sale Document
and the Final Offering Memorandum under the caption “Use of Proceeds.” 
 (h) Transaction Documents. The Company agrees to do and
perform all things required to be done and performed under the Documents prior to and after the applicable Closing Date, and to satisfy all conditions precedent to the Initial Purchasers’ obligations hereunder to purchase the Securities. 

(i) Integration. The Company agrees not to, and to ensure that no affiliate of the Company will, sell, offer for sale or solicit offers to buy
or otherwise negotiate in respect of any “security” (as defined in the Securities Act) that would be integrated with the sale of the Securities in a manner that would require the registration under the Securities Act of the sale to the
Initial Purchasers or to the Subsequent Purchasers of the Securities. 
 (j) Stabilization or Manipulation. The Company agrees not to take,
and to ensure that no affiliate of the Company will take, directly or indirectly, any action designed to or that could be reasonably expected to cause or result in stabilization or manipulation of the price of the Securities or any other reference
security, whether to facilitate the sale or resale of the Securities or otherwise. Notwithstanding any prior agreement between the Company and the Initial Purchasers to the contrary, the Company acknowledges and agrees that, subject only to
compliance with applicable laws, the Initial Purchasers and their respective affiliates may, directly or indirectly, hold long or short positions, trade and otherwise conduct such activities in or with respect to debt and/or equity securities and/or
bank debt of, and/or derivative products 

  
 Page 22 

 
related to, the Company and otherwise effect the transactions with respect to the Securities, Common Stock and other securities of the Company contemplated in the Final Offering Memorandum. 

(k) DTC. The Company agrees to use its best efforts to permit the Securities to be eligible for clearance and settlement through DTC. 

(l) Rule 144A Information. For so long as any of the Securities remain outstanding, during any period in which the Company is not subject to
Section 13 or 15(d) of the Exchange Act, the Company agrees to make available, upon request, to any owner of the Securities in connection with any sale thereof and any prospective Subsequent Purchasers of such Securities from such owner, the
information required by Rule 144A(d)(4) under the Securities Act. 
 (m) Additional Offering Materials. The Company agrees not to, and not to
authorize or permit any person acting on its behalf to, (i) distribute any offering material in connection with the offer and sale of the Securities other than the Time of Sale Document and the Final Offering Memorandum and any amendments and
supplements to the Preliminary Offering Memorandum or the Final Offering Memorandum prepared in compliance with this Agreement or (ii) solicit any offer to buy or offer to sell the Securities by means of any form of general solicitation or
general advertising (including, without limitation, as such terms are used in Regulation D under the Securities Act) or in any manner involving a public offering within the meaning of Section 4(a)(2) of the Securities Act. 

(n) Sale of Restricted Securities. During the one year period after the applicable Closing Date (or such shorter period as may be provided for
in Rule 144 under the Securities Act, as the same may be in effect from time to time), the Company agrees not to, and will use its reasonable best efforts not to permit any future Subsidiaries of either the Company or any other affiliates controlled
by the Company to, resell any of the Securities which constitute “restricted securities” under Rule 144 that have been reacquired by the Company, any future Subsidiaries or any other affiliates controlled by the Company, except pursuant to
an effective registration statement under the Securities Act. 
 (o) Conversion Shares. The Company agrees to reserve and keep available at
all times, free of preemptive rights, the maximum number of Conversion Shares issuable upon conversion of the Securities. The Company will use its best efforts to list, subject to notice of issuance, the Conversion Shares on the Nasdaq. 

(p) Company Lock-Up. During the period commencing on and including the date hereof and ending on and
including the 60th day following the date of this Agreement ( the “Lock-Up Period”) the Company will not, without the prior written consent of Cantor Fitzgerald & Co. (which consent
may be withheld at the sole discretion of Cantor Fitzgerald & Co.), directly or indirectly offer, sell (including, without limitation, any short sale), assign, transfer, pledge, contract to sell, establish an open “put equivalent
position” within the meaning of Rule 16a-1(h) under the Exchange Act, or otherwise dispose of, or announce the offering of, or file any registration statement under the Securities Act in respect of, any
Common Stock, options, rights or warrants to acquire Common Stock or securities exchangeable or exercisable for or convertible into Common Stock (other than is contemplated by this Agreement with respect to

  
 Page 23 

 
the Conversion Shares) or publicly announce any intention to do any of the foregoing; provided, however, that the Company may (i) issue and sell the Securities hereunder
(including any Conversion Shares upon conversion thereof), (ii) issue restricted Common Stock or options to acquire Common Stock pursuant to the Company’s employee benefit plans, qualified stock option plans or other employee compensation plans
as such plans are in existence on the date hereof and described in the Final Offering Memorandum, (iii) issue Common Stock pursuant to the valid exercises, vesting or settlements of options, warrants or rights outstanding on the date hereof,
(iv) issue Common Stock or other securities to financial institutions or other lenders in connection with debt financing transactions (a “Financing Transaction”), (v) issue Common Stock in connection with an equity line
financing (an “Equity Line Transaction”), (vi) enter into, exercise its rights under or terminate the Capped Call Confirmations, (vii) issue Common Stock upon the conversion of the Securities and (viii) file a registration
statement relating to a Financing Transaction or an Equity Line Transaction (notwithstanding the foregoing, the actions set forth in clauses (iv), (v) and (vi) may not be taken under this paragraph (p) during the period commencing on
and including the date hereof and ending on and including the 30th day following the date of this Agreement). The Company will cause each officer and director listed in Exhibit B to furnish to Cantor Fitzgerald & Co. prior to the
Closing Date, a letter, substantially in the form of Exhibit A hereto. The Company also agrees that during the Lock-Up Period, other than for the sale of the Securities hereunder, the Company will not
file any registration statement, preliminary prospectus or prospectus, or any amendment or supplement thereto, under the Securities Act for any such transaction or which registers, or offers for sale, Common Stock or any securities convertible into
or exercisable or exchangeable for Common Stock, except for (i) a registration statement on Form S-8 relating to employee benefit plans and (ii) one or more registration statements, preliminary
prospectus or prospectus, or any amendment or supplement thereto relating to a Financing Transaction or an Equity Line Transaction (notwithstanding the foregoing, the actions set forth in clause (ii) may not be taken under this paragraph
(k) during the period commencing on and including the date hereof and ending on and including the 30th day following the date of this Agreement). 

(q) Investment Company. The Company will conduct its business in a manner so as to not be required to register under the Investment
Company Act. 
 (r) No Adjustment to Conversion Rate. The Company agrees not to, between the date hereof and the issuance of
the Securities, take any action which would result in a conversion rate adjustment to the Securities assuming they are outstanding. 

6. Representations and Warranties of the Initial Purchasers. Each Initial Purchaser represents and warrants that:

 (a) Initial Purchaser Status, Resale Terms. It is a QIB and an “accredited investor” within the meaning of Rule
501(a) under the Securities Act and it will offer the Securities for resale only upon the terms and conditions set forth in this Agreement and in the Time of Sale Document and the Final Offering Memorandum. 

(b) Sale of Restricted Exchange Securities. It has not sold, and will not sell, the Securities as part of their initial offering except to
persons whom it reasonably believes to be QIBs in transactions pursuant to Rule 144A under the Securities Act (“Rule 144A”) and in connection 

  
 Page 24 

 
with such sale, it has taken or will take reasonable steps to ensure that the purchaser of the Securities is aware that such sale is being made in reliance on Rule 144A. 

7. Conditions of the Obligations of the Initial Purchasers. The obligations of the Initial Purchasers hereunder to
purchase and pay for the Initial Securities as provided herein on the First Closing Date and, with respect to the Optional Securities, each Option Closing Date, shall be subject to the accuracy of the representations and warranties on the part of
the Company set forth in Section 4 hereof as of the date hereof and as of the First Closing Date as though then made and, with respect to the Optional Securities, as of each Option Closing Date as though then made, to the timely performance by
the Company of its covenants and other obligations hereunder, and to each of the following additional conditions: 
 (a) No Untrue Statements.
The Initial Purchasers shall not have discovered and disclosed to the Company on or prior to each such Closing Date that the Time of Sale Document or the Final Offering Memorandum or any amendment or supplement thereto contains an untrue statement
of fact which, in the opinion of counsel for the Initial Purchasers, is material or omits to state any fact which, in the opinion of such counsel, is material and is required to be stated therein or is necessary to make the statements therein not
misleading. 
 (b) Corporate Proceedings. All corporate proceedings and other legal matters incident to the authorization, form and validity
of each of this Agreement, the Securities, the Time of Sale Document and the Final Offering Memorandum and all other legal matters relating to this Agreement and the transactions contemplated hereby shall be reasonably satisfactory in all material
respects to counsel for the Initial Purchasers, and the Company shall have furnished to such counsel all documents and information that they may reasonably request to enable them to pass upon such matters. 

(c) Opinion of Counsel for the Company. As of each Closing Date, Covington & Burling LLP shall have furnished to the Initial Purchasers
such counsel’s written opinion, as special counsel to the Company, addressed to the Initial Purchasers and dated each such Closing Date, in form and substance reasonably satisfactory to the Initial Purchasers and substantially as set forth on
Exhibit C hereto. 
 (d) General Counsel Opinion. As of each Closing Date, Marcia S. Kelbon, Vice President, Patent & General
Counsel of the Company, shall have furnished to the Initial Purchasers such counsel’s written opinion, as intellectual property and General Counsel to the Company, addressed to the Initial Purchasers and dated as of each such Closing Date, in
form and substance reasonably satisfactory to the Initial Purchasers and substantially as set forth on Exhibit D hereto. 
 (e) Opinion of
Washington Counsel. As of each Closing Date, Keller Rohrback L.L.P. shall have furnished to the Initial Purchasers such counsel’s written opinion, as Washington State counsel to the Company, addressed to the Initial Purchasers and dated
such Closing Date, in form and substance reasonably satisfactory to the Initial Purchasers and substantially as set forth on Exhibit E hereto. 
 (f)
Officers’ Certificate. As of each Closing Date, the Company shall have furnished to the Initial Purchasers a certificate, dated such Closing Date, of its Chairman and Chief Executive

  
 Page 25 

 
Officer and its Chief Regulatory Officer and Vice President, Regulatory Affairs and Quality Systems in form and substance reasonably satisfactory to the Initial Purchasers and substantially as
set forth on Exhibit F hereto. 
 (g) Opinion of Counsel for the Initial Purchasers. As of each Closing Date, the Initial Purchasers
shall have received from Latham & Watkins LLP, counsel for the Initial Purchasers, such opinion or opinions, dated such Closing Date, with respect to such matters as the Initial Purchasers may reasonably require, and the Company shall have
furnished to such counsel such documents as they request for enabling them to pass upon such matters. 
 (h) Comfort
Letter. At the time of the execution of this Agreement, the Initial Purchasers shall have received from Ernst & Young LLP a letter, addressed to the Initial Purchasers, executed and dated such date, in form and substance
satisfactory to the Initial Purchasers (i) confirming that they are an independent registered accounting firm with respect to the Company and its Subsidiaries within the meaning of the Securities Act and the Rules and Regulations and rules and
regulations of the PCAOB and (ii) stating the conclusions and findings of such firm, of the type ordinarily included in accountants’ “comfort letters” to underwriters, with respect to the financial statements and certain
financial information contained or incorporated by reference in the Time of Sale Document and the Final Offering Memorandum. 
 (i) Bring Down Comfort
Letters. On each Closing Date, the Initial Purchasers shall have received a letter (the “bring-down letter”) from Ernst & Young LLP addressed to the Initial Purchasers and dated such Closing Date confirming, as of
the date of the bring- down letter (or, with respect to matters involving changes or developments since the respective dates as of which specified financial information is given in the Time of Sale Document and the Final Offering Memorandum, as the
case may be, as of a date not more than three (3) business days prior to the date of the bring-down letter), the conclusions and findings of such firm, of the type ordinarily included in accountants’ “comfort letters” to
underwriters, with respect to the financial information and other matters covered by its letter delivered to the Initial Purchasers concurrently with the execution of this Agreement pursuant to paragraph (h) of this Section 7. 

(j) Chairman and CEO Certificate. As of each Closing Date, the Company shall have furnished to the Initial Purchasers a certificate, dated such
Closing Date, of its Chairman of the Board and Chief Executive Officer and its Vice President, Patent & General Counsel stating that (i) such officers have examined the Time of Sale Document and Final Offering Memorandum and, in their
opinion, the Time of Sale Document, as of the date hereof and as of such Closing Date, the Final Offering Memorandum and each amendment or supplement thereto, as of the respective date thereof and as of such Closing Date, did not include any untrue
statement of a material fact and did not omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances in which they were made, not misleading, (ii) since the date hereof, no event has
occurred which should have been set forth in a supplement or amendment to the Time of Sale Document or the Final Offering Memorandum that has not been so set forth therein, (iii) to the best of their knowledge after reasonable investigation, as
of such Closing Date, the representations and warranties of the Company in this Agreement are true and correct and the Company has complied with all agreements and satisfied all conditions on its part to be performed or satisfied hereunder at or
prior to such Closing Date, and (iv) there has not been, subsequent to the date of the most recent audited financial statements included or 

  
 Page 26 

 
incorporated by reference in the Time of Sale Document, any material adverse change in the financial position or results of operations of the Company and its Subsidiaries, or any change or
development that, singularly or in the aggregate, would involve a material adverse change or a prospective material adverse change, in or affecting the condition (financial or otherwise), results of operations, business, assets or prospects of the
Company and its Subsidiaries taken as a whole, except as set forth in the Final Offering Memorandum; it being understood that the certifications provided by the Vice President, Patent & General Counsel pursuant to this Section 7(j)
will exclude the financial statements and the notes thereto, the financial schedules and other financial data and information included or incorporated or deemed incorporated by reference in the Time of Sale Document or the Final Offering Memorandum.

 (k) No Material Change or Loss. Since the date of the latest audited financial statements included in the Time of Sale Document or
incorporated by reference in the Time of Sale Document as of the date hereof, (i) neither the Company nor any of its Subsidiaries shall have sustained any loss or interference with its business from fire, explosion, flood or other calamity,
whether or not covered by insurance, or from any labor dispute or court or governmental action, order or decree, otherwise than as set forth in the Time of Sale Document, and (ii) other than as disclosed in the Time of Sale Document there shall
not have been any change in the capital stock or long-term debt of the Company or any of its Subsidiaries (other than stock option and warrant exercises and stock repurchases in the ordinary course of business and repayments of existing
indebtedness), or any change, or any development involving a prospective change, in or affecting the business, general affairs, management, financial position, shareholders’ equity or results of operations of the Company and its Subsidiaries,
otherwise than as set forth in the Time of Sale Document, the effect of which, in any such case described in clause (i) or (ii) of this paragraph (l), is, in the judgment of the Initial Purchasers, so material and adverse as to make it
impracticable or inadvisable to proceed with the sale or delivery of the Securities on the terms and in the manner contemplated in the Time of Sale Document. 

(l) No Action or Legal Impediment. No action shall have been taken and no law, statute, rule, regulation or order shall have been enacted,
adopted or issued by any governmental agency or body which would prevent the issuance or sale of the Securities or materially and adversely affect or could be reasonably expected to materially and adversely affect the business or operations of the
Company; and no injunction, restraining order or order of any other nature by any federal or state court of competent jurisdiction shall have been issued which would prevent the issuance or sale of the Securities or materially and adversely affect
or could reasonably be expected to materially and adversely affect the business or operations of the Company. 
 (m) No Suspension in Trading; Banking
Moratorium. Subsequent to the execution and delivery of this Agreement there shall not have occurred any of the following: (i) trading in securities generally on the New York Stock Exchange, Nasdaq Global Market (the
“Nasdaq”) or the NYSE MKT LLC or in the over-the-counter market, or trading in any securities of the Company on any exchange or in the over-the-counter market, shall have been suspended or materially limited, or minimum or maximum prices or maximum range for prices shall have been established on any such
exchange or such market by the SEC, by such exchange or market or by any other regulatory body or governmental authority having jurisdiction, (ii) a banking moratorium shall have been declared by federal or state authorities or a material
disruption has occurred in commercial banking or securities settlement or clearance services in the United 

  
 Page 27 

 
States, (iii) the United States shall have become engaged in hostilities, or the subject of an act of terrorism, or there shall have been an outbreak of or escalation in hostilities
involving the United States, or there shall have been a declaration of a national emergency or war by the United States, or (iv) there shall have occurred such a material adverse change in general economic, political or financial conditions (or
the effect of international conditions on the financial markets in the United States shall be such), in the case of clauses (i), (ii), (iii) and (iv) above, so as to make it, in the judgment of the Initial Purchasers, impracticable or
inadvisable to proceed with the sale or delivery of the Securities on the terms and in the manner contemplated in the Time of Sale Document and the Final Offering Memorandum. 

(n) Good Standing. The Initial Purchasers shall have received on and as of such Closing Date satisfactory evidence of the good standing of the
Company and its Subsidiaries in their respective jurisdictions of organization and their good standing as foreign entities in such other jurisdictions as the Initial Purchasers may reasonably request, in each case in writing or any standard form of
telecommunication from the appropriate governmental authorities of such jurisdictions. 
 (o) Lock-up
Agreements. The Initial Purchasers shall have received the written agreements, substantially in the form of Exhibit A hereto, of the officers and directors of the Company listed in Exhibit B to this Agreement. 

(p) Listing Application. The Company shall have filed with the Nasdaq an application for the listing of the maximum number of Conversion Shares.

 (q) Additional Documentation. On or prior to such Closing Date, the Company shall have furnished to the Initial Purchasers such further
certificates and documents as the Initial Purchasers may reasonably request. 
 All opinions, letters, evidence and certificates mentioned above or
elsewhere in this Agreement shall be deemed to be in compliance with the provisions hereof only if they are in form and substance reasonably satisfactory to counsel for the Initial Purchasers. 

8. Indemnification and Contribution. 

(a) Indemnification by the Company. The Company shall indemnify and hold harmless: the Initial Purchasers, their respective directors,
officers, managers, members, employees, representatives and agents and each person, if any, who controls an Initial Purchaser within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act (collectively the
“Initial Purchaser Indemnified Parties,” and each an “Initial Purchaser Indemnified Party”) against any loss, claim, damage, expense or liability whatsoever (or any action, investigation or proceeding in respect
thereof), joint or several, to which such Initial Purchaser Indemnified Party may become subject, under the Securities Act or otherwise, insofar as such loss, claim, damage, expense, liability, action, investigation or proceeding arises out of or is
based upon (A) any untrue statement or alleged untrue statement of a material fact contained in the Time of Sale Document, the Final Offering Memorandum, or in any amendment or supplement thereto or document incorporated by reference therein,
or in any Company Additional Written Communication or (B) the omission or alleged omission to state in any Time of Sale Document, 

  
 Page 28 

 
the Final Offering Memorandum, or in any amendment or supplement thereto or document incorporated by reference therein, or in any Company Additional Written Communication, a material fact
required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they are made, not misleading, and shall reimburse each Initial Purchaser Indemnified Party promptly upon demand for any legal fees
or other expenses reasonably incurred by that Initial Purchaser Indemnified Party in connection with investigating, or preparing to defend, or defending against, or appearing as a third party witness in respect of, or otherwise incurred in
connection with, any such loss, claim, damage, expense, liability, action, investigation or proceeding, as such fees and expenses are incurred; provided, however, that the Company shall not be liable in any such case to the extent that
any such loss, claim, damage, expense or liability arises out of or is based upon an untrue statement or alleged untrue statement in, or omission or alleged omission from the Time of Sale Document, Final Offering Memorandum, or any amendment or
supplement thereto, or any Company Additional Written Communication made in reliance upon and in conformity with written information furnished to the Company by or on behalf of the Initial Purchasers specifically for use therein, which information
the parties hereto agree is limited to the Initial Purchasers’ Information (as defined in Section 14(d)). 
 The indemnity agreement in this
Section 8(a) is not exclusive and is in addition to each other liability which the Company might have under this Agreement or otherwise, and shall not limit any rights or remedies which may otherwise be available under this Agreement, at law or
in equity to any Initial Purchaser Indemnified Party. 
 (b) Indemnification by the Initial Purchaser. The Initial Purchasers, severally and
not jointly, shall indemnify and hold harmless the Company and its directors, its officers and each person, if any, who controls the Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act
(collectively the “Company Indemnified Parties” and each a “Company Indemnified Party”) against any loss, claim, damage, expense or liability whatsoever (or any action, investigation or proceeding in respect
thereof), joint or several, to which such Company Indemnified Party may become subject, under the Securities Act or otherwise, insofar as such loss, claim, damage, expense, liability, action, investigation or proceeding arises out of or is based
upon (i) any untrue statement or alleged untrue statement of a material fact contained in the Time of Sale Document, the Final Offering Memorandum, or in any amendment or supplement thereto or document incorporated by reference therein, or any
Company Additional Written Communication or (ii) the omission or alleged omission to state in any Time of Sale Document, the Final Offering Memorandum, or in any amendment or supplement thereto or document incorporated by reference therein, or
any Company Additional Written Communication, a material fact required to be stated therein or necessary to make the statements therein in light of the circumstances under which they are made not misleading, but in each case only to the extent that
the untrue statement or alleged untrue statement or omission or alleged omission was made in reliance upon and in conformity with written information furnished to the Company by or on behalf of the Initial Purchasers specifically for use therein,
which information the parties hereto agree is limited to the Initial Purchasers’ Information as defined in Section 14(d), and shall reimburse the Company Indemnified Parties for any legal or other expenses reasonably incurred by such party
in connection with investigating or preparing to defend or defending against or appearing as third party witness in connection with any such loss, claim, damage, liability, action, investigation or proceeding, as such fees and expenses are

  
 Page 29 

 
incurred. This indemnity agreement is not exclusive and will be in addition to any liability which the Initial Purchasers might otherwise have and shall not limit any rights or remedies which may
otherwise be available under this Agreement, at law or in equity to the Company Indemnified Parties. 
 (c) Notifications and Other Indemnification
Procedures. Promptly after receipt by an indemnified party under this Section 8 of notice of the commencement of any action, the indemnified party shall, if a claim in respect thereof is to be made against an indemnifying party under
this Section 8, notify such indemnifying party in writing of the commencement of that action; provided, however, that the failure to notify the indemnifying party shall not relieve it from any liability which it may have under this
Section 8 except to the extent it has been materially prejudiced by such failure; and, provided, further, that the failure to notify an indemnifying party shall not relieve it from any liability which it may have to an indemnified party
otherwise than under this Section 8. If any such action shall be brought against an indemnified party, and it shall notify the indemnifying party thereof, the indemnifying party shall be entitled to participate therein and, to the extent that
it wishes, jointly with any other similarly notified indemnifying party, to assume the defense of such action with counsel reasonably satisfactory to the indemnified party (which counsel shall not, except with the written consent of the indemnified
party, be counsel to the indemnifying party). After notice from the indemnifying party to the indemnified party of its election to assume the defense of such action, except as provided herein, the indemnifying party shall not be liable to the
indemnified party under Section 8 for any legal or other expenses subsequently incurred by the indemnified party in connection with the defense of such action other than reasonable costs of investigation; provided, however, that any
indemnified party shall have the right to employ separate counsel in any such action and to participate in the defense of such action but the fees and expenses of such counsel (other than reasonable costs of investigation) shall be at the expense of
such indemnified party unless (i) the employment thereof has been specifically authorized in writing by the Company in the case of a claim for indemnification under Section 8(a) or the Initial Purchasers in the case of a claim for
indemnification under Section 8(b), (ii) such indemnified party shall have been advised by its counsel that there may be one or more legal defenses available to it which are different from or additional to those available to the
indemnifying party, or (iii) the indemnifying party has failed to assume the defense of such action and employ counsel reasonably satisfactory to the indemnified party within a reasonable period of time after notice of the commencement of the
action or the indemnifying party does not diligently defend the action after assumption of the defense, in which case, if such indemnified party notifies the indemnifying party in writing that it elects to employ separate counsel at the expense of
the indemnifying party, the indemnifying party shall not have the right to assume the defense of (or, in the case of a failure to diligently defend the action after assumption of the defense, to continue to defend) such action on behalf of such
indemnified party and the indemnifying party shall be responsible for legal or other expenses subsequently and reasonably incurred by such indemnified party in connection with the defense of such action; provided, however, that the
indemnifying party shall not, in connection with any one such action or separate but substantially similar or related actions in the same jurisdiction arising out of the same general allegations or circumstances, be liable for the reasonable fees
and expenses of more than one separate firm of attorneys at any time for all such indemnified parties (in addition to any local counsel), which firm shall be designated in writing by the Initial Purchasers, if the indemnified parties under this
Section 8 consist of any Initial Purchaser Indemnified Party or by the Company if the indemnified parties under this Section 8 

  
 Page 30 

 
consist of any Company Indemnified Parties. Subject to this Section 8(c), the amount payable by an indemnifying party under Section 8 shall include, but not be limited to,
(x) reasonable legal fees and expenses of counsel to the indemnified party and any other expenses in investigating, or preparing to defend or defending against, or appearing as a third party witness in respect of, or otherwise incurred in
connection with, any action, investigation, proceeding or claim, and (y) all amounts paid in settlement of any of the foregoing. No indemnifying party shall, without the prior written consent of the indemnified parties, settle or compromise or
consent to the entry of judgment with respect to any pending or threatened action or any claim whatsoever, in respect of which indemnification or contribution could be sought under this Section 8 (whether or not the indemnified parties are
actual or potential parties thereto), unless such settlement, compromise or consent (i) includes an unconditional release of each indemnified party in form and substance reasonably satisfactory to such indemnified party from all liability
arising out of such action or claim and (ii) does not include a statement as to or an admission of fault, culpability or a failure to act by or on behalf of any indemnified party. Subject to the provisions of the following sentence, no
indemnifying party shall be liable for settlement of any pending or threatened action or any claim whatsoever that is effected without its written consent (which consent shall not be unreasonably withheld or delayed), but if settled with its written
consent, if its consent has been unreasonably withheld or delayed or if there be a judgment for the plaintiff in any such matter, the indemnifying party agrees to indemnify and hold harmless any indemnified party from and against any loss or
liability by reason of such settlement or judgment. In addition, if at any time an indemnified party shall have requested that an indemnifying party reimburse the indemnified party for reasonable fees and expenses of counsel, such indemnifying party
agrees that it shall be liable for any settlement of the nature contemplated by Section 8(a) or 8(b) effected without its written consent if (i) such settlement is entered into more than forty-five (45) days after receipt by such
indemnifying party of the request for reimbursement, (ii) such indemnifying party shall have received notice of the terms of such settlement at least thirty (30) days prior to such settlement being entered into and (iii) such
indemnifying party shall not have reimbursed such indemnified party in accordance with such request prior to the date of such settlement. 
 (d)
Contribution. If the indemnification provided for in this Section 8 is unavailable or insufficient to hold harmless an indemnified party under Section 8(a) or 8(b), then each indemnifying party shall, in lieu of indemnifying
such indemnified party, contribute to the amount paid, payable or otherwise incurred by such indemnified party as a result of such loss, claim, damage, expense or liability (or any action, investigation or proceeding in respect thereof), as
incurred, (i) in such proportion as shall be appropriate to reflect the relative benefits received by the Company on the one hand and the Initial Purchasers on the other from the offering of the Securities, or (ii) if the allocation
provided by clause (i) of this Section 8(d) is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) of this Section 8(d) but also the relative
fault of the Company on the one hand and the Initial Purchasers on the other with respect to the statements, omissions, acts or failures to act which resulted in such loss, claim, damage, expense or liability (or any action, investigation or
proceeding in respect thereof) as well as any other relevant equitable considerations. The relative benefits received by the Company on the one hand and the Initial Purchasers on the other with respect to such offering shall be deemed to be in the
same proportion as the total net proceeds from the offering of the Securities purchased under this Agreement (before deducting expenses) received by the Company bear to the total underwriting discounts and commissions received by the Initial
Purchasers with respect to the Securities 

  
 Page 31 

 
purchased under this Agreement, in each case as set forth in the table on the cover page of the Final Offering Memorandum. The relative fault of the Company on the one hand and the Initial
Purchasers on the other shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the
Company on the one hand or the Initial Purchasers on the other, the intent of the parties and their relative knowledge, access to information and opportunity to correct or prevent such untrue statement, omission, act or failure to act; provided
that the parties hereto agree that the written information furnished to the Company by or on behalf of the Initial Purchasers for use in the Time of Sale Document, the Final Offering Memorandum, or in any amendment or supplement thereto,
consists solely of the Initial Purchasers’ Information as defined in Section 14(d). 
 (e) Contribution. In circumstances in which
the indemnity agreements provided for in this Section is unavailable to, or insufficient to hold harmless, an indemnified party in respect of any losses, claims, damages, liabilities or expenses (or actions in respect thereof), each indemnifying
party, in order to provide for just and equitable contributions, shall contribute to the amount paid or payable by such indemnified party as a result of such losses, claims, damages, liabilities or expenses (or actions in respect thereof) in such
proportion as is appropriate to reflect (i) the relative benefits received by the indemnifying party or parties, on the one hand, and the indemnified party, on the other hand, from the Offering or (ii) if the allocation provided by the
foregoing clause (i) is not permitted by applicable law, not only such relative benefits but also the relative fault of the indemnifying party or parties, on the one hand, and the indemnified party, on the other hand, in connection with the
statements or omissions or alleged statements or omissions that resulted in such losses, claims, damages or liabilities (or actions in respect thereof). The relative benefits received by the Company, on the one hand, and the Initial Purchasers, on
the other hand, shall be deemed to be in the same proportion as the total proceeds from the Offering (before deducting expenses) received by the Company bear to the total discounts and commissions received by the Initial Purchasers. The relative
fault of the parties shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the
Company, on the one hand, or the Initial Purchasers pursuant to Section 8(b) above, on the other hand, the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission or
alleged statement or omissions, and any other equitable considerations appropriate in the circumstances. 
 (f) Equitable Consideration.
The Company and the Initial Purchasers agree that it would not be just and equitable if contributions pursuant to Section 8(d) above were to be determined by pro rata allocation or by any other method of allocation which does not take into
account the equitable considerations referred to in Section 8(d) above. The amount paid or payable by an indemnified party as a result of the loss, claim, damage, expense, liability, action, investigation or proceeding referred to in
Section 8(d) above shall be deemed to include, subject to the limitations set forth above, any legal or other expenses reasonably incurred by such indemnified party in connection with investigating, preparing to defend or defending against or
appearing as a third party witness in respect of, or otherwise incurred in connection with, any such loss, claim, damage, expense, liability, action, investigation or proceeding. Notwithstanding the provisions of this Section 8, the Initial
Purchasers shall not be required to contribute any amount in excess of the amount by which the total underwriting discounts and commissions received by the Initial 

  
 Page 32 

 
Purchasers with respect to the offering of the Securities exceeds the amount of any damages which the Initial Purchasers have otherwise paid or become liable to pay by reason of any untrue or
alleged untrue statement, omission or alleged omission, act or alleged act or failure to act or alleged failure to act. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be
entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. Each Initial Purchaser’s obligation to contribute hereunder shall be several in proportion to their respective purchase obligations hereunder and
not joint. 
 9. Termination. The obligations of the Initial Purchasers hereunder may be terminated by the Initial
Purchasers, in their absolute discretion by notice given to the Company prior to delivery of and payment for the Securities if, prior to that time, any of the events described in Sections 7(k), 7(l) or 7(m) have occurred or if the Initial Purchasers
shall decline to purchase the Securities for any reason permitted under this Agreement. 
 10. Reimbursement of Initial
Purchasers’ Expenses. Notwithstanding anything to the contrary in this Agreement, if (a) this Agreement shall have been terminated pursuant to Section 9, (b) the Company shall fail to tender the Securities for
delivery to the Initial Purchasers for any reason not permitted under this Agreement, (c) the Initial Purchasers shall decline to purchase the Securities for any reason permitted under this Agreement or (d) the sale of the Securities is
not consummated because any condition to the obligations of the Initial Purchasers set forth herein is not satisfied or because of the refusal, inability or failure on the part of the Company to perform any agreement herein or to satisfy any
condition or to comply with the provisions hereof, then in addition to the payment of amounts in accordance with Section 5(f), the Company shall reimburse the Initial Purchasers for the fees and expenses of Initial Purchasers’ counsel and
for such other out-of-pocket expenses as shall have been reasonably incurred by them in connection with this Agreement and the proposed purchase of the Securities,
including, without limitation, travel and lodging expenses of the Initial Purchasers, and upon demand the Company shall pay the full amount thereof to the Initial Purchasers. 

11. Defaulting Initial Purchaser. If, on the applicable Closing Date, any one of the Initial Purchasers shall fail or
refuse to purchase Securities that it has agreed to purchase hereunder on such date, and the aggregate principal amount of Securities which such defaulting Initial Purchaser agreed but failed or refused to purchase is not more than one tenth of the
aggregate principal amount of Securities to be purchased on such date, the other Initial Purchaser shall be obligated in the proportion that the principal amount of Securities set forth opposite its respective name in Schedule II hereto bears
to the aggregate principal amount of Securities set forth opposite the name of the non-defaulting Initial Purchaser to purchase the Securities which such defaulting Initial Purchaser agreed but failed or
refused to purchase on such date. If, on the applicable Closing Date any Initial Purchaser shall fail or refuse to purchase Securities which it has agreed to purchase hereunder on such date and the aggregate principal amount of Securities with
respect to which such default occurs is more than one tenth of the aggregate principal amount of Securities to be purchased on such date, and arrangements satisfactory to the non-defaulting Initial Purchaser
and the Company for the purchase of such Securities are not made within 36 hours after such default, this Agreement shall terminate without liability on the part of the non-defaulting Initial Purchaser or of
the Company. Any action taken under this Section shall 

  
 Page 33 

 
not relieve any defaulting Initial Purchaser from liability in respect of any default of such Initial Purchaser under this Agreement. 

12. Survival of Indemnities, Representations, Warranties, Etc. The respective indemnities, covenants, agreements,
representations, warranties and other statements of the Company and the Initial Purchasers, as set forth in this Agreement or made by them respectively, pursuant to this Agreement, shall remain in full force and effect, regardless of any
investigation made by or on behalf of the Initial Purchasers, the Company or any person controlling any of them and shall survive delivery of and payment for the Securities. Notwithstanding any termination of this Agreement, including without
limitation any termination pursuant to Section 9, the indemnities, covenants, agreements, representations, warranties and other statements forth in Sections 4, 5(f), 8 and 10 and Sections 11 through 14, inclusive, of this Agreement shall not
terminate and shall remain in full force and effect at all times. 
 13. Absence of Fiduciary Relationship. The Company
acknowledges and agrees that: 
 (a) the Initial Purchasers’ responsibility to the Company is solely contractual in nature, the Initial
Purchasers have been retained solely to act as initial purchasers in connection with the sale of the Securities and no fiduciary, advisory or agency relationship between the Company and the Initial Purchasers have been created in respect of any of
the transactions contemplated by this Agreement, irrespective of whether the Initial Purchasers have advised or are advising the Company on other matters; 

(b) the price of the Securities set forth in this Agreement was established by the Company following discussions and arms-length negotiations
with the Initial Purchasers and the Company is capable of evaluating and understanding, and understands and accepts, the terms, risks and conditions of the transactions contemplated by this Agreement; 

(c) it has been advised that the Initial Purchasers and their respective affiliates are engaged in a broad range of transactions which may
involve interests that differ from those of the Company and that the Initial Purchasers have no obligation to disclose such interests and transactions to the Company by virtue of any fiduciary, advisory or agency relationship; and 

(d) it waives, to the fullest extent permitted by law, any claims it may have against the Initial Purchasers for breach of fiduciary duty or
alleged breach of fiduciary duty and agrees that the Initial Purchasers shall have no liability (whether direct or indirect) to the Company in respect of such a fiduciary duty claim or to any person asserting a fiduciary duty claim on behalf of or
in right of the Company, including shareholders, employees or creditors of the Company. 
 14. Miscellaneous. 

(a) Notices. All statements, requests, notices and agreements hereunder shall be in writing, and: 

  
 Page 34 

 (i) if to the Initial Purchasers, shall be delivered or sent by mail, telex, facsimile
transmission or email to Cantor Fitzgerald & Co., Attention: General Counsel, Fax: (212) 829-4708 and Attention: Equity-Linked Capital Markets, 499 Park Avenue, 5th Floor, New York, NY 10022, and to UBS Securities LLC, 1285 6th Ave, New York, NY 10019; and 

(ii) if to the Company shall be delivered or sent by mail, telex, facsimile transmission or email to Omeros Corporation Attention: Greg
Demopulos and Marcia Kelbon, Fax: (206) 676-5005, email: gdemopulos@omeros.com; mkelbon@omeros.com; 
 Any such
statements, requests, notices or agreements shall take effect at the time of receipt thereof. 
 (b) Successors; Persons Entitled to Benefit of
Agreement. This Agreement shall inure to the benefit of and be binding upon the Initial Purchasers, the Company and their respective successors and assigns. Nothing expressed or mentioned in this Agreement is intended or shall be
construed to give any person, other than the persons mentioned in the preceding sentence, any legal or equitable right, remedy or claim under or in respect of this Agreement, or any provisions herein contained, this Agreement and all conditions and
provisions hereof being intended to be and being for the sole and exclusive benefit of such persons and for the benefit of no other person; except that the representations, warranties, covenants, agreements and indemnities of the Company contained
in this Agreement shall also be for the benefit of the Initial Purchaser Indemnified Parties, and the indemnities of the Initial Purchasers shall be for the benefit of the Company Indemnified Parties. It is understood that the Initial
Purchasers’ responsibility to the Company is solely contractual in nature and the Initial Purchasers do not owe the Company, or any other party, any fiduciary duty as a result of this Agreement. No purchaser of any of the Securities from an
Initial Purchaser shall be deemed to be a successor or assign by reason merely of such purchase. 
 (c) Governing Law and Jurisdiction.
This Agreement shall be governed by and construed in accordance with the laws of the State of New York, including without limitation Section 5-1401 of the New York General Obligations.
The Company irrevocably (a) submits to the non-exclusive jurisdiction of the federal and state courts in the Borough of Manhattan in The City of New York for the purpose of any suit, action or other
proceeding arising out of this Agreement or the transactions contemplated by this Agreement, the Time of Sale Document and the Final Offering Memorandum, (b) agrees that all claims in respect of any such suit, action or proceeding may be heard
and determined by any such court, (c) waives to the fullest extent permitted by applicable law, any immunity from the jurisdiction of any such court or from any legal process, (d) agrees not to commence any such suit, action or proceeding
other than in such courts, and (e) waives, to the fullest extent permitted by applicable law, any claim that any such suit, action or proceeding is brought in an inconvenient forum. 

(d) Initial Purchasers’ Information. The parties hereto acknowledge and agree that, for all purposes of this Agreement, the
Initial Purchasers’ Information consists solely of the statements set forth in the fourth paragraph and the second sentence of the fifth paragraph under the heading “Plan of Distribution” and statements set forth in the first
paragraph under the 

  
 Page 35 

 
caption “Plan of Distribution—Stabilization” in the Preliminary Offering Memorandum and the Final Offering Memorandum. 

(e) General. This Agreement constitutes the entire agreement of the parties to this Agreement and supersedes all prior written or oral and all
contemporaneous oral agreements, understandings and negotiations with respect to the subject matter hereof. In this Agreement, the masculine, feminine and neuter genders and the singular and the plural include one another. The section headings in
this Agreement are for the convenience of the parties only and will not affect the construction or interpretation of this Agreement. This Agreement may be amended or modified, and the observance of any term of this Agreement may be waived, only by a
writing signed by the Company and the Initial Purchasers. 
 (f) Counterparts. This Agreement may be signed in any number of counterparts,
each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. 
 (g) Definition of
Certain Terms. For purposes of this Agreement, (a) “business day” means any day on which the Nasdaq Global Market is open for trading and (b) “Subsidiary” has the meaning set forth in Rule 405 of the Rules and
Regulations but in no event shall “Subsidiary” include the Foreign Subsidiaries. 
 (h) Headings. The headings in this Agreement are
for convenience of reference only and shall not limit or otherwise affect the meaning hereof. 
 (i) Separability. If any term, provision,
covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and
effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their reasonable best efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such
term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be
hereafter declared invalid, illegal, void or unenforceable. 
 (j) Amendment. This Agreement may be amended, modified or supplemented, and
waivers or consents to departures from the provisions hereof may be given, provided that the same are in writing and signed by all of the signatories hereto. 

(k) USA Patriot Act and other Disclosures. The parties acknowledge that in accordance with the requirements of the USA
Patriot Act (Title III of Pub. L. 107-56 (signed into law October 26, 2011)), the Initial Purchasers are required to obtain, verify and record information that identifies its clients, including the
Company, which information may include the name and address of its clients, as well as other information that will allow the Initial Purchasers to properly identify their clients. The Company acknowledges that it has been informed by the Initial
Purchasers that subject to certain conditions, the Initial Purchasers may receive a fee from the Capped Call Counterparty in connection with the Capped Call Confirmations. 

  
 Page 36 

 Please confirm that the foregoing correctly sets forth the agreement between the Company and
the Initial Purchasers. 
  

			
	 Very truly yours,
  

OMEROS CORPORATION

		
	By:	 	/s/ Gregory A. Demopulos, M.D.
		 	Name:  Gregory A. Demopulos, M.D.
		 	Title:    Chairman & CEO

  

			
	 Accepted and Agreed to:
  

CANTOR FITZGERALD & CO.

		
	By:	 	/s/ John Belle
		 	Name:  John Belle
		 	Title:    COO

  

			
	UBS SECURITIES LLC
		
	By:	 	/s/ Alexander Li
		 	Name:  Alexander Li
		 	Title:    Authorized Signatory
		
	By:	 	/s/ Christian Parrish
		 	Name:  Christian Parrish
		 	Title:    Associate Director

  
 [Signature Page to
Purchase Agreement] 

 SCHEDULE I 

PRICING SUPPLEMENT 

[Attached] 

			
	 PRICING TERM SHEET
 November 8,
2018
	  	CONFIDENTIAL

 Omeros Corporation 

Offering of 
 $210,000,000
Aggregate Principal Amount of 
 6.25% Convertible Senior Notes due 2023 

The information in this pricing term sheet supplements Omeros Corporation’s preliminary offering memorandum, dated November 8, 2018 (the
“Preliminary Offering Memorandum”), and supersedes the information in the Preliminary Offering Memorandum to the extent inconsistent with the information in the Preliminary Offering Memorandum. Terms used, but not defined, in this pricing
term sheet have the respective meanings set forth in the Preliminary Offering Memorandum. As used in this pricing term sheet, “we,” “our” and “us” refer to Omeros Corporation and not to its subsidiaries. 

 

	 Issuer 
	Omeros Corporation. 

  

	 Ticker / Exchange for Common Stock 
	OMER / Nasdaq Global Market (“Nasdaq”). 

  

	 Trade Date 
	November 9, 2018. 

  

	 Settlement Date 
	November 15, 2018 (T+4). Currently, trades in the secondary market for convertible notes ordinarily settle two trading days after the date of execution, unless the parties to the trade agree otherwise. Accordingly, investors in this
offering who wish to sell their Notes before the second trading day preceding the Settlement Date must specify an alternate settlement arrangement at the time of the trade to prevent a failed settlement. Those investors should consult their
advisors. 

  

	 Notes 
	6.25% convertible senior notes due 2023 (the “Notes”). 

  

	 Principal Amount 
	$210,000,000 (or, if the initial purchasers fully exercise their option to purchase additional Notes, $250,000,000) aggregate principal amount of Notes. 

  

	 Offering Price 
	100% of the principal amount of the Notes, plus accrued interest, if any, from the Settlement Date. 

  

	 Maturity 
	November 15, 2023, unless earlier repurchased, redeemed or converted. 

  
 Page 39 

	 Stated Interest Rate 
	6.25% per annum. 

  

	 Interest Payment Dates 
	May 15 and November 15 of each year, beginning on May 15, 2019. 

  

	 Record Dates 
	May 1 and November 1. 

  

	 Last Reported Sale Price per Share of Common Stock on Nasdaq on November 8, 2018 
	$16.02. 

  

	 Conversion Premium 
	Approximately 20% above the Last Reported Sale Price per Share of Common Stock on Nasdaq on November 8, 2018. 

  

	 Initial Conversion Price 
	Approximately $19.22 per share of our common stock. 

  

	 Initial Conversion Rate 
	52.0183 shares of our common stock per $1,000 principal amount of Notes. 

  

	 Use of Proceeds 
	 We estimate that the net proceeds to us from this offering will be approximately $203.2 million (or approximately $242.0 million if the
initial purchasers fully exercise their option to purchase additional Notes), after deducting the initial purchasers’ discounts and commissions and our estimated offering expenses. We intend to use approximately $146.0 million of the net
proceeds to repay in full the amounts outstanding under our Term Loan Agreement, or the CRG Loan Agreement, with CRG Servicing LLC, as administrative and collateral agent and the lenders named therein, which will include payment of the facility and
prepayment fees, and accrued but unpaid interest under the CRG Loan Agreement. We also intend to use approximately $33.2 million of the net proceeds to fund the cost of entering into the capped call transaction described in the Preliminary
Offering Memorandum. We intend to use the remainder of the net proceeds for general corporate purposes, including funding research and development for our OMS721 programs and clinical trials, pre-clinical
studies, manufacturing and other costs associated with advancing our product candidates toward Marketing Authorization 

  
 Page 40 

	 	 
Application, Biologics License Application and New Drug Application submissions. If the initial purchasers exercise their option to purchase additional Notes, then we expect to use a portion of
the additional net proceeds to fund the cost of entering into an additional capped call transaction. 

  

	 Sole Structuring Advisor 
	Cantor Fitzgerald & Co. 

  

	 Joint Bookrunners 
	Cantor Fitzgerald & Co. 

  

	 	UBS Securities LLC 

  

	 CUSIP / ISIN Numbers 
	682143 AF9 / US682143AF97. 

  

	 Increase to Conversion Rate in Connection with a Make-Whole Fundamental Change 
	If a make-whole fundamental change occurs and the conversion date for the conversion of a Note occurs during the related make-whole fundamental change conversion period, then, subject to the provisions described in the Preliminary Offering
Memorandum under the caption “Description of Notes—Conversion Rights—Increase in Conversion Rate in Connection with a Make-Whole Fundamental Change,” the conversion rate applicable to such conversion will be increased by a number
of shares set forth in the table below corresponding (after interpolation, as described below) to the effective date and the stock price of such make-whole fundamental change: 

 

																																																					
	 	  	Stock Price	 
	 Effective Date
	  	$16.02	 	  	$17.00	 	  	$18.00	 	  	$19.22	 	  	$22.00	 	  	$25.00	 	  	$28.83	 	  	$45.00	 	  	$60.00	 	  	$75.00	 	  	$90.00	 	  	$105.00	 	  	$125.00	 
	 November 15, 2018
	  	 	10.4036	 	  	 	10.4036	 	  	 	10.4036	 	  	 	10.2836	 	  	 	7.2386	 	  	 	4.9296	 	  	 	3.0097	 	  	 	0.8380	 	  	 	0.4965	 	  	 	0.3036	 	  	 	0.1753	 	  	 	0.0837	 	  	 	0.0000	 
	 November 15, 2019
	  	 	10.4036	 	  	 	10.4036	 	  	 	10.4036	 	  	 	9.6748	 	  	 	6.6805	 	  	 	4.3388	 	  	 	2.0905	 	  	 	0.0000	 	  	 	0.0000	 	  	 	0.0000	 	  	 	0.0000	 	  	 	0.0000	 	  	 	0.0000	 
	 November 15, 2020
	  	 	10.4036	 	  	 	10.4036	 	  	 	10.4036	 	  	 	8.9475	 	  	 	6.0605	 	  	 	3.9228	 	  	 	1.9043	 	  	 	0.0000	 	  	 	0.0000	 	  	 	0.0000	 	  	 	0.0000	 	  	 	0.0000	 	  	 	0.0000	 
	 November 15, 2021
	  	 	10.4036	 	  	 	10.0857	 	  	 	9.7678	 	  	 	7.9017	 	  	 	5.0673	 	  	 	3.2248	 	  	 	1.5914	 	  	 	0.0000	 	  	 	0.0000	 	  	 	0.0000	 	  	 	0.0000	 	  	 	0.0000	 	  	 	0.0000	 
	 November 15, 2022
	  	 	10.4036	 	  	 	9.5663	 	  	 	8.7289	 	  	 	6.4631	 	  	 	3.4145	 	  	 	1.9936	 	  	 	1.0420	 	  	 	0.0000	 	  	 	0.0000	 	  	 	0.0000	 	  	 	0.0000	 	  	 	0.0000	 	  	 	0.0000	 
	 November 15, 2023
	  	 	10.4036	 	  	 	6.8052	 	  	 	3.5373	 	  	 	0.0000	 	  	 	0.0000	 	  	 	0.0000	 	  	 	0.0000	 	  	 	0.0000	 	  	 	0.0000	 	  	 	0.0000	 	  	 	0.0000	 	  	 	0.0000	 	  	 	0.0000	 

 If such effective date or stock price is not set forth in the table above, then: 

 

	 	•	 	 if such stock price is between two stock prices in the table above or the effective date is between two dates in
the table above, then the number of additional shares will be determined by a straight-line interpolation between the numbers of additional shares set forth for the higher and lower stock prices in the table and the earlier and later dates in the
table above, as applicable, based on a 365- or 366-day year, as applicable; and 

 

	 	•	 	 if the stock price is greater than $125.00 (subject to adjustment in the same manner as the stock prices set
forth in the column headings of the table above are adjusted, as described 

  
 Page 41 

	 	 
in the Preliminary Offering Memorandum under the caption “Description of Notes—Conversion Rights—Increase in Conversion Rate in Connection with a Make-Whole Fundamental
Change—Adjustment of Stock Prices and Number of Additional Shares”), or less than $16.02 (subject to adjustment in the same manner), per share, then no additional shares will be added to the conversion rate. 

Notwithstanding anything to the contrary, in no event will the conversion rate be increased to an amount that exceeds 62.4219 shares of our common stock per
$1,000 principal amount of Notes, which amount is subject to adjustment in the same manner as, and at the same time and for the same events for which, the conversion rate is required to be adjusted pursuant to the provisions described in the
Preliminary Offering Memorandum under the caption “Description of Notes—Conversion Rights—Conversion Rate Adjustments—Generally.” 

* * * 
 This communication is confidential and
is intended for the sole use of the person to whom it is provided by the sender. The information in this pricing term sheet does not purport to be a complete description of the Notes or the offering. 

The offer and sale of the Notes and any shares of common stock issuable upon conversion of the Notes have not been, and will not be,
registered under the Securities Act of 1933, as amended (the “Securities Act”), or any other securities laws, and the Notes and any such shares cannot be offered or sold except pursuant to an exemption from, or in a transaction not subject
to, the registration requirements of the Securities Act and any other applicable securities laws. The initial purchasers are initially offering the Notes only to qualified institutional buyers as defined in, and in reliance on, Rule 144A under the
Securities Act. The Notes and any shares of common stock issuable upon conversion of the Notes are not transferable except in accordance with the restrictions described in the Preliminary Offering Memorandum under the caption “Transfer
Restrictions.” 
 You should rely only on the information contained or incorporated by reference in the Preliminary Offering Memorandum, as
supplemented by this pricing term sheet, in making an investment decision with respect to the Notes. 
 Neither this pricing term sheet nor the
Preliminary Offering Memorandum constitutes an offer to sell or a solicitation of an offer to buy any Notes in any jurisdiction where it is unlawful to do so, where the person making the offer is not qualified to do so or to any person who cannot
legally be offered the Notes. 
 ANY DISCLAIMERS OR OTHER NOTICES THAT MAY APPEAR BELOW ARE NOT APPLICABLE TO THIS COMMUNICATION AND SHOULD BE
DISREGARDED. SUCH DISCLAIMERS OR OTHER NOTICES WERE AUTOMATICALLY GENERATED AS A RESULT OF THIS COMMUNICATION BEING SENT VIA BLOOMBERG OR ANOTHER EMAIL SYSTEM. 

  
 Page 42 

 SCHEDULE II 

INITIAL PURCHASERS 
  

					
	 Initial Purchasers
	  	Principal
Amount	 
	 Cantor Fitzgerald & Co.
	  	$	171,500,000	 
	 UBS Securities LLC
	  	$	38,500,000	 
		  	  
	  
	 
	 Total
	  	$	210,000,000	 

 EXHIBIT A 

Form of Lock-up Agreement 

November     , 2018 
 Cantor
Fitzgerald & Co. 
 499 Park Avenue 
 New York, NY
10022 
  

	RE:	 Omeros Corporation (the “Company”) 

Ladies & Gentlemen: 
 This agreement is being delivered
to you in connection with the proposed Purchase Agreement (the “Purchase Agreement”) among Omeros Corporation, a Washington corporation (the “Company”), Cantor Fitzgerald & Co. (“Cantor”)
and UBS Securities LLC, relating to the proposed issuance by the Company of its 6.25% Convertible Senior Notes due 2023 (the “Securities”). 

In order to induce you to enter into the Purchase Agreement, and in light of the benefits that the offering of Securities will confer upon the undersigned in
its capacity as a securityholder and/or an officer, director or employee of the Company, and for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the undersigned agrees with Cantor that, during the
period beginning on and including the date of the Purchase Agreement through and including the date that is the 60th day after the date of the Purchase Agreement (the “Lock-Up Period”), the
undersigned will not, without the prior written consent of Cantor, directly or indirectly, (i) offer, sell, assign, transfer, pledge, contract to sell, or otherwise dispose of, or announce the intention to otherwise dispose of, any shares of
the common stock, par value $0.01 per share, of the Company (the “Common Stock”) (including, without limitation, Common Stock which may be deemed to be beneficially owned by the undersigned in accordance with the rules and
regulations promulgated by the Securities and Exchange Commission, as the same may be amended or supplemented from time to time) or securities convertible into or exercisable or exchangeable in Common Stock, (ii) enter into any swap, hedge or
similar agreement or arrangement that transfers in whole or in part, the economic risk of ownership of the Common Stock or securities convertible into or exercisable or exchangeable in Common Stock, whether now owned or hereafter acquired by the
undersigned or with respect to which the undersigned has or hereafter acquires the power of disposition, or (iii) engage in any short selling of Common Stock. 

The restrictions set forth in the immediately preceding paragraph shall not apply to: 

(1) if the undersigned is a natural person, any transfers made by the undersigned (a) as a bona fide gift to any member of the immediate family (as
defined below) of the undersigned or to a trust the beneficiaries of which are exclusively the undersigned or members of the undersigned’s 

  
 A-1 

 
immediate family, (b) by will or intestate succession upon the death of the undersigned or (c) as a bona fide gift to a charity, non-profit
organization or educational institution, 
 (2) if the undersigned is a corporation, partnership, limited liability company or other business entity, any
transfers to any shareholder, partner or member of, or owner of a similar equity interest in, the undersigned, as the case may be, if, in any such case, such transfer is not for value, 

(3) if the undersigned is a corporation, partnership, limited liability company or other business entity, any transfer made by the undersigned (a) in
connection with the sale or other bona fide transfer in a single transaction of all or substantially all of the undersigned’s capital stock, partnership interests, membership interests or other similar equity interests, as the case may be, or
all or substantially all of the undersigned’s assets, in any such case not undertaken for the purpose of avoiding the restrictions imposed by this agreement or (b) to another corporation, partnership, limited liability company or other
business entity so long as the transferee is an affiliate (as defined below) of the undersigned and such transfer is not for value; 
 (4) the transfer or
sale of any shares of Common Stock or other securities pursuant to any contract, instruction or plan meeting the requirements of Rule 10b5-1 under the Exchange Act, that has been entered into by the
undersigned (or a member of the undersigned’s immediate family) prior to the date of the Purchase Agreement; 
 (5)(i) the pledge of any shares of
Common Stock or other securities pursuant to a loan or security agreement between the undersigned (or a member of the undersigned’s immediate family) and a bank or other financial institution that has been entered into by the parties thereto
prior to the date of the Purchase Agreement, (ii) the pledge of any shares of Common Stock or other securities pursuant to a refinancing, repricing or other amendment to any such loan or security agreement, whether or not with the same lender,
that occurs on or after the date hereof and (iii) any transfer or sale of any shares of Common Stock or securities thereunder; provided, that the undersigned or other holder of the pledged shares or other securities notifies Cantor if there is
a default or other event pursuant to which such bank or other financial institution would be permitted to foreclose on such shares or other securities or pursuant to which the undersigned or the holder of such pledged shares or other securities
would otherwise be required to transfer or sell such shares or other securities prior to any such foreclosure, transfer or sale; and [NOTE: This clause 5 to be included only in lock-up agreements for
Greg Demopulos and the Demopulos Family Trust.]  
 provided, however, that in the case of any transfer described in clause (1)(a), 1(b), (2) or
(3) above, it shall be a condition to the transfer that (A) the transferee executes and delivers to Cantor, not later than one business day prior to such transfer, a written agreement, in substantially the form of this agreement (it being
understood that any references to “immediate family” in the agreement executed by such transferee shall expressly refer only to the immediate family of the undersigned and not to the immediate family of the transferee) and otherwise
satisfactory in form and substance to Cantor, and (B) if the undersigned is required to file a report under Section 16(a) of the Exchange Act reporting a reduction in beneficial ownership of shares of Common Stock or any securities
convertible into or exercisable or exchangeable for 

  
 Page 2 

 
Common Stock during the Lock-Up Period (as the same may be extended as described above), the undersigned shall include a statement in such report to the
effect that, in the case of any transfer pursuant to clause (1) above, such transfer is being made as a gift or by will or intestate succession or, in the case of any transfer pursuant to clause (2) above, such transfer is being made to a
shareholder, partner or member of, or owner of a similar equity interest in, the undersigned and is not a transfer for value or, in the case of any transfer pursuant to clause (3) above, such transfer is being made either (a) in connection
with the sale or other bona fide transfer in a single transaction of all or substantially all of the undersigned’s capital stock, partnership interests, membership interests or other similar equity interests, as the case may be, or all or
substantially all of the undersigned’s assets or (b) to another corporation, partnership, limited liability company or other business entity that is an affiliate of the undersigned and such transfer is not for value. 

Notwithstanding the restrictions described herein, the undersigned may at any time after the date hereof (A) exercise any options or warrants to purchase
shares of Common Stock (including any cashless exercise to the extent permitted by the instruments representing such options or warrants); provided that in any such case the shares of Common Stock issued upon exercise shall remain subject to the
provisions of this agreement and, if the undersigned is required to file a report under Section 16(a) of the Exchange Act during the Lock-Up Period (as the same may be extended as described above) in
connection with such exercise, the undersigned shall include a statement in such report to the effect that such disposition was pursuant to cashless exercise of an option or warrant, as applicable, or (B) enter into a trading plan (a
“New Plan”) meeting the requirements of Rule 10b5-1 under the Exchange Act, relating to the sale of shares of Common Stock or other securities, if then permitted by the Company and applicable
law; provided, that the shares of Common Stock or other securities subject to such New Plan shall not be sold during the Lock-Up Period if such sale is otherwise prohibited by this agreement. For purposes of
this paragraph, “immediate family” shall mean a spouse, domestic partner, child, grandchild or other lineal descendant (including by adoption), father, mother, brother or sister of the undersigned; and “affiliate” shall have the
meaning set forth in Rule 405 under the Securities Act. 
 The undersigned further agrees that (i) it will not, during the Lock-Up Period (as the same may be extended as described above), make any demand or request for or exercise any right with respect to the registration under the Securities Act, of any shares of Common Stock or any
securities convertible into or exercisable or exchangeable for Common Stock, and (ii) the Company may, with respect to any Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock owned or held (of record
or beneficially) by the undersigned, cause the transfer agent or other registrar to enter stop transfer instructions and implement stop transfer procedures with respect to such securities during the Lock-Up
Period (as the same may be extended as described above). In addition, the undersigned hereby waives, from the date hereof until the expiration of the Lock-Up Period and any extension of such period pursuant to
the terms hereof, any and all rights, if any, to request or demand registration pursuant to the Securities Act, of any shares of Common Stock that are registered in the name of the undersigned. 

It is understood that, if (i) the Company notifies Cantor in writing that it does not intend to proceed with the offering of Securities contemplated by
the Purchase Agreement; (ii) if the 

  
 Page 3 

 
Purchase Agreement relating to the offering of Securities is not executed on or before November 30, 2018; or (iii) the Purchase Agreement (other than the provisions thereof that survive
termination) shall terminate or be terminated for any reason prior to payment for and delivery of the Securities to be sold thereunder, this agreement shall immediately terminate and the undersigned shall automatically be released from all of his,
her or its obligations under this agreement. 
 The undersigned hereby represents and warrants that the undersigned has full power and authority to enter
into this agreement and that this agreement has been duly authorized (if the undersigned is not a natural person), executed and delivered by the undersigned and is a valid and binding agreement of the undersigned. This agreement and all authority
herein conferred are irrevocable and shall survive the death or incapacity of the undersigned (if a natural person) and shall be binding upon the heirs, personal representatives, successors and assigns of the undersigned. 

This agreement shall be governed by and construed in accordance with the law of the State of New York, without regard to the conflict of laws principles
thereof. 
 The undersigned acknowledges and agrees that whether or not any offering of Securities actually occurs depends on a number of factors, including
market conditions. 
 [signature page follows] 

  
 Page 4 

 Very truly yours, 
  

									
	IF AN INDIVIDUAL:	 		 	IF AN ENTITY:
				
	By:	 	 	 		 	 
		 	(duly authorized signature)	 		 	(please print complete name of entity)
					
	Name:	 	 	 		 	By:	 	 
		 	(please print full name)	 		 		 	(duly authorized signature)
					
		 		 		 	Name:	 	 
		 		 		 		 	(please print full name)
					
	Date:	 	 	 		 	Date:	 	 

 [Signature Page to Lock-Up Agreement] 

  
 Page 5 

 EXHIBIT B 

PERSONS DELIVERING LOCK-UP AGREEMENT 

Directors and Officers: 
  

	1.	 Gregory A. Demopulos, M.D. 

 

	2.	 Ray Aspiri 

  

	3.	 Thomas J. Cable 

  

	4.	 Peter A. Demopulos, M.D. 

 

	5.	 Leroy E. Hood, M.D., Ph.D. 

 

	6.	 Arnold C. Hanish 

  

	7.	 Rajiv Shah, M.D. 

  

	8.	 Michael A. Jacobsen 

  

	9.	 Marcia S. Kelbon, J.D., M.S. 

Entities: 
  

	1.	 The Demopulos Family Trust 

 

	2.	 Aspiri Enterprises LLC 

  
 1EX-10.2

 Exhibit 10.2 

DATE: [    ] 
  

			
	TO:	  	 Omeros Corporation
 201 Elliott Avenue West

Seattle
 Washington, 98119

	 ATTENTION:
 TELEPHONE:

FACSIMILE:
	  	 [    ]

[    ]

[    ]

		
	 FROM:
 TELEPHONE:

FACSIMILE:
	  	 [    ]

[    ]

[    ]

		
	SUBJECT:	  	[Base] [Additional] Capped Call Transaction

 The purpose of this communication (this “Confirmation”) is to set forth the terms and conditions of the above-referenced transaction entered into on the Trade Date specified below (the “Transaction”) between [    ] (“Dealer”) and Omeros Corporation
(“Counterparty”). This communication constitutes a “Confirmation” as referred to in the ISDA Master Agreement specified below. 

1.   This Confirmation is subject to, and incorporates, the definitions and provisions of the 2002 ISDA Equity Derivatives
Definitions (the “Equity Definitions”), as published by the International Swaps and Derivatives Association, Inc. (“ISDA”). Certain defined terms used herein have the meanings assigned to them in the Indenture to be
dated November 15, 2018, between Counterparty and Wells Fargo Bank, National Association, as trustee (the “Indenture”) relating to the USD210,000,000 principal amount of 6.25% Convertible Senior Notes due 2023 [(the
“Initial Securities”) and the additional USD40,000,000 principal amount of 6.25% Convertible Senior Notes due 2023 issued pursuant to the option to purchase additional convertible securities exercised on the date hereof] ([the
“Option Securities” and, together with the Initial Securities,] the “Convertible Securities”). In the event of any inconsistency between the terms defined in the Indenture and this Confirmation, this Confirmation
shall govern. For the avoidance of doubt, references herein to sections of the Indenture are based on [the draft of the Indenture most recently reviewed by the parties at the time of execution of this Confirmation. If any relevant sections of the
Indenture are changed, added or renumbered following execution of this Confirmation but prior to the execution of the Indenture, the parties will amend this Confirmation in good faith to preserve the economic intent of the parties based on the draft
of the Indenture so reviewed] [the Indenture as executed]. The parties further acknowledge that references to the Indenture herein are references to the Indenture as in effect on the date of its execution and if the Indenture is amended following
its execution, any such amendment will be disregarded for purposes of this Confirmation (other than as provided in Section 8(c) below) unless the parties agree otherwise in writing. 

This Confirmation evidences a complete and binding agreement between Dealer and Counterparty as to the terms of the Transaction to which this
Confirmation relates. This Confirmation shall be subject to an agreement (the “Agreement”) in the form of the ISDA 2002 Master Agreement as if Dealer and Counterparty had executed an agreement in such form (without any Schedule
except for (i) the election of US Dollars (“USD”) as the Termination Currency, and (ii) (a) the election that the “Cross Default” provisions of Section 5(a)(vi) of the Agreement shall apply to Dealer
with a “Threshold Amount” of three percent of Dealer’s shareholders’ equity; provided that “Specified Indebtedness” shall not include obligations in respect of deposits received in the ordinary course of
Dealer’s banking business, (b) the phrase “or becoming capable at such time of being declared” shall be deleted from clause (1) of such Section 5(a)(vi) and (c) the following language shall be added to the end
thereof: “Notwithstanding the foregoing, a default under subsection (2) hereof shall not constitute an Event of Default if (x) the default was caused solely by error or omission of an administrative or operational nature;
(y) funds were available to enable the party to make the payment when due; and (z) the payment is made within two Local Business Days of such party’s receipt of written notice of its failure to pay.”). For the avoidance of doubt,
the Transaction shall be the only transaction under the Agreement. 

 All provisions contained in, or incorporated by reference to, the Agreement will govern this
Confirmation except as expressly modified herein. In the event of any inconsistency between this Confirmation and either the Equity Definitions or the Agreement, this Confirmation shall govern, and in the event of any inconsistency between either
the Equity Definitions or this Confirmation and the Agreement, the Equity Definitions or this Confirmation, as the case may be, shall govern. For the avoidance of doubt, except to the extent of an express conflict, the application of any provision
of this Confirmation, the Agreement or the Equity Definitions shall not be construed to exclude or limit the application of any other provision of this Confirmation, the Agreement or the Equity Definitions. 

2.   The Transaction constitutes a Share Option Transaction for purposes of the Equity Definitions. The terms of the particular
Transaction to which this Confirmation relates are as follows: 
  

	 Trade Date: 
	[      ] 

  

	 Effective Date: 
	The closing date for the [initial] issuance of the Convertible Securities [issued pursuant to the option to purchase additional Convertible Securities exercised on the date hereof] 

 

	 Option Type: 
	Call 

  

	 Seller: 
	Dealer 

  

	 Buyer: 
	Counterparty 

  

	 Shares: 
	The common stock of Counterparty, par value USD0.01 per share (Ticker Symbol: “OMER”). 

  

	 Number of Options: 
	[      ]. For the avoidance of doubt, the Number of Options shall be reduced by any Options exercised hereunder. In no event will the Number of Options be less than zero. 

 

	 Cap Price: 
	[      ]. For the avoidance of doubt, the Cap Price shall be subject to adjustment from time to time to the extent provided herein. 

 

	 Number of Shares: 
	As of any date, the product of the Number of Options and the Option Entitlement. 

  

	 Option Entitlement: 
	The product of the Applicable Percentage and the Conversion Rate. 

  

	 Applicable Percentage: 
	100%. 

  

	 Conversion Rate: 
	[      ]. For the avoidance of doubt, the Conversion Rate shall be subject to adjustment from time to time, as described under “Method of Adjustment” below. 

 

	 Premium: 
	USD[      ] 

  

	 Premium Payment Date: 
	The Effective Date. 

  

	 Exchange: 
	The Nasdaq Global Market. 

  

	 Related Exchanges: 
	All Exchanges. 

 Procedure for Exercise: 
  

	 Exercise Dates: 
	Each Conversion Date. 

  

	 Conversion Date: 
	 Each “Conversion Date” for Convertible Securities, each in denominations of USD1,000 principal amount, that are submitted for conversion on
such Conversion Date in accordance with the terms of the Indenture [that are not “Relevant Convertible Securities” under (and as defined in) the confirmation between the parties hereto regarding the Base Capped Call Transaction dated
[    ], 2018 (Transaction Ref. No. [    ]) (the “Base Capped Call Transaction 

  
 2 

	 	 
Confirmation”)]; provided that, no Conversion Date shall be deemed to have occurred with respect to Excluded Convertible Securities [or “Excluded Convertible
Securities” under (and as defined in) the Base Capped Call Transaction Confirmation] (such Convertible Securities, other than Excluded Convertible Securities and “Excluded Convertible Securities” under (and as defined in) the Base
Capped Call Transaction Confirmation, the “Relevant Convertible Securities” for such Conversion Date). [For the purposes of determining whether any Convertible Securities will be Relevant Convertible Securities or Excluded
Convertible Securities hereunder, or “Relevant Convertible Securities” or “Excluded Convertible Securities” under, and as defined in, the Base Capped Call Transaction Confirmation, Convertible Securities that are converted
pursuant to the Indenture shall be allocated first to the Base Capped Call Transaction Confirmation until all Options thereunder are exercised or terminated.] 

 

	 Required Exercise on Conversion Dates: 
	On each Conversion Date, a number of Options equal to the lesser of (i) the number of Relevant Convertible Securities for such Conversion Date in denominations of USD1,000 principal amount and (ii) the Number of Options on such date
shall be automatically exercised. 

  

	 Expiration Date: 
	November 15, 2023 

  

	 Automatic Exercise: 
	As provided under “Required Exercise on Conversion Dates”. 

  

	 Exercise Notice Deadline: 
	In respect of any exercise of Options hereunder on any Conversion Date, the Exchange Business Day immediately following such Conversion Date; provided that in the case of any exercise of Options hereunder in connection with the conversion
of any Relevant Convertible Securities on any Conversion Date occurring during the period beginning on the 95th Scheduled Trading Day immediately preceding the Expiration Date and ending on and including the second Scheduled Trading Day
immediately preceding the Expiration Date (the “Free Convertibility Period”), the Exercise Notice Deadline shall be the Scheduled Trading Day immediately preceding the Expiration Date. 

  
 3 

	 Notice of Exercise: 
	Notwithstanding anything to the contrary herein or in the Equity Definitions, Dealer shall have no obligation to make any payment or delivery in respect of any exercise of Options hereunder unless Counterparty notifies Dealer in writing (the
“Notice of Exercise”) prior to 4:00 PM, New York City time, on the Exercise Notice Deadline in respect of such exercise of (i) the number of Options being exercised on the relevant Exercise Date, (ii) the scheduled
settlement date under the Indenture for the Convertible Securities converted on the Conversion Date corresponding to such Exercise Date, (iii) whether such Convertible Securities will be settled by Counterparty by delivery of cash, Shares or a
combination of cash and Shares and, if such a combination, the “Specified Dollar Amount” (as defined in the Indenture) and (iv) the first Scheduled Trading Day of the Settlement Averaging Period; provided that in the case of
any exercise of Options hereunder in connection with the conversion of any Relevant Convertible Securities on any Conversion Date occurring during the Free Convertibility Period, the contents of such notice shall be as set forth in clause
(i) above[; provided, further, that any “Notice of Exercise delivered to Dealer pursuant to the Base Capped Call Transaction Confirmation shall be deemed to be a Notice of Exercise pursuant to this Confirmation and the terms of such
Notice of Exercise shall apply, mutatis mutandis, to this Confirmation]. For the avoidance of doubt, if Counterparty fails to give such notice when due in respect of any exercise of Options hereunder, Dealer’s obligation to make any
payment or delivery in respect of such exercise shall be permanently extinguished, and late notice shall not cure such failure; provided that notwithstanding the foregoing, such notice (and the related exercise of Options) shall be effective
if given after the Exercise Notice Deadline, but prior to 4:00 PM New York City time, on the fifth Exchange Business Day following the Exercise Notice Deadline, in which event the Calculation Agent shall have the right to adjust the Delivery
Obligation as appropriate to reflect the commercially reasonable additional costs (including, but not limited to, hedging mismatches and market losses) and expenses incurred by Dealer in connection with its commercially reasonable hedging activities
(including the unwinding of any commercially reasonable hedge position) as a result of Dealer not having received such notice on or prior to the Exercise Notice Deadline. 

 

	 Notice of Convertible Security Settlement Method: 
	Counterparty shall notify Dealer in writing before 4:00 P.M. (New York City time) on the 95th Scheduled Trading Day preceding the Expiration Date of the irrevocable election by the Counterparty, in accordance with Section 5.03(A)
of the Indenture, of the settlement method and, if applicable, the “Specified Dollar Amount” (as defined in the Indenture) applicable to Relevant Convertible Securities with a Conversion Date occurring on or after the 95th Scheduled
Trading Day preceding the Expiration Date. If Counterparty fails timely to provide such notice, Counterparty shall be deemed to have notified Dealer of combination settlement with a “Specified Dollar Amount” (as defined in the Indenture)
of USD1,000 for all conversions occurring on or after the 95th Scheduled Trading Day preceding the Expiration Date. Counterparty agrees that it shall settle any Relevant Convertible Securities with a Conversion Date occurring during the Free
Convertibility Period in the same manner as provided in the Notice of Convertible Security Settlement Method it provides or is deemed to have provided hereunder. 

  
 4 

	 Excluded Convertible Securities: 
	Convertible Securities subject to the occurrence of an Excluded Conversion Event, as described in Section 8(c) below. 

Settlement Terms: 
  

	 Settlement Date: 
	The date that is one Settlement Cycle immediately following the final day of the relevant Settlement Averaging Period. 

  

	 Delivery Obligation: 
	 In lieu of the obligations set forth in Sections 8.1 and 9.1 of the Equity Definitions, and subject to (w) the provisions opposite the caption
“Notice of Exercise” above, (x) the provisions opposite the caption “Dividends” under the heading “Share Adjustments” below, (y) the second and third paragraphs of the provisions opposite the caption
“Method of Adjustment” below and (z) Section 8(i), in respect of any Option exercised on any Exercise Date occurring on a Conversion Date, Dealer shall deliver to Counterparty, on the related Settlement Date, a number of Shares
and/or amount of cash in USD equal to the product of (i) the Applicable Percentage and (ii) the number of Shares and/or amount of cash in USD included in the applicable Settlement Amount, as determined by the Calculation Agent; provided
that Dealer will pay cash in lieu of delivering any fractional Shares that would otherwise be deliverable by Dealer hereunder, calculated on an aggregate basis in respect of all Options exercised on any Exercise Date, valued at the Daily VWAP
for the last Scheduled Trading Day of the Settlement Averaging Period; provided further that if such exercise relates to the conversion of Convertible Securities as to which additional Shares would be added to the Conversion Rate (as defined
in the Indenture) pursuant to Section 5.07 of the Indenture in connection with a “Make-Whole Fundamental Change” (as defined in the Indenture but excluding any “Fundamental Change”
described in clause (ii) of the definition thereof that would also constitute a “Make-Whole Fundamental Change”), then, notwithstanding the foregoing, in determining the Delivery Obligation set
forth in clause (ii) above, the Conversion Rate shall be deemed to include such additional Shares, except that the Delivery Obligation shall be capped so that the value of the Delivery Obligation per Option (with the value of any Shares
included in the Delivery Obligation determined by the Calculation Agent using the Daily VWAP on the last day of the relevant Settlement Averaging Period) does not exceed the amount determined by the Calculation Agent that would be payable by Dealer
pursuant to Section 6 of the Agreement as if (1) an Early Termination Date had been designated in respect of a transaction having terms identical to the Transaction and a Number of Options equal to the number of Options exercised on such
Exercise Date, (2) Counterparty were the sole Affected Party to such transaction and (3) such transaction were the sole Affected Transaction (and, for the avoidance of doubt, in determining the amount payable pursuant to Section 6 of
the Agreement, the Calculation Agent shall not take into account any adjustments to the Option Entitlement that result from corresponding adjustments to the Conversion Rate pursuant to Section 5.07 of the Indenture). Notwithstanding the
foregoing, and in addition to the cap described in the further proviso to the preceding sentence, in all events the Delivery Obligation shall be capped so that the value of the Delivery Obligation does not exceed the product of (A) the
Applicable Percentage and (B) the excess, if any, of (x) the value of the aggregate number of Shares and/or cash that Counterparty is obligated under Section 5.03(B) of the Indenture to deliver in respect of the conversion of such
Relevant 

  
 5 

	 	 
Convertible Securities (such aggregate number of Shares and/or cash, the “Convertible Obligation”) (with the value of any Shares included in either the Delivery Obligation or such
Convertible Obligation determined by the Calculation Agent using the opening price as displayed under the heading “Op” on Bloomberg page “OMER <Equity>” (or any successor thereto) on the applicable Settlement Date)
over (y) USD1,000 per Relevant Convertible Security. 

  

	 Settlement Amount: 
	If the Convertible Security Settlement Method is (notwithstanding any different actual election by Counterparty in respect of such Relevant Convertible Securities) (i) Cash Settlement, cash in USD in an amount equal to the sum of the Daily
Net Conversion Values for each Trading Day in the relevant Settlement Averaging Period; or (ii) Combination Settlement with a Specified Dollar Amount equal to or greater than USD1,000, (x) a number of Shares equal to the sum of the Daily
Share Amounts for each Trading Day in the relevant Settlement Averaging Period and (y) an amount of cash in USD equal to the sum of the Daily Cash Amounts for each Trading Day in such Settlement Averaging Period. 

 

	 Daily Share Amount: 
	For any Trading Day in the relevant Settlement Averaging Period, a number of Shares equal to the greater of (i) (a) the excess, if any, of (x) the Daily Net Conversion Value for such Trading Day over (y) (I) the
Specified Dollar Amount applicable to the Convertible Security Settlement Method minus USD 1,000 divided by (II) the number of Trading Days in such Settlement Averaging Period, divided by (b) the Daily VWAP for such Trading Day and
(ii) zero Shares. 

  

	 Daily Net Conversion Value: 
	For any Trading Day in the relevant Settlement Averaging Period, the greater of (A) (i) the difference of (a) the product of (x) the Conversion Rate on such Trading Day and (y) the lesser of (I) the Daily VWAP for
such Trading Day and (II) the Cap Price minus (b) USD 1,000 divided by (ii) the number of Trading Days in such Settlement Averaging Period and (B) zero. 

 

	 Daily Cash Amount 
	For any Trading Day in the relevant Settlement Averaging Period, an amount of cash in USD equal to the greater of (i) the lesser of (x) the Daily Net Conversion Value for such Trading Day and (y) (I) the applicable Specified
Dollar Amount applicable to the Convertible Security Settlement Method minus USD 1,000 divided by (II) the number of Trading Days in such Settlement Averaging Period, and (ii) zero. 

 

	 Convertible Security Settlement Method: 
	 For any Relevant Convertible Securities, if Counterparty has notified Dealer in the related Notice of Exercise (or in the Notice of Convertible Security
Settlement Method, as the case may be) that it has elected to satisfy its conversion obligation in respect of such Relevant Convertible Securities in cash or in a combination of cash and Shares in accordance with Section 5.03(A) of the
Indenture (a “Cash Election”) with a “Specified Dollar Amount” (as defined in the Indenture) of at least USD1,000, the Convertible Security Settlement Method shall be the settlement method actually so elected by
Counterparty in respect of such Relevant Convertible Securities; otherwise, the Convertible Security Settlement Method shall (i) assume Counterparty made a Cash Election with respect to such Relevant Convertible Securities with a
“Specified Dollar Amount” (as defined in the Indenture) of USD1,000 per Relevant Convertible Security and (ii) be calculated as if the relevant Settlement Averaging

  
 6 

	 	 
Period consisted of 90 Trading Days commencing on (x) the third Trading Day (as defined in the Indenture) after the Conversion Date for conversions occurring prior to the
95th Scheduled Trading Day prior to the Expiration Date; or (y) the 91st Scheduled Trading Day prior to the Expiration Date for conversions occurring on or after the 95th Scheduled Trading Day prior to the Expiration Date.

  

	 Notice of Delivery Obligation: 
	No later than the Exchange Business Day immediately following the last day of the relevant Settlement Averaging Period, Counterparty shall give Dealer notice of the final number of Shares and/or cash comprising the Convertible Obligation;
provided that, with respect to any Exercise Date occurring during the Free Convertibility Period, Counterparty may provide Dealer with a single notice of an aggregate number of Shares and/or cash comprising the Convertible Obligations for all
Exercise Dates occurring in such period (it being understood, for the avoidance of doubt, that the requirement of Counterparty to deliver such notice shall not limit Counterparty’s obligations with respect to Notice of Exercise or Notice of
Convertible Security Settlement Method or Dealer’s obligations with respect to Delivery Obligation, each as set forth above, in any way). 

  

	 Daily VWAP: 
	For each of the Trading Days during the applicable Settlement Averaging Period, the per Share volume-weighted average price as displayed under the heading “Bloomberg VWAP” on Bloomberg page
“OMER <EQUITY> AQR” (or its equivalent successor if such page is not available) in respect of the period from the scheduled open of trading until the scheduled close of trading of the primary trading session on such Trading Day (or
if such volume-weighted average price is unavailable, the market value of one Share on such Trading Day determined, using, if practicable, a volume-weighted average
method, by the Calculation Agent, provided that such market value shall in no event be greater than the market value of one Share determined by the nationally recognized independent investment banking firm retained by Counterparty pursuant to the
definition of “Daily VWAP” in Section 1.01 of the Indenture). The “Daily VWAP” shall be determined without regard to after-hours trading or any other trading outside of the regular
trading session trading hours. 

  

	 Settlement Averaging Period: 
	With respect to any Exercise Date, 

  

	 	(i)	 if such Exercise Date occurs prior to the 95th Scheduled Trading Day immediately prior to the Expiration
Date, the 45 consecutive Trading Day period beginning on, and including, the third Trading Day immediately following such Exercise Date; and 

  

	 	(ii)	 if such Exercise Date occurs on or after the 95th Scheduled Trading Day immediately prior to the
Expiration Date, the 45 consecutive Trading Day period beginning on, and including, the 46th Scheduled Trading Day immediately preceding the Expiration Date, 

 

	 	provided that, unless Counterparty has validly elected to satisfy its Conversion Obligation via Cash Settlement or made a Cash Election with a “Specified Dollar Amount” (as defined in the Indenture) of
at least USD1,000 and notified Dealer of such election in accordance with the requirements set forth herein, the Settlement Averaging Period shall be as described in the section titled “Convertible Security Settlement Method” above.

  
 7 

	 Trading Day: 
	A day on which (x) there is no Market Disruption Event and (y) trading in the Shares generally occurs on the Relevant Exchange or, if the Shares are not then listed on the Relevant Exchange, on the principal other market on which the
Shares are then listed or admitted for trading, except that if the Shares are not so listed or admitted for trading, “Trading Day” means a Business Day. 

 

	 Scheduled Trading Day: 
	Notwithstanding anything to the contrary in the Equity Definitions, “Scheduled Trading Day” means a day that is scheduled to be a Trading Day; provided that if the Shares are not listed or admitted for trading on the
Relevant Exchange, “Scheduled Trading Day” means a Business Day. 

  

	 Business Day: 
	Each Monday, Tuesday, Wednesday, Thursday and Friday that is not a day on which the banking institutions in New York City are authorized or required by law or executive order to close or be closed. 

 

	 Market Disruption Event: 
	Notwithstanding anything to the contrary in the Equity Definitions, “Market Disruption Event” means (a) a failure by the Relevant Exchange to open for trading during its regular trading session, or (b) the occurrence
or existence, prior to 1:00 p.m., New York City time, on any Scheduled Trading Day for the Shares, of an aggregate one half-hour period of any suspension or limitation imposed on trading (by reason of
movements in price exceeding limits permitted by the relevant stock exchange or otherwise) in the Shares or in any options contracts or futures contracts relating to the Shares. 

 

	 Relevant Exchange: 
	The Nasdaq Global Market or, if the Shares are not then listed on the Nasdaq Global Market, the principal U.S. national or regional securities exchange on which the Shares are listed for trading. 

 

	 Other Applicable Provisions: 
	To the extent Dealer is obligated to deliver Shares hereunder, the provisions of Sections 9.1(c), 9.8, 9.9, 9.10, and 9.11 (except that the Representation and Agreement contained in Section 9.11 of the Equity Definitions shall be
modified by excluding any representations therein relating to restrictions, obligations, limitations or requirements under applicable securities laws arising as a result of the fact that Counterparty is the Issuer of the Shares) of the Equity
Definitions will be applicable as if “Physical Settlement” applied to the Transaction. 

  

	 Restricted Certificated Shares: 
	Notwithstanding anything to the contrary in the Equity Definitions, Dealer may, in whole or in part, deliver Shares required to be delivered to Counterparty hereunder in certificated form in lieu of delivery through the Clearance System. With
respect to such certificated Shares, the Representation and Agreement contained in Section 9.11 of the Equity Definitions shall be modified by deleting the remainder of the provision after the word “encumbrance” in the fourth line
thereof. 

 Share Adjustments: 
  

	 Dividends: 
	If an ex-dividend date for a cash dividend on the Shares occurs on or after the Trade Date and on or prior to the Expiration Date and the amount of such dividend is less than Ordinary Dividend Amount, or
if no ex-dividend date for a cash dividend on the Shares occurs in any regular quarterly dividend period of Counterparty that falls, in whole or in part, after the Trade Date and on or prior to the Expiration
Date, then the Calculation Agent will make adjustments to the Delivery Obligation in respect of each Exercise Date as it determines appropriate to account for the economic effect on the Transaction of such shortfall. 

  
 8 

	 Ordinary Dividend Amount: 
	USD0.00. 

  

	 Potential Adjustment Events: 
	Notwithstanding Section 11.2(e) of the Equity Definitions (but subject to clause (ii) under “Method of Adjustment” below), a “Potential Adjustment Event” means an occurrence of any event or condition, as set
forth in set forth in Section 5.05(A)(i), (A)(ii), (A)(iii), (A)(iv) or (A)(v), Section 5.05(H) or Section 5.05(F) of the Indenture (the “Adjustment Provisions”) that would result in an adjustment to the
“Conversion Rate” under the Indenture. 

  

	 Method of Adjustment: 
	Notwithstanding Section 11.2 of the Equity Definitions, (i) upon the occurrence of any Potential Adjustment Event that results in an adjustment under the Indenture (other than an increase to the “Conversion Rate” (as defined
under the Indenture) pursuant to Section 5.06 or Section 5.07 of the Indenture (the “Excluded Adjustment Provisions”)), the Calculation Agent shall make a corresponding adjustment in good faith and in a commercially
reasonable manner to the terms relevant to the exercise, settlement or payment of the Transaction (other than the Cap Price) and (ii) upon the occurrence of any event or condition under the Adjustment Provisions and/or any “Potential
Adjustment Event” (as defined in Section 11.2(e) of the Equity Definitions, as modified hereby), the Calculation Agent may, but without duplication of any adjustment pursuant to clause (i) above, make any further adjustment to the Cap
Price to the extent appropriate and commercially reasonable to preserve the fair value of the Transaction to Dealer after taking into account such event, condition and/or Potential Adjustment Event; provided that the Cap Price shall not be adjusted
so that it is less than an amount equal to USD1,000 divided by the Conversion Rate. Counterparty shall (x) as promptly as practicable upon the occurrence of any Potential Adjustment Event and/or Merger Event, notify the Calculation Agent
of such Potential Adjustment Event and/or Merger Event, (y) give Dealer commercially reasonable advance (but in no event less than one Exchange Business Day) written notice of the section or sections of the Indenture and, if applicable, the
formula therein, pursuant to which any adjustment will be made to the Convertible Securities in connection with any Potential Adjustment Event or Merger Event and (z) once the adjustments to be made to the terms of the Indenture and the
Convertible Securities in respect of such Potential Adjustment Event and/or Merger Event have been determined, as promptly as practicable notify the Calculation Agent in writing of the details of such adjustments. 

 

	 Discretionary Adjustments: 
	Notwithstanding anything to the contrary herein: 

  

	 	 (i) if Counterparty or its board of directors exercises discretion under the terms of the Indenture with respect to any
determination, calculation or adjustment for which Counterparty or its board of directors is permitted or required to exercise discretion (including, without limitation, any adjustment under Section 5.05(H) of the Indenture, any adjustment
pursuant to the terms of a Merger Supplemental Indenture or any determination of the fair market value 

  
 9 

	 	 
of distributed property, the volume-weighted average price of Shares (in the event of an extraordinary event or transaction such as the unavailability of
the relevant Bloomberg page or a volume-weighted average price as set forth in the definition of “Daily VWAP” above or a merger or similar event) or the value of a “unit of Reference
Property” (as defined under the Indenture)) (any such determination, calculation or adjustment, a “Counterparty Determination”), and the Calculation Agent disagrees reasonably and in good faith with such determination,
calculation or adjustment, the Calculation Agent shall make the relevant determination, calculation or adjustment (any such determination, calculation or adjustment, the “Calculation Agent’s Determination”) for purposes of the
Transaction (provided that the Calculation Agent’s Determination shall not result in a Delivery Obligation that would exceed the Delivery Obligation determined without regard to this paragraph) and, for the avoidance of doubt, shall determine
any Delivery Obligation and Settlement Date (if, in the commercially reasonable discretion of the Calculation Agent, an adjustment to the Settlement Date is reasonably necessary or appropriate to properly make such determination, calculation or
adjustment) thereafter as if the Calculation Agent’s Determination were applicable under the Indenture (to the extent relevant), acting, in each case, in a commercially reasonable manner; provided that, notwithstanding the foregoing, if
any Potential Adjustment Event occurs during the relevant “Observation Period” (as defined in the Indenture) but no adjustment was made to any Convertible Security under the Indenture because the relevant holder was deemed to be a record
owner of the underlying Shares on the related Conversion Date, then the Calculation Agent shall make an adjustment, as determined by it, to the terms hereof in order to account for such Potential Adjustment Event; 

 

	 	(ii) in connection with any Potential Adjustment Event as a result of an event or condition set forth in Section 5.05(A)(ii) of the Indenture or Section 5.05(A)(iii) of the Indenture where, in either case, the
period for determining “Y” (as such term is used in Section 5.05(A)(ii) of the Indenture) or “SP” (as such term is used in Section 5.05(A)(iii) of the Indenture), as the case may be, begins before Counterparty has
publicly announced the event or condition giving rise to such Potential Adjustment Event, then the Calculation Agent shall have the right to adjust any variable relevant to the exercise, settlement or payment for the relevant Transaction as
appropriate to reflect the costs (including, but not limited to, hedging mismatches and market losses) and expenses incurred by Dealer in connection with its hedging activities as a result of such event or condition not having been publicly
announced prior to the beginning of such period; and 

  

	 	 (iii) if any Potential Adjustment Event is declared and (a) the event or condition giving rise to such Potential
Adjustment Event is subsequently amended, modified, cancelled or abandoned, (b) the “Conversion Rate” (as defined in the Indenture) is otherwise not adjusted at the time or in the manner contemplated by the relevant provisions of the
Indenture, based on such declaration or (c) the “Conversion Rate” (as defined in the Indenture) is adjusted as a result of such Adjustment Event and subsequently re-adjusted (each of clauses (a), (b) and (c), an
“Adjustment Event Change”) then, in each case, the Calculation Agent shall have the right to adjust any variable relevant to the exercise, settlement or payment for the Transaction as

  
 10 

	 	 
appropriate to reflect the commercially reasonable costs (including, but not limited to, hedging mismatches and market losses) and expenses incurred by Dealer in connection with its hedging
activities as a result of such Adjustment Event Change. 

  

	 	For the avoidance of doubt, Dealer shall not have any delivery obligation hereunder in respect of any “Distributed Property” (as defined under the Indenture) delivered by Counterparty pursuant to
Section 5.05(A)(iii) of the Indenture or any payment obligation in respect of any cash paid by Counterparty pursuant to Section 5.05(A)(iv) of the Indenture (collectively, the “Conversion Rate Adjustment Fallback
Provisions”), and no adjustment shall be made to the terms of the Transaction on account of any event or condition described in the Conversion Rate Adjustment Fallback Provisions. 

Extraordinary Events: 
  

	 Merger Events: 
	Notwithstanding Section 12.1(b) of the Equity Definitions, except to the extent set forth under the provisions set forth under “Consequences of Announcement Events” and “Announcement Event” below, (but subject to clause
(ii) under “Consequences of Merger Events” below) a “Merger Event” means the occurrence of any event or condition set forth in Section 5.09 of the Indenture. 

 

	 Notice of Merger Consideration: 
	Upon the occurrence of a Merger Event, Counterparty shall reasonably promptly (but, in any event prior to the relevant merger date) notify the Calculation Agent of (i) the weighted average of the types and amounts of consideration received
by the holders of Shares entitled to receive cash, securities or other property or assets with respect to or in exchange for such Shares in any Merger Event who affirmatively make such an election, if applicable, and (ii) the details of the
adjustment made under the Indenture in respect of such Merger Event. In addition, Counterparty shall deliver a copy of the supplemental indenture effecting such adjustments (a “Merger Supplemental Indenture”) as required under the
Indenture as promptly as practicable following execution thereof. 

  

	 Consequences of Merger Events: 
	 Notwithstanding Sections 12.2 and 12.3 of the Equity Definitions, (i) upon the occurrence of a Merger Event that results in an adjustment
under the Indenture (including, for the avoidance of doubt, pursuant to Section 5.09 of the Indenture), the Calculation Agent shall make a corresponding adjustment to the terms relevant to the exercise, settlement or payment of the Transaction
(other than the Cap Price), subject to the provision under “Method of Adjustment” above relating to Counterparty Determinations; provided that such adjustment shall be made without regard to any increase to the “Conversion
Rate” (as defined under the Indenture) pursuant to the Excluded Adjustment Provisions; and provided further that if, with respect to a Merger Event, the consideration for the Shares includes (or, at the option of a holder of Shares, may
include) shares of an entity or person that is not a corporation organized under the laws of the United States, any State thereof or the District of Columbia, Cancellation and Payment (Calculation Agent Determination) may apply at Dealer’s
commercially reasonable discretion; and (ii) upon the occurrence of a Merger Event, a “Merger Event” (as defined in the Equity Definitions) and/or a Tender Offer, the Calculation Agent may, but without duplication of any adjustment
pursuant to clause (i) above, 

  
 11 

	 	 
make any further adjustment to the Cap Price consistent with the “Modified Calculation Agent Adjustment” set forth in Section 12.2(e) or 12.3(d) of the Equity Definitions, as
applicable; provided that the Cap Price shall not be adjusted so that it is less than an amount equal to USD1,000 divided by the Conversion Rate. 

  

	 Tender Offer: 
	Applicable with respect to the Cap Price as set forth herein. 

  

	 Consequences of Announcement Event: 
	Modified Calculation Agent Adjustment as set forth in Section 12.3(d) of the Equity Definitions; provided that, in respect of an Announcement Event, references to “Tender Offer” shall be replaced by references to
“Announcement Event” and references to “Tender Offer Date” shall be replaced by references to “date of such Announcement Event” and the following parenthetical will be deemed to be inserted immediately following the
parenthetical ending on the sixth line thereof: “(including, for the avoidance of doubt, any economic effect arising from a market reaction to the contents of the Announcement Event which occurs prior to a formal public announcement
constituting such Announcement Event)”; provided further that, in respect of an Announcement Event, Section 12.3(d)(i)(A) shall be amended by replacing the words “exercise, settlement, payment or any other terms of the Transaction
(including, without limitation, the spread)” with “Cap Price”. An Announcement Event shall be an “Extraordinary Event” for purposes of the Equity Definitions, to which Article 12 of the Equity Definitions is applicable.

  

	 Announcement Event: 
	(i) The announcement of any Merger Event, “Merger Event” (as defined in the Equity Definitions) or Tender Offer, the intention to enter into a Merger Event, “Merger Event” (as defined in the Equity Definitions) or Tender
Offer or any transaction or event that, if completed, would constitute a Merger Event, “Merger Event” (as defined in the Equity Definitions) or Tender Offer, (ii) the announcement by Issuer or any of its subsidiaries of any
acquisition where the aggregate consideration exceeds 25% of the market capitalization of Issuer as of the date of such announcement (an “Acquisition Transaction”), (iii) the announcement by Issuer of an intention to solicit or enter
into, or to explore strategic alternatives or other similar undertaking that may include, a Merger Event, “Merger Event” (as defined in the Equity Definitions), Tender Offer and/or Acquisition Transaction or (iv) any subsequent
announcement of a change to a transaction or intention that is the subject of an announcement of the type described in clause (i), (ii) or (iii) of this sentence (including, without limitation, a new announcement, whether or not by the
same party, relating to such a transaction or intention or the announcement of a withdrawal from, or the abandonment or discontinuation of, such a transaction or intention) (in each case, whether such announcement is made by Issuer or a third
party); provided that, for the avoidance of doubt, (x) the occurrence of an Announcement Event with respect to any transaction or intention shall not preclude the occurrence of a later Announcement Event with respect to such transaction or
intention and (y) any announcement referred to above may include, without limitation, an informal announcement that the Calculation Agent determines has had a material economic effect on the Transaction and is likely to lead to the relevant
transaction and/or communicate the contents of the relevant intention (it being understood that the Calculation Agent may make such determination by reference to the impact of such announcement on the market for the Shares or options relating to the
Shares and such other factors as the Calculation Agent deems relevant in its commercially reasonable discretion). 

  
 12 

	 Nationalization, Insolvency or Delisting: 
	Cancellation and Payment (Calculation Agent Determination); provided that, in addition to the provisions of Section 12.6(a)(iii) of the Equity Definitions, it shall also constitute a Delisting if the Exchange is located in the United
States and the Shares are not immediately re-listed, re-traded or re-quoted on any of the New York Stock Exchange, The Nasdaq
Global Select Market or The Nasdaq Global Market (or their respective successors); if the Shares are immediately re-listed, re-traded or
re-quoted on any such exchange or quotation system, such exchange or quotation system shall thereafter be deemed to be the Exchange. 

Additional Disruption Events: 
  

	 Change in Law: 
	Applicable; provided that Section 12.9(a)(ii) of the Equity Definitions is hereby amended (i) by inserting the parenthetical “ (including, for the avoidance of doubt and without limitation, adoption, effectiveness or
promulgation of regulations authorized or mandated by existing statute)” at the end of clause (A) thereof and (ii) by the replacement of the word “Shares” with “Hedge Positions” in clause (X) thereof; and
provided further that Dealer may exercise its termination rights with respect to a “Change in Law” described in clause (Y) of Section 12.9(a)(ii) of the Equity Definitions only if Dealer determines, based upon advice of
counsel, that it is generally exercising its right to terminate or adjust as a result of such event with respect to similarly situated customers. 

  

	 Insolvency Filing: 
	Applicable 

  

	 Hedging Disruption: 
	Applicable; provided that Section 12.9(a)(v) of the Equity Definitions is hereby amended by (a) inserting the following words at the end of clause (A) thereof: “in the manner contemplated by the Hedging Party on the
Trade Date” and (b) inserting the following three phrases at the end of such Section: 

  

	 	“For the avoidance of doubt, the term “equity price risk” shall be deemed to include, but shall not be limited to, stock price and volatility risk. And, for the further avoidance of doubt, any such
transactions or assets referred to in phrases (A) or (B) above must be available on commercially reasonable pricing terms.” Furthermore, notwithstanding the foregoing, such inability described in phrases (A) or (B) above
shall not constitute a “Hedging Disruption” if such inability results solely from the Hedging Party’s creditworthiness or financial position, or from particular actions or transactions undertaken by the Hedging Party with third
parties unrelated to the hedging of the Transaction.” 

  

	 Hedging Party: 
	For all applicable Potential Adjustment Events and Extraordinary Events, Dealer 

  

	 Determining Party: 
	For all applicable Extraordinary Events, Dealer 

 Acknowledgements: 

 

	 Non-Reliance: 
	Applicable 

  

	 Agreements and Acknowledgements Regarding Hedging Activities: 
	Applicable 

  
 13 

	 Additional Acknowledgements: 
	Applicable 

  

									
	 3.
	 	Calculation Agent:	 		 	Dealer; provided that all calculations and determinations by the Calculation Agent (other than calculations or determinations made by reference to the Indenture) shall be made in good faith and in a commercially
reasonable manner and assuming for such purposes that Dealer is maintaining, establishing and/or unwinding, as applicable, a commercially reasonable hedge position; provided further that if an Event of Default of the type described in
Section 5(a)(vii) of the Agreement with respect to which Dealer is the sole Defaulting Party occurs, Counterparty shall have the right to appoint a successor calculation agent which shall be a nationally recognized third-party dealer in
over-the-counter corporate equity derivatives. Calculation Agent agrees that it will promptly, upon written notice from Counterparty, provide a statement displaying in reasonable detail the basis for such determination, adjustment or calculation, as
the case may be (including any quotations, market data or information from internal or external sources used in making such determination, adjustment or calculation, it being understood that the Calculation Agent shall not be required to disclose
any confidential information or proprietary models used by it in connection with such determination, adjustment or calculation, as the case may be).
			
	 4.
	 	Account Details:	 	Account for payments to Dealer:
				
		 		 		 	 [    ]

[    ]

Reference: [    ]

				
		 		 		 	Counterparty Payment Instructions: To be provided by Counterparty
			
	 5.
	 	Offices:	 	The Office of Dealer for the Transaction is: [    ]
				
		 		 		 	[    ]
		 		 	        	 	 Attention:
 Telephone:

Facsimile:
	 	 [    ]

[    ]

[    ]

				
		 		 		 	The Office of Counterparty for the Transaction is: Not Applicable
			
	 6.
	 	Notices:	 	For purposes of this Confirmation:
				
		 		 		 	Address for notices of communications to Counterparty:
		 		 		 	To:	 	 Omeros Corporation
 201 Elliott Avenue West

Seattle
 Washington, 98119

		 		 		 	 Attn:
 Telephone:

Facsimile:
	 	 [    ]

[    ]

[    ]

  
 14 

									
		
	 (a)
	 	Address for notices or communications to Dealer:
				
		 		 		 	For purpose of Giving Notice:
		 		 		 	 To:
 Attention:

Email:
	 	 [    ]

[    ]

[    ]

				
		 		 		 	For Trade Affirmations and Settlements:
		 		 		 	 To:
 Attention:

Email:
	 	 [    ]

[    ]

[    ]

				
		 		 		 	For Trade Confirmations:
		 		 		 	 To:
 Attention:

Email:
	 	 [    ]

[    ]

[    ]

 7.   Representations, Warranties and Agreements: 

(a) In addition to the representations and warranties in the Agreement and those contained elsewhere herein, Counterparty represents and
warrants to and for the benefit of, and agrees with, Dealer as follows: 
 (i) On the Trade Date, and as of the date of any
election by Counterparty of the Share Termination Alternative under (and as defined in) Section 8(a) below, (A) none of Counterparty and its officers and directors is aware of any material nonpublic information regarding Counterparty or
the Shares and (B) all reports and other documents filed by Counterparty with the Securities and Exchange Commission pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”) when considered as a whole
(with the more recent such reports and documents deemed to amend inconsistent statements contained in any earlier such reports and documents), do not contain any untrue statement of a material fact or any omission of a material fact required to be
stated therein or necessary to make the statements therein, in the light of the circumstances in which they were made, not misleading. 

(ii) Without limiting the generality of Section 13.1 of the Equity Definitions, Counterparty acknowledges that Dealer is
not making any representations or warranties with respect to the treatment of the Transaction under any accounting standards including FASB Statements 128, 133, 149 (each as amended), or 150, EITF Issue
No. 00-19, 01-6, 03-6 or 07-5 (or any successor issue statements) or under
FASB’s Liabilities & Equity Project. 
 (iii) Without limiting the generality of Section 3(a)(iii) of the
Agreement, the Transaction will not violate Rule 13e-1 or Rule 13e-4 under the Exchange Act. 

(iv) On or prior to the Trade Date, Counterparty shall deliver to Dealer a resolution of Counterparty’s board of directors
authorizing the Transaction. 
 (v) Counterparty is not entering into this Confirmation to create actual or apparent trading
activity in the Shares (or any security convertible into or exchangeable for Shares) or to raise or depress or otherwise manipulate the price of the Shares (or any security convertible into or exchangeable for Shares) or otherwise in violation of
the Exchange Act. 
 (vi) Counterparty is not, and after giving effect to the transactions contemplated hereby will not be,
required to register as an “investment company” as such term is defined in the Investment Company Act of 1940, as amended. 

  
 15 

 (vii) On each of the Trade Date and the Premium Payment Date, Counterparty
is not, or will not be, “insolvent” (as such term is defined under Section 101(32) of the U.S. Bankruptcy Code (Title 11 of the United States Code) (the “Bankruptcy Code”)) and Counterparty would be able to purchase a
number of Shares equal to the Number of Shares in compliance with the corporate laws of the jurisdiction of its incorporation. 

(viii) To the knowledge of Counterparty, no state or local law, rule, regulation or regulatory order applicable to the Shares
would give rise to any reporting, consent, registration or other requirement (including without limitation a requirement to obtain prior approval from any person or entity) as a result of Dealer or its affiliates having the power to vote, owning or
holding (however defined) Shares in connection with the Transaction; provided that Counterparty makes no representation or warranty regarding any such requirement that is applicable generally to the ownership of U.S. listed equity securities
of U.S. incorporated issuers by Dealer or any of its affiliates solely as a result of it or any of such affiliates being financial institutions or broker-dealers. 

(ix) The representations and warranties of Counterparty set forth in Section 3 of the Agreement and Section 4 of the
Purchase Agreement dated as of November 8, 2018, among Counterparty and Cantor Fitzgerald & Co. and UBS Securities LLC as initial purchasers (the “Purchase Agreement”) are true and correct and are hereby deemed to be
repeated to Dealer as if set forth herein. 
 (x) Counterparty understands no obligations of Dealer to it hereunder will be
entitled to the benefit of deposit insurance and that such obligations will not be guaranteed by any affiliate of Dealer or any governmental agency. 

(xi) On the Trade Date, Counterparty is not engaged in any “distribution,” as such term is defined in
Regulation M under the Exchange Act (“Regulation M”) of any securities of Counterparty, other than a distribution meeting the requirements of the exceptions set forth in sections 101(b)(10) and 102(b)(7) of
Regulation M. 
 (xii)(A) Counterparty is acting for its own account, and it has made its own independent decisions to
enter into the Transaction and as to whether the Transaction is appropriate or proper for it based upon its own judgment and upon advice from such advisers as it has deemed necessary, (B) Counterparty is not relying on any communication
(written or oral) of Dealer or any of its affiliates as investment advice or as a recommendation to enter into the Transaction (it being understood that information and explanations related to the terms and conditions of the Transaction shall not be
considered investment advice or a recommendation to enter into the Transaction) and (C) no communication (written or oral) received from Dealer or any of its affiliates shall be deemed to be an assurance or guarantee as to the expected results
of the Transaction. 
 (xiii) Counterparty (i) is capable of evaluating investment risks independently, both in general
and with regard to all transactions and investment strategies involving a security or securities; (ii) will exercise independent judgment in evaluating the recommendations of any broker-dealer or its
associated persons, unless it has otherwise notified the broker-dealer in writing; and (iii) has total assets of at least USD50 million as of the date hereof. 

(b) Each of Dealer and Counterparty agrees and represents that it is an “eligible contract participant” as defined in
Section 1a(18) of the U.S. Commodity Exchange Act, as amended. 
 (c) Each of Dealer and Counterparty acknowledges that the offer and
sale of the Transaction to it is intended to be exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”), by virtue of Section 4(a)(2) thereof. Accordingly, Counterparty represents and
warrants to Dealer that (i) it has the financial ability to bear the economic risk of its investment in the Transaction and is able to bear a total loss of its investment, (ii) it is an “accredited investor” as that term is
defined in Regulation D as promulgated under the Securities Act, (iii) it is entering into the Transaction for its own account and without a view to the distribution or resale thereof and (iv) the assignment, transfer or other disposition
of the Transaction has not been and will not be registered under the Securities Act and is restricted under this Confirmation, the Securities Act and state securities laws. 

  
 16 

 (d) Each of Dealer and Counterparty agrees and acknowledges that Dealer is a “financial
institution,” “swap participant” and, to the best of Counterparty’s information and belief, “financial participant” within the meaning of Sections 101(22), 101(53C) and 101(22A) of Title 11 of the Bankruptcy
Code. The parties hereto further agree and acknowledge that it is the intent of the parties (A) that this Confirmation is (i) a “securities contract,” as such term is defined in Section 741(7) of the Bankruptcy Code, with
respect to which each payment and delivery hereunder or in connection herewith is a “termination value,” “payment amount” or “other transfer obligation” within the meaning of Section 362 of the Bankruptcy Code and
a “settlement payment,” as such term is defined in Section 741(8) of the Bankruptcy Code, and (ii) a “swap agreement,” as such term is defined in Section 101(53B) of the Bankruptcy Code, with respect to which each
payment and delivery hereunder or in connection herewith is a “termination value,” “payment amount” or “other transfer obligation” within the meaning of Section 362 of the Bankruptcy Code and a
“transfer,” as such term is defined in Section 101(54) of the Bankruptcy Code, and (B) that Dealer is entitled to the protections afforded by, among other sections, Sections 362(b)(6), 362(b)(17), 362(o), 546(e), 546(g),
548(d)(2), 555 and 560 of the Bankruptcy Code. 
 (e) It is the intent of the parties that, in respect of Counterparty and to the extent
Dealer is an “insured depository institution” as defined under the Federal Deposit Insurance Act, (a) the Transaction shall constitute a “qualified financial contract” within the meaning of 12 U.S.C.
Section 1821(e)(8)(D)(i) and (b) a Non-defaulting Party’s rights under Sections 5 and 6 of the Agreement constitute rights of the kind referred to in 12 U.S.C. Section 1821(e)(8)(A).

 (f) Counterparty shall deliver to Dealer an opinion or opinions of counsel reasonably acceptable to Dealer, dated as of the Effective Date
and reasonably acceptable to Dealer in form and substance, with respect to the matters set forth in Section 3(a) of the Agreement, Section 7(a)(vi) above, and such other matters as Dealer may reasonably request; provided that any
such opinion of counsel may contain customary assumptions, qualifications and exceptions. 
 8.   Miscellaneous: 

(a) Alternative Calculations and Dealer Payment on Early Termination and on Certain Extraordinary Events. If Dealer shall owe
Counterparty any amount pursuant to “Consequences of Merger Events” above or Sections 12.6, 12.7 or 12.9 of the Equity Definitions or pursuant to Section 6(d)(ii) of the Agreement (a “Payment Obligation”),
Counterparty shall have the right, in its sole discretion, to require Dealer to satisfy any such Payment Obligation by the Share Termination Alternative (as defined below) by giving irrevocable telephonic notice to Dealer, confirmed in writing or by
email (with confirmation of receipt by Dealer) within one Scheduled Trading Day, no later than 12:00 P.M. New York City time on the relevant merger date, Announcement Date, Early Termination Date or date of cancellation or termination in
respect of an Extraordinary Event, as applicable (“Notice of Share Termination”); provided that if Counterparty does not elect to require Dealer to satisfy its Payment Obligation by the Share Termination Alternative, Dealer
shall have the right, in its sole discretion, to elect to satisfy its Payment Obligation by the Share Termination Alternative, notwithstanding Counterparty’s failure to elect or election to the contrary; and provided further that
Counterparty shall not have the right to so elect (but, for the avoidance of doubt, Dealer shall have the right to so elect) in the event of (i) an Insolvency, a Nationalization or a Merger Event, in each case, in which the consideration or
proceeds to be paid to holders of Shares consists solely of cash or (ii) an Event of Default in which Counterparty is the Defaulting Party, a Termination Event in which Counterparty is the Affected Party or an Extraordinary Event, in each case,
which resulted from an event or events within Counterparty’s control. Upon such Notice of Share Termination, the following provisions shall apply on the Scheduled Trading Day immediately following the relevant merger date, Announcement Date,
Early Termination Date or date of cancellation or termination in respect of an Extraordinary Event, as applicable: 
  

	 Share Termination Alternative: 
	Applicable and means that Dealer shall deliver to Counterparty the Share Termination Delivery Property on the date on which the Payment Obligation would otherwise be due pursuant to “Consequences of Merger Events” above,
Section 12.7 or 12.9 of the Equity Definitions or Section 6(d)(ii) of the Agreement, as applicable, or such commercially reasonable later date as the Calculation Agent may reasonably determine (the “Share Termination Payment
Date”), in satisfaction of the Payment Obligation. 

  
 17 

	 Share Termination Delivery Property: 
	A number of Share Termination Delivery Units, as calculated by the Calculation Agent, equal to the Payment Obligation divided by the Share Termination Unit Price. The Calculation Agent shall adjust the Share Termination Delivery Property by
replacing any fractional portion of the aggregate amount of a security therein with an amount of cash equal to the value of such fractional security based on the values used to calculate the Share Termination Unit Price. 

 

	 Share Termination Unit Price: 
	The value of property contained in one Share Termination Delivery Unit on the date such Share Termination Delivery Units are to be delivered as Share Termination Delivery Property, as determined by the Calculation Agent in a commercially
reasonable manner and notified by the Calculation Agent to Dealer at the time of notification of the Payment Obligation. 

  

	 Share Termination Delivery Unit: 
	In the case of a Termination Event, Event of Default, Delisting or Additional Disruption Event, one Share or, in the case of an Insolvency, Nationalization or Merger Event, one Share or a unit consisting of the number or amount of each type of
property received by a holder of one Share (without consideration of any requirement to pay cash or other consideration in lieu of fractional amounts of any securities) in such Insolvency, Nationalization or Merger Event, as applicable. If such
Insolvency, Nationalization or Merger Event involves a choice of consideration to be received by holders, such holder shall be deemed to have elected to receive the maximum possible amount of cash. 

 

	 Failure to Deliver: 
	Applicable 

  

	 Other applicable provisions: 
	If Share Termination Alternative is applicable, the provisions of Sections 9.8, 9.9, 9.10, 9.11 (except that the Representation and Agreement contained in Section 9.11 of the Equity Definitions shall be modified by excluding any
representations therein relating to restrictions, obligations, limitations or requirements under applicable securities laws arising as a result of the fact that Counterparty is the issuer of the Shares or any portion of the Share Termination
Delivery Units) and 9.12 of the Equity Definitions will be applicable as if “Physical Settlement” applied to the Transaction, except that all references to “Shares” shall be read as references to “Share Termination Delivery
Units.” 

 (b) Payment by Counterparty. In the event, following payment of the Premium, that (i) an Early
Termination Date occurs or is designated with respect to the Transaction as a result of a Termination Event or an Event of Default (other than an Event of Default of the type described in Section 5(a)(ii) or 5(a)(iv) of the Agreement) and, as a
result, Counterparty owes to Dealer an amount pursuant to Section 6 of the Agreement, or (ii) Counterparty owes to Dealer an amount pursuant to Article 12 of the Equity Definitions (including, for the avoidance of doubt, any amount
payable in connection with an Extraordinary Event), such amount shall be deemed to be zero. 

  
 18 

 (c) Additional Termination Events. 

(i) The occurrence of (A) an “Event of Default” with respect to Counterparty under the terms of the Convertible
Securities as set forth in Section 7.01 of the Indenture with respect to which the Convertible Securities are declared immediately due and payable under the terms of the Indenture, (B) an Amendment Event or (C) Dealer’s receipt
of a notice from Counterparty, within the time period set forth under “Notice of Exercise” above, of a Notice of Exercise in respect of an Excluded Conversion Event, shall be an Additional Termination Event with respect to which the
Transaction is the sole Affected Transaction and Counterparty is the sole Affected Party and Dealer shall be the party entitled to designate an Early Termination Date pursuant to Section 6(b) of the Agreement, or, in the case of an Additional
Termination Event pursuant to clause (i)(C) above, shall designate the Early Termination Date so that the corresponding settlement date or payment date with respect to such Additional Termination Date will occur on, or as promptly as reasonably
practicable after, the related settlement date under the Indenture for the conversion of the relevant Excluded Convertible Securities; provided that in the case of an Excluded Conversion Event the Transaction shall be subject to termination
only in respect of a number of Options (the “Affected Number of Options”), equal to the lesser of (1) the number of Convertible Securities that cease to be outstanding in connection with or as a result of such Excluded
Conversion Event [minus the “Affected Number of Options” (as defined in the Base Capped Call Transaction Confirmation), if any, that relate to such Excluded Conversion Event (and, for the purposes of determining whether any Options
under this Confirmation or under the Base Capped Call Transaction Confirmation will be among the Affected Number of Options hereunder or among the “Affected Number of Options” under, and as defined in, the Base Capped Call Transaction
Confirmation, the Affected Number of Options shall be allocated first to the Base Capped Call Transaction Confirmation until all Options thereunder are exercised or terminated)], and (2) the number of Options then outstanding; provided,
further that in the case of an Excluded Conversion Event, the Excluded Conversion Unwind Payment shall be subject to a cap equal to the product of (x) the Applicable Percentage and (y) the excess, if any, of (i) the value of
the Convertible Obligation (with the value of any Shares included in either the Delivery Obligation or such Convertible Obligation determined by the Calculation Agent using the opening price as displayed under the heading “Op” on Bloomberg
page “OMER <Equity>” (or any successor thereto) on the applicable Settlement Date) that would apply with respect to such Affected Number of Options if (I) the number of Excluded Convertible Securities related to such Affected
Number of Options were the “Relevant Convertible Securities”, (II) the Conversion Date with respect to such Excluded Convertible Securities were the Conversion Date, and (III) the date of payment with respect to such Early
Termination Date were the “Settlement Date”over (ii) USD1,000 multiplied by the number of Excluded Convertible Securities related to such Affected Number of Option. For the avoidance of doubt, in determining the amount
payable in respect of such Affected Transaction pursuant to Section 6 of the Agreement in connection with an Excluded Conversion Event (such amount, the “Excluded Conversion Unwind Payment”), the Calculation Agent shall assume
(x) that the relevant Excluded Convertible Securities shall not have been converted and remain outstanding, (y) in the case of an Induced Conversion, that any adjustments, agreements, additional payments, deliveries or acquisitions by or
on behalf of Counterparty or any affiliate of Counterparty in connection therewith had not occurred and (z) except for purposes of determining the cap applicable to such amount as described in the second proviso to the immediately preceding
sentence, that no holders of Convertible Securities were entitled to receive any additional Shares pursuant to any adjustment, if any, made to account for a “Make-Whole Fundamental Change” (as
defined in the Indenture). Counterparty shall notify Dealer promptly following the occurrence of any Excluded Conversion Event. 

If Counterparty has notified, or deemed to have notified, Dealer, in accordance with the requirements set forth herein, in the
applicable Notice of Exercise (or in the Notice of Convertible Security Settlement Method, as the case may be) that it has elected to satisfy its conversion obligation in respect of the related Excluded Convertible Securities entirely in Shares or
in a combination of cash and Shares, then in lieu of paying the Excluded Conversion Unwind Payment entirely in cash, Dealer shall pay and/or deliver to Counterparty, on the date such Excluded Conversion Unwind Payment would otherwise be due (or
within a commercially reasonable period of time thereafter, as determined by Dealer taking into account existing liquidity conditions and Dealer’s commercially reasonable hedging and hedge unwind activity or settlement activity in connection
with delivery) (A) in the case where Counterparty has elected to 

  
 19 

 
satisfy its conversion obligation in respect of the related Excluded Convertible Securities entirely in Shares or in a combination of cash and Shares with a “Specified Dollar Amount”
(as defined in the Indenture) equal to or less than USD 1,000, a number of Shares equal to the quotient of (x) the amount of such Excluded Conversion Unwind Payment divided by (y) a market price per Share (which market price
per Share may, but is not required to, correspond to the Daily VWAP over the Settlement Averaging Period, if applicable, with respect to the Excluded Convertible Securities) (the “Market Price”) determined by the Calculation Agent
or (B) in the case where Counterparty has elected to satisfy its conversion obligation in respect of the related Excluded Convertible Securities in a combination of cash and Shares with a “Specified Dollar Amount” (as defined in the
Indenture) greater than USD 1,000, (x) an amount of cash equal to the lesser of (1) the amount of such Excluded Conversion Unwind Payment and (2) the product of (I) the Applicable Percentage, (II) the excess of such
“Specified Dollar Amount” (as defined in the Indenture) over USD 1,000 and (III) the Affected Number of Options and (y) if the amount of such Excluded Conversion Unwind Payment exceeds the amount of cash calculated pursuant to
the immediately preceding clause (B)(x)(2), a number of Shares equal to the quotient of (x) the amount of such excess divided by (y) the Market Price. Notwithstanding anything to the contrary herein, any payment calculated
pursuant to this Section 8(c) in respect of an Excluded Conversion Event shall not be a “Payment Obligation” to which the Share Termination Alternative provisions of Section 8(a) above apply; provided that, for the
avoidance of doubt, in the case of a payment or delivery pursuant to this Section 8(c) following an Extraordinary Event, the Calculation Agent may adjust the composition of the Shares as appropriate and determined in good faith and a
commercially reasonable manner to reflect the composition of consideration received by holders of Shares in such Extraordinary Event (as determined in a manner consistent with the provisions opposite the caption “Share Termination Delivery
Unit” below) and the provisions opposite the caption “Other Applicable Provisions” in Section 8(a) above shall apply. 

“Amendment Event” means that Counterparty amends, modifies, supplements, waives or obtains a waiver in
respect of any term of the Indenture or the Convertible Securities governing the principal amount, coupon, maturity, repurchase obligation of Counterparty, redemption right of Counterparty, any term relating to conversion of the Convertible
Securities (including changes to the conversion rate, conversion rate adjustment provisions, conversion settlement dates or conversion conditions), or any term that would require consent of the holders of not less than 100% of the principal amount
of the Convertible Securities to amend, in each case, without the consent of Dealer. 
 “Excluded Conversion
Event” means any conversion of Convertible Securities with a Conversion Date occurring prior to the 95th Scheduled Trading Day immediately preceding the Expiration Date. 

“Induced Conversion” means a conversion of any Excluded Convertible Securities (A) in connection with
(x) an adjustment to the Conversion Rate effected by Counterparty that is not required under the terms of the Indenture or (y) an agreement by Counterparty with the holder(s) of such Convertible Securities whereby, in the case of either
(x) or (y), the holder(s) of such Convertible Securities receive upon conversion or pursuant to such agreement, as the case may be, a payment of cash or delivery of Shares or any other property or item of value that was not required under the
terms of the Indenture or (B) after having been acquired from a holder of Convertible Securities by or on behalf of Counterparty or any of its affiliates other than pursuant to a conversion by such holder and thereafter converted by or on
behalf of Counterparty or any affiliate of Counterparty. 
 (ii) (A) Promptly following any Repayment Event (as defined
below) (but, in any event, within 5 Scheduled Trading Days following settlement thereof), Counterparty may notify Dealer of such Repayment Event and the aggregate principal amount of Convertible Securities subject to such Repayment Event (the
“Repayment Convertible Securities”) (any such notice, a “Repayment Notice”)[; provided that any “Repayment Notice” delivered to Dealer pursuant to the Base Capped Call Transaction Confirmation

  
 20 

 
shall be deemed to be a Repayment Notice pursuant to this Confirmation and the terms of such Repayment Notice shall apply, mutatis mutandis, to this Confirmation]. The receipt by Dealer
from Counterparty of any Repayment Notice shall constitute an Additional Termination Event as provided in this Section 8(c)(ii). 

(B) Upon receipt of any such Repayment Notice, Dealer shall designate an Exchange Business Day following receipt of such
Repayment Notice (which Exchange Business Day shall be on or as promptly as reasonably practicable after the related settlement date for the relevant Repayment Event) as an Early Termination Date with respect to a portion (the “Repayment
Terminated Portion”) of the Transaction consisting of a number of Options (the “Repayment Options”) equal to the lesser of (x) the number of Repayment Convertible Securities in denominations of USD1,000 that are
subject to the relevant Repayment Event [(and for the purposes of determining whether any Convertible Securities will be Repayment Securities hereunder or under, and as defined in, the Base Capped Call Transaction Confirmation, Convertible
Securities that are subject to a Repayment Event shall be allocated first to the Base Capped Call Transaction Confirmation until all Options thereunder are exercised or terminated)] and (y) the Number of Options as of the date Dealer designates
such Early Termination Date, and as of such date, the Number of Options shall be reduced by the number of Repayment Options. 

(C) Any payment or delivery in respect of such termination of the Repayment Terminated Portion of the Transaction shall be made
pursuant to Section 6 of the Agreement and, if applicable, Section 8(c) of this Confirmation. Counterparty shall be the sole Affected Party with respect to such Additional Termination Event and the Repayment Terminated Portion of the
Transaction shall be the sole Affected Transaction. “Repayment Event” means that (i) any Convertible Securities are repurchased (whether pursuant to Section 4.02 of the Indenture or Section 4.03 of the Indenture or
for any other reason) by Counterparty or any of its subsidiaries, (ii) any Convertible Securities are delivered to Counterparty in exchange for delivery of any property or assets of Counterparty or any of its subsidiaries (howsoever described),
(iii) any principal of any of the Convertible Securities is repaid prior to the final maturity date of the Convertible Securities (other than upon acceleration of the Convertible Securities described in Section 8(c)(i) of the
Confirmation), or (iv) any Convertible Securities are exchanged by or for the benefit of the Holders (as defined in the Indenture) thereof for any other securities of Counterparty or any of its Affiliates (as defined in the Indenture) (or any
other property, or any combination thereof) pursuant to any exchange offer or similar transaction; provided that no conversion of Convertible Securities pursuant to the terms of the Indenture shall constitute a Repayment Event. Counterparty
acknowledges its responsibilities under applicable securities laws, and in particular Section 9 and Section 10(b) of the Exchange Act and the rules and regulations thereunder, in respect of any action taken by Counterparty in respect of a
Repayment Event, including, without limitation, the delivery of a Repayment Notice. 
 (D) Counterparty shall cause any
Convertible Securities subject to a Repayment Event to be promptly cancelled and acknowledges and agrees that, except to the extent provided above in this Section 8(c)(ii), all such Convertible Securities subject to a Repayment Event will be
deemed for all purposes under the Transaction to be permanently extinguished and no longer outstanding. 
 (d) Disposition of Hedge
Shares. Counterparty hereby agrees that if, in the good faith reasonable judgment of Dealer, based upon advice of legal counsel, any Shares (the “Hedge Shares”) acquired by Dealer for the purpose of hedging its obligations
pursuant to the Transaction cannot be freely sold in the public market by Dealer without registration under the Securities Act, Counterparty shall, at its election: (i) in order to allow Dealer to sell the Hedge Shares in a registered offering,
make available to Dealer an effective registration statement under the Securities Act to cover the resale of such Hedge Shares and (A) enter into an agreement, in form 

  
 21 

 
and substance satisfactory to Dealer, substantially in the form of an underwriting agreement for a registered offering of similar size and in a similar industry, (B) provide
accountant’s “comfort” letters in customary form for registered offerings of equity securities of similar size and in a similar industry, (C) provide disclosure opinions of nationally recognized outside counsel to Counterparty
reasonably acceptable to Dealer, (D) provide other customary opinions, certificates and closing documents customary in form for registered offerings of equity securities of similar size and in a similar industry and (E) afford Dealer a
reasonable opportunity to conduct a “due diligence” investigation with respect to Counterparty customary in scope for underwritten offerings of equity securities of similar size and in a similar industry; provided, however,
that if Dealer, in its good faith and reasonable judgment, is not satisfied with access to due diligence materials, the results of its due diligence investigation, or the procedures and documentation for the registered offering referred to above,
then clause (ii) or clause (iii) of this Section 8(d) shall apply at the election of Counterparty; (ii) in order to allow Dealer to sell the Hedge Shares in a private placement, enter into a private placement agreement
substantially similar to private placement purchase agreements customary for private placements of equity securities of similar size and in a similar industry, in form and substance reasonably satisfactory to Dealer, including customary
representations, covenants, blue sky and other governmental filings and/or registrations, indemnities to Dealer, due diligence rights (for Dealer or any designated buyer of the Hedge Shares from Dealer), opinions and certificates and such other
documentation as is customary for private placements agreements, all reasonably acceptable to Dealer (in which case, the Calculation Agent shall make any adjustments to the terms of the Transaction that are necessary, in its commercially reasonable
judgment, to compensate Dealer for any discount from the public market price of the Shares incurred on the sale of Hedge Shares in a private placement); or (iii) purchase the Hedge Shares from Dealer at the Daily VWAP on such Exchange Business
Days, and in the amounts, requested by Dealer. 
 (e) Repurchase and Conversion Rate Adjustment Notices Counterparty shall, at least
five Scheduled Trading Days prior to effecting any repurchase of Shares or consummating or otherwise executing or engaging in any transaction or event (a “Conversion Rate Adjustment Event”) that would lead to an increase in the
Conversion Rate (as such term is defined in the Indenture), give Dealer a written notice of such repurchase or Conversion Rate Adjustment Event (a “Repurchase Notice”) if, following such repurchase or Conversion Rate Adjustment
Event, the Notice Percentage as determined on the date of such Repurchase Notice is (i) greater than 9% and (ii) greater by 0.5% than the Notice Percentage included in the immediately preceding Repurchase Notice (or, in the case of the
first such Repurchase Notice, greater than the Notice Percentage as of the date hereof (calculated as if any Other Call Option Transaction had been entered into as of such date)). The “Notice Percentage” as of any day is the
fraction, expressed as a percentage, the numerator of which is the sum of (x) the Number of Shares and (y) the number of Shares underlying any other call option (including any capped call option) transaction (an “Other Call Option
Transaction”) between Dealer as seller and Counterparty as buyer, and the denominator of which is the number of Shares outstanding on such day. In the event that Counterparty fails to provide Dealer with a Repurchase Notice on the day and
in the manner specified in this Section 8(e), then Counterparty agrees to indemnify and hold harmless Dealer, its affiliates and their respective directors, officers, employees, agents and controlling persons (Dealer and each such person being
an “Indemnified Party”) from and against any and all reasonable losses, claims, damages and liabilities (or actions in respect thereof), joint or several, to which such Indemnified Party may become subject under applicable
securities laws, including without limitation, Section 16 of the Exchange Act, relating to or arising out of such failure. If for any reason the foregoing indemnification is unavailable to any Indemnified Party or insufficient to hold harmless
any Indemnified Party, then Counterparty shall contribute, to the maximum extent permitted by law, to the amount paid or payable by the Indemnified Party as a result of such reasonable loss, claim, damage or liability. In addition, Counterparty will
reimburse any Indemnified Party for all reasonable expenses (including reasonable counsel fees and expenses) as they are incurred (after notice to Counterparty) in connection with the investigation of, preparation for or defense or settlement of any
pending or threatened claim or any action, suit or proceeding arising therefrom, whether or not such Indemnified Party is a party thereto and whether or not such claim, action, suit or proceeding is initiated or brought by or on behalf of
Counterparty. This indemnity shall survive the completion of the Transaction contemplated by this Confirmation and any assignment and delegation of the Transaction made pursuant to this Confirmation or the Agreement shall inure to the benefit of any
permitted assignee of Dealer. 
 (f) Transfer or Assignment. Either party may transfer any of its rights or obligations under the
Transaction with the prior written consent of the non-transferring party, such consent not to be unreasonably withheld or delayed. For the avoidance of doubt, Dealer may condition its consent on any of the
following, without limitation: (i) the receipt by Dealer of opinions and documents reasonably satisfactory to Dealer in connection with 

  
 22 

 
such assignment, (ii) such assignment being effected on terms reasonably satisfactory to Dealer with respect to any legal and regulatory requirements relevant to Dealer, (iii) the
transferee being a United States person (as defined in the Internal Revenue Code of 1986, as amended), (iv) that, in Dealer’s reasonable determination, Dealer will not be required, as a result of such transfer, to pay the transferee an
amount under Section 2(d)(i)(4) of the Agreement greater than the amount, if any, that Dealer would have been required to pay to Counterparty in the absence of such transfer, (v) that, in Dealer’s reasonable determination, no Event of
Default, Potential Event of Default or Termination Event will occur as a result of such transfer, (vi) Counterparty shall have caused the transferee to make such Payee Tax Representations and to provide such tax documentation as may be
reasonably requested by Dealer to permit Dealer to determine that results described in clauses (iv) and (v) will not occur upon or after such transfer and assignment and (vii) Counterparty continuing to be obligated to provide notices
hereunder relating to the Convertible Securities and continuing to be obligated with respect to “Disposition of Hedge Shares” and “Repurchase Notices” above. In addition, Dealer may transfer or assign without any consent of the
Counterparty its rights and obligations hereunder and under the Agreement, in whole or in part, to (i) any of its affiliates or (ii) solely to the extent required to eliminate an Excess Ownership Position (as defined below), to any other
recognized dealer in transactions such as the Transaction, where in each case, the assignee shall have a rating (or whose guarantor shall have a rating) for its long term, unsecured and unsubordinated indebtedness of
A- or better by Standard & Poor’s Ratings Services or its successor (“S&P”), or A3 or better by Moody’s Investors Service, Inc. or its successor
(“Moody’s”) or, if either S&P or Moody’s ceases to rate such debt, at least an equivalent rating or better by a substitute rating agency mutually agreed by Counterparty and Dealer; provided that in the case of
clause (i), Counterparty will not, as a result of such transfer and/or assignment, be required under the Agreement or this Confirmation to (x) pay to the transferee or assignee an amount greater than the amount that it would have been required
to pay to Dealer in the absence of such transfer or assignment or (y) receive from the transferee or assignee an amount less than the amount that Counterparty would have received from Dealer in the absence of such transfer or assignment, in
each case, based on the circumstances in effect on the date of such transfer. Dealer shall provide Counterparty with written notice of any transfer or assignment to the foregoing sentence on, or as reasonably practicable following, the date of such
transfer or assignment. At any time at which any Excess Ownership Position exists, if Dealer, in its discretion, is unable to effect a transfer or assignment to a third party in accordance with the requirements set forth above after using its
commercially reasonable efforts on pricing terms and within a time period reasonably acceptable to Dealer such that an Excess Ownership Position no longer exists, Dealer may designate any Exchange Business Day as an Early Termination Date with
respect to a portion (the “Terminated Portion”) of the Transaction, such that such Excess Ownership Position no longer exists. In the event that Dealer so designates an Early Termination Date with respect to a portion of the
Transaction, a payment or delivery shall be made pursuant to Section 6 of the Agreement and Section 8(a) of this Confirmation as if (i) an Early Termination Date had been designated in respect of an Additional Termination Event under
a Transaction having terms identical to the Terminated Portion of the Transaction, (ii) Counterparty were the sole Affected Party with respect to such Additional Termination Event and (iii) the Terminated Portion of the Transaction shall
be the only Terminated Transaction. “Excess Ownership Position” means any of the following: (i) the Equity Percentage exceeds 9.0%, (ii) Dealer or any “affiliate” or “associate” of Dealer would own 9%
or more of the outstanding Shares for purposes of Chapter 23B.19 of the Washington Business Corporation Act or (iii) Dealer, Dealer Group (as defined below) or any person whose ownership position would be aggregated with that of Dealer or
Dealer Group (Dealer, Dealer Group or any such person, a “Dealer Person”) under any federal, state or local laws, regulations or regulatory orders applicable to ownership of Shares (“Applicable Laws”), owns,
beneficially owns, constructively owns, controls, holds the power to vote or otherwise meets a relevant definition of ownership in excess of a number of Shares equal to (x) the number of Shares that would give rise to reporting or registration
obligations or other requirements (including obtaining prior approval by a state or federal regulator) of a Dealer Person under Applicable Laws and with respect to which such requirements have not been met or the relevant approval has not been
received or that would give rise to any consequences under the constitutive documents of Counterparty or any contract or agreement to which Counterparty is a party, in each case, minus (y) 1% of the number of Shares outstanding on the
date of determination. The “Equity Percentage” as of any day is the fraction, expressed as a percentage, (A) the numerator of which is the number of Shares that Dealer and any of its affiliates or any other person subject to
aggregation with Dealer, for purposes of the “beneficial ownership” test under Section 13 of the Exchange Act, or of any “group” (within the meaning of Section 13) of which Dealer is or may be deemed to be a part
(Dealer and any such affiliates, persons and groups, collectively, “Dealer Group”), beneficially owns (within the meaning of Section 13 of the Exchange Act), without duplication, on such day and (B) the denominator of
which is the number of Shares outstanding on such day. Notwithstanding anything to the contrary in this Section 8(f), it shall be a further condition to a transfer or assignment by Dealer without Counterparty’s consent that such transfer
or assignment is made to a transferee or assignee that is a “dealer in securities” within the meaning of Section 475(c)(1) of the Internal Revenue Code of 1986, as amended. 

  
 23 

 (g) Adjustments. For the avoidance of doubt, whenever the Calculation Agent, Dealer,
Determining Party, Hedging Party or Seller is called upon to make an adjustment pursuant to the terms of this Confirmation or the Equity Definitions to take into account the effect of an event, the Calculation Agent, Dealer, Determining Party,
Hedging Party or Seller shall make such adjustment in good faith and in a commercially reasonable manner by reference to the effect of such event on the Hedging Party, assuming that the Hedging Party maintains a commercially reasonable hedge
position. 
 (h) Staggered Settlement. Dealer may, by notice to Counterparty on or prior to any Settlement Date (a “Nominal
Settlement Date”), elect to deliver the Shares on two or more dates (each, a “Staggered Settlement Date”) or at two or more times on the Nominal Settlement Date as follows: 

(i) in such notice, Dealer will specify to Counterparty the related Staggered Settlement Dates (each of which will be on or
prior to such Nominal Settlement Date, but not prior to the earlier of the relevant Conversion Date and the first day of the relevant Settlement Averaging Period) or delivery times and how it will allocate the Shares it is required to deliver under
“Delivery Obligation” (above) among the Staggered Settlement Dates or delivery times; and 
 (ii) the aggregate
number of Shares that Dealer will deliver to Counterparty hereunder on all such Staggered Settlement Dates and delivery times will equal the number of Shares that Dealer would otherwise be required to deliver on such Nominal Settlement Date. 

(i) Right to Extend. Dealer may postpone any Exercise Date or Settlement Date or any other date of valuation or delivery by Dealer with
respect to some or all of the relevant Options, as applicable (in which event the Calculation Agent shall make appropriate adjustments to the Delivery Obligation), if Dealer determines, in its reasonable discretion, based on advice of counsel in the
case of clause (ii) below, that such extension is reasonably necessary or appropriate to (i) preserve Dealer’s commercially reasonable hedging or hedge unwind activity hereunder in light of existing liquidity conditions in the cash
market, the stock loan market or any other relevant market or (ii) enable Dealer to effect transactions with respect to Shares in a commercially reasonable manner in connection with its commercially reasonable hedging, hedge unwind or
settlement activity hereunder in a manner that would, if Dealer were Counterparty or an affiliated purchaser of Counterparty, be in compliance with applicable legal, regulatory or self-regulatory requirements,
or with related policies and procedures applicable to Dealer, provided that such requirements, policies and procedures are generally applicable in similar situations and applied to the Transaction in a
non-discriminatory manner. 
 (j) No Netting and
Set-Off. Each party waives any and all rights it may have to set off obligations arising under the Agreement and the Transaction against other obligations between the parties, whether arising under any
other agreement, applicable law or otherwise. 
 (k) Status of Claims in Bankruptcy Dealer acknowledges and agrees that this
Confirmation is not intended to convey to it rights with respect to the Transaction that are senior to the claims of common stockholders or Counterparty in the event of Counterparty’s bankruptcy. For the avoidance of doubt, the parties agree
that the preceding sentence shall not apply at any time other than during Counterparty’s bankruptcy. 
 (l) No Collateral.
Notwithstanding any provision of this Confirmation, the Agreement, the Equity Definitions or any other agreement between the parties to the contrary, the obligations of Counterparty under the Transaction are not secured by any collateral. 

(m) Disclosure. Effective from the date of commencement of discussions concerning the Transaction, Counterparty and each of its
employees, representatives, or other agents may disclose to any and all persons, without limitation of any kind, the tax treatment and tax structure of the Transaction and all materials of any kind (including opinions or other tax analyses) that are
provided to Counterparty relating to such tax treatment and tax structure. 

  
 24 

 (n) [Reserved.] 

(o) Early Unwind. In the event the sale by Counterparty of the [Initial Securities] [Option Securities] is not consummated with the
underwriters pursuant to the Purchase Agreement for any reason by the close of business in New York on November 15, 2018 (or such later date as agreed upon by the parties) (November 15, 2018 or such later date being the “Early
Unwind Date”), the Transaction shall automatically terminate (the “Early Unwind”) on the Early Unwind Date and (x) the Transaction and all of the respective rights and obligations of Dealer and Counterparty thereunder
shall be cancelled and terminated and (y) except to the extent that the Early Unwind Date occurred as a result of a breach of the Purchase Agreement by Dealer or any of its affiliates, Counterparty shall, at its election, either (1) pay to
Dealer an amount in cash equal to the aggregate amount of commercially reasonable costs and expenses relating to the unwinding of Dealer’s commercially reasonable hedging activities in respect of the Transaction (including market losses
incurred in reselling any Shares purchased by Dealer or its affiliates in connection with such hedging activities) (such amount, the “Cash Amount”) or (2) deliver to Dealer Shares with a value (as reasonably determined by the
Calculation Agent) equal to the Cash Amount. Following such termination, cancellation and payment, each party shall be released and discharged by the other party from and agrees not to make any claim against the other party with respect to any
obligations or liabilities of either party arising out of and to be performed in connection with the Transaction either prior to or after the Early Unwind Date. If Counterparty elects to deliver Shares pursuant to this paragraph, the following
provisions shall apply: 
 (i) At the election of Counterparty by notice to Dealer within one Exchange Business Day after the
Early Unwind Date, either (A) all Shares delivered by Counterparty to Dealer shall be, at the time of such delivery, covered by an effective registration statement of Counterparty for immediate resale by Dealer (such registration statement and
the corresponding prospectus (the “Prospectus”) (including, without limitation, any sections describing the plan of distribution) in form and content commercially reasonably satisfactory to Dealer) or (B) Counterparty shall
deliver additional Shares, so that the value of such Shares, as reasonably determined by the Calculation Agent to reflect an appropriate liquidity discount, equals the Cash Amount. Notwithstanding anything herein or in the Agreement to the contrary,
the aggregate number of Shares that Counterparty may be required to deliver to Dealer under this Transaction shall not exceed twice the Number of Shares as of the date hereof as such number may be adjusted by the Calculation Agent from time to time
to account for any subdivision, stock-split, stock combination, reclassification or similar dilutive or anti-dilutive event with respect to the Shares. 

(ii) If Counterparty makes the election described in clause (i)(A) above: 

(A) Dealer (or an affiliate of Dealer designated by Dealer) shall be afforded a reasonable opportunity to conduct a due
diligence investigation with respect to Counterparty that is customary in scope for underwritten offerings of equity securities of similar size and in a similar industry and that yields results that are commercially reasonably satisfactory to Dealer
or such affiliate, as the case may be, in its discretion; and 
 (B) Dealer (or an affiliate of Dealer designated by Dealer)
and Counterparty shall enter into an agreement (a “Registration Agreement”) on commercially reasonable terms in connection with the public resale of such Shares by Dealer or such affiliate substantially similar to underwriting
agreements customary for underwritten offerings of equity securities of similar size and in a similar industry (and in particular on terms reasonably similar to these contained in the Purchase Agreement), in form and substance reasonably
satisfactory to Dealer or such affiliate and Counterparty, which Registration Agreement shall include, without limitation, provisions substantially similar to those contained in such underwriting agreements relating to the indemnification of, and
contribution in connection with the liability of, Dealer and its affiliates and Counterparty, shall provide for the payment by Counterparty of all expenses in connection with such resale, including all registration costs and all commercially
reasonable fees and expenses of counsel for Dealer, and shall provide for the delivery of accountants’ “comfort letters” to Dealer or such affiliate with respect to the financial statements and certain financial information contained
in or incorporated by reference into the Prospectus. 

  
 25 

 (iii) If Counterparty makes the election described in clause (i)(B) above:

 (A) Dealer (or an affiliate of Dealer designated by Dealer) and any potential institutional purchaser of any such Shares
from Dealer or such affiliate identified by Dealer shall be afforded a commercially reasonable opportunity to conduct a due diligence investigation in compliance with applicable law with respect to Counterparty customary in scope for private
placements of equity securities of similar size and in a similar industry (including, without limitation, the right to have made available to them for inspection such financial and other records, pertinent corporate documents and other information
reasonably requested by them), subject to execution by such recipients of customary confidentiality agreements reasonably acceptable to Counterparty; 

(B) Dealer (or an affiliate of Dealer designated by Dealer) and Counterparty shall enter into an agreement (a “Private
Placement Agreement”) on commercially reasonable terms in connection with the private placement of such Shares by Counterparty to Dealer or such affiliate and the private resale of such shares by Dealer or such affiliate, substantially
similar to private placement purchase agreements customary for private placements of equity securities of similar size, in form and substance reasonably satisfactory to Dealer and Counterparty, which Private Placement Agreement shall include,
without limitation, provisions substantially similar to those contained in such private placement purchase agreements relating to the indemnification of, and contribution in connection with the liability of, Dealer and its affiliates and
Counterparty, shall provide for the payment by Counterparty of all commercially reasonable expenses in connection with such resale, including all reasonable fees and expenses of counsel for Dealer, shall contain customary representations, warranties
and agreements of Counterparty reasonably necessary or advisable to establish and maintain the availability of an exemption from the registration requirements of the Securities Act for such resales, and shall use commercially reasonable efforts to
provide for the delivery of accountants’ “comfort letters” to Dealer or such affiliate with respect to the financial statements and certain financial information contained in or incorporated by reference into the offering memorandum
prepared for the resale of such Shares; 
 (C) Counterparty agrees that any Shares so delivered to Dealer, (i) subject
to applicable securities laws, may be transferred by and among Dealer and its affiliates, and Counterparty shall effect such transfer without any further action by Dealer and (ii) after the minimum “holding period” within the meaning
of Rule 144(d) under the Securities Act has elapsed with respect to such Shares, Counterparty shall promptly remove, or cause the transfer agent for such Shares or securities to remove, any legends referring to any such restrictions or
requirements from such Shares or securities upon delivery by Dealer (or such affiliate of Dealer) to Counterparty or such transfer agent of seller’s and broker’s representation letters customarily delivered in connection with resales of
restricted securities pursuant to Rule 144 under the Securities Act, without any further requirement for the delivery of any certificate, consent, agreement, opinion of counsel, notice or any other document, any transfer tax stamps or payment
of any other amount or any other action by Dealer (or such affiliate of Dealer); and 
 (D) Counterparty shall not take (and
shall cause any such affiliate not to take), or cause to be taken, any action that would make unavailable either the exemption pursuant to Section 4(a)(2) of the Securities Act for the sale by Counterparty to Dealer (or any affiliate designated
by Dealer) of the Shares or the exemption pursuant to Section 4(a)(1) or Section 4(a)(3) of the Securities Act for resales of the Shares by Dealer (or any such affiliate of Dealer). 

  
 26 

 (iv) Dealer or its affiliate may sell (which sale shall be made in a
commercially reasonable manner) such Shares during a period (the “Resale Period”) commencing on the Exchange Business Day following delivery of such Shares and ending on the Exchange Business Day on which Dealer completes the sale
of all such Shares or a sufficient number of Shares so that the realized net proceeds of such sales exceed the Cash Amount. If any of such delivered Shares remain after such realized net proceeds exceed the Cash Amount, Dealer shall return such
remaining Shares to Counterparty. If the Cash Amount exceeds the realized net proceeds from such resale, Counterparty shall transfer to Dealer by the open of the regular trading session on the Exchange on the Exchange Business Day immediately
following the last day of the Resale Period the amount of such excess (the “Additional Amount”) either in cash or in a number of additional Shares (“Make-whole Shares”) at the
sole election of the Counterparty in an amount that, based on the Relevant Price on the last day of the Resale Period (as if such day was the “Valuation Date” for purposes of computing such Relevant Price), has a dollar value equal to the
Additional Amount. The Resale Period shall continue to enable the sale of the Make-whole Shares in the manner contemplated by this paragraph (it being understood that any delivery of Make-whole Shares will be
subject to the cap on Counterparty’s delivery of Shares set forth above in this Section 8(o)). This provision shall be applied successively until the Additional Amount is equal to zero. 

(p) [Reserved]. 
 (q)
Agreements and Acknowledgments Regarding Hedging. Counterparty understands, acknowledges and agrees that: (A) at any time on and prior to the Expiration Date, Dealer and its affiliates may buy or sell Shares or other securities or buy or
sell options or futures contracts or enter into swaps or other derivative securities in order to adjust its hedge position with respect to the Transaction; (B) Dealer and its affiliates also may be active in the market for Shares other than in
connection with hedging activities in relation to the Transaction; (C) Dealer shall make its own determination as to whether, when or in what manner any hedging or market activities in securities of Issuer shall be conducted and shall do so in
a manner that it deems appropriate to hedge its price and market risk with respect to the Daily VWAP; and (D) any market activities of Dealer and its affiliates with respect to Shares may affect the market price and volatility of Shares, as
well as the Daily VWAP, each in a manner that may be adverse to Counterparty. 
 (r) Wall Street Transparency and Accountability Act.
In connection with Section 739 of the Wall Street Transparency and Accountability Act of 2010 (“WSTAA”), the parties hereby agree that neither the enactment of WSTAA or any regulation under the WSTAA, nor any requirement under
WSTAA or an amendment made by WSTAA, shall limit or otherwise impair either party’s otherwise applicable rights to terminate, renegotiate, modify, amend or supplement this Confirmation or the Agreement, as applicable, arising from a termination
event, force majeure, illegality, increased costs, regulatory change or similar event under this Confirmation, the Equity Definitions incorporated herein, or the Agreement (including, but not limited to, rights arising from Change in Law, Hedging
Disruption, an Excess Ownership Position, or Illegality (as defined in the Agreement)). 
 (s) Tax Matters. For purpose of Sections
4(a)(i) and (ii) of the Agreement, (i) Counterparty agrees to deliver to Dealer one duly executed and completed United States Internal Revenue Service Form W-9 (or successor thereto) and
(ii) Dealer agrees to deliver to Counterparty one duly executed and completed United States Internal Revenue Form W-8 or Form W-9 (or successor thereto),
as applicable. In each case, such form shall be completed accurately and in a manner reasonably acceptable to the other party and shall be delivered (a) upon execution of this Confirmation, (b) promptly upon reasonable demand by the other
party and (c) promptly upon learning that the information on any such previously delivered form is inaccurate or incorrect. “Tax” and “Indemnifiable Tax”, each as defined in Section 14 of the Agreement, shall not
include any U.S. federal withholding tax imposed or collected pursuant to Sections 1471 through 1474 of the U.S. Internal Revenue Code of 1986, as amended (the “Code”), any current or future regulations or official
interpretations thereof, any agreement entered into pursuant to Section 1471(b) of the Code, or any fiscal or regulatory legislation, rules or practices adopted pursuant to any intergovernmental agreement entered into in connection with the
implementation of such Sections of the Code (a “FATCA Withholding Tax”). For the avoidance of doubt, a FATCA Withholding Tax is a Tax the deduction or withholding of which is required by applicable law for the purposes of Section 2(d)
of the Agreement. The parties agree that the definitions and provisions contained in the ISDA 2015 Section 871(m) Protocol, as published by ISDA and as may be amended, supplemented, replaced or superseded from time to time (the “871(m)
Protocol”) shall apply to this Confirmation as if the parties had adhered to the 871(m) Protocol as of the effective date of this Confirmation. If there is any inconsistency between this provision and a provision in any other agreement
executed between the parties with respect to the Transaction, this provision shall prevail unless such other agreement expressly overrides the provisions of the 871(m) Protocol. 

  
 27 

 (t) Payee Tax Representations. For the purpose of Section 3(f) of the Agreement,
Counterparty makes the following representation to Dealer: 
 Counterparty is a corporation established under the laws of the State of
Washington and is a “United States person” (as that term is defined in Section 7701(a)(30) of the Code). 
 (u) Amendments
to the Equity Definitions. The following amendments shall be made to the Equity Definitions. 
 (i)
Section 11.2(e)(vii) of the Equity Definitions is hereby amended by deleting the words “diluting or concentrative” and replacing them with the word “material”; and adding the phrase “, options relating to the Shares
and/or the Transaction” at the end of the sentence. 
 (ii) Section 12.6(a)(ii) of the Equity Definitions is hereby
amended by (1) deleting from the fourth line thereof the word “or” after the word “official” and inserting a comma therefor, and (2) deleting the semi-colon at the end of subsection (B) thereof and inserting the
following words therefor “or (C) the occurrence of any of the events specified in Section 5(a)(vii)(1) through (9) of the ISDA Master Agreement with respect to that Issuer.” 

(v) Severability; Illegality. Notwithstanding anything to the contrary in the Agreement, if compliance by either party with any
provision of the Transaction would be unenforceable or illegal, (a) the parties shall negotiate in good faith to resolve such unenforceability or illegality in a manner that preserves the economic benefits of the transactions contemplated
hereby and (b) the other provisions of the Transaction shall not be invalidated, but shall remain in full force and effect. 
 (w)
Waiver of Jury Trial. EACH OF COUNTERPARTY AND DEALER HEREBY IRREVOCABLY WAIVES (ON ITS OWN BEHALF AND, TO THE EXTENT PERMITTED BY APPLICABLE LAW, ON BEHALF OF ITS STOCKHOLDERS) ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, PROCEEDING OR
COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THE TRANSACTION OR THE ACTIONS OF DEALER OR ITS AFFILIATES IN THE NEGOTIATION, PERFORMANCE OR ENFORCEMENT HEREOF. 

(x) Governing law; Jurisdiction. THIS CONFIRMATION AND ANY CLAIM, CONTROVERSY OR DISPUTE ARISING UNDER OR RELATED TO THIS
CONFIRMATION SHALL BE GOVERNED BY THE LAWS OF THE STATE OF NEW YORK. THE PARTIES HERETO IRREVOCABLY SUBMIT TO THE EXCLUSIVE JURISDICTION OF THE COURTS OF THE STATE OF NEW YORK AND THE UNITED STATES COURT FOR THE SOUTHERN DISTRICT OF NEW YORK IN
CONNECTION WITH ALL MATTERS RELATING HERETO AND WAIVE ANY OBJECTION TO THE LAYING OF VENUE IN, AND ANY CLAIM OF INCONVENIENT FORUM WITH RESPECT TO, THESE COURTS. 

  
 28 

 This Confirmation may be executed in several counterparts, each of which shall be deemed an original but all
of which together shall constitute one and the same instrument. 
 Counterparty hereby agrees to check this Confirmation and to confirm that the foregoing
correctly sets forth the terms of the Transaction by signing in the space provided below and returning to Dealer a facsimile of the fully-executed Confirmation to Dealer. Originals shall be provided for your
execution upon your request. 
 We are very pleased to have executed the Transaction with you and we look forward to completing other transactions with you
in the near future. 
  

			
	Very truly yours,
	
	[DEALER]
		
	By:	 	 
		 	Name:
		 	Title:

 Counterparty hereby agrees to, accepts and confirms the terms of the foregoing as of the Trade Date. 

 

			
	OMEROS CORPORATION
		
	By:	 	 
		 	Name:
		 	Title:

 [Signature Page to Capped Call]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00289-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00289-of-00352.parquet"}]]